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here is an emerging interest in the extracellular matrix (ECM) of the lung, especially in the 
role it plays in development and disease. There is a rapid change from the classical view 
of the ECM as a supporting structure towards a view of the ECM as a regulatory entity 
with profound effects on proliferation, migration and differentiation of pulmonary cells. In the 
ECM a variety of molecules is present in a highly organized pattern. Next to the abundant 
fiber-forming molecules such as collagens and elastin, a large number of less abundant 
molecules are part of the ECM, including proteoglycans. In this review, we will focus on 
one class of proteoglycans, the heparan sulfate proteoglycans. We will particularly address 
the structure, biosynthesis, and function of their saccharide moiety, the heparan sulfates, 
including their role in development and (patho)physiology.
T
The lung is a highly dynamic organ which 
during life undergoes a constant change 
in volume. This puts special demands 
on the pulmonary connective tissue, par-
ticularly lung alveoli, where the actual 
gas exchange process takes place. For 
efficient functioning of the lung, alveolar 
walls have to be thin to obtain proper 
gas exchange, firm to prevent collapse 
of the alveolus, and flexible to cope with 
volume changes during breathing.
The extracellular matrix (ECM) maintains 
the functions of the lung by supporting 
its structure and by interactions with a 
large number of regulatory components. 
Providing structural and mechanical pro-
perties has been considered the prime 
role of the ECM for a long time. It is 
now becoming increasingly clear that 
the ECM has many other physiological 
roles, mediated through the regulation of 
a variety of cellular processes 1. Proper 
functioning of the ECM can only be 
attained when components are fine-tuned 
with respect to each other. The constant 
change in volume during breathing puts 
high demands on the ECM, and even 
minor disturbances in the ECM can be 
expected to have an impact on the lungs’ 
functioning. 
 The most prominent structural (fi-
brillar) components of the lungs’ ECM 
are collagen and elastin. Collagens are 
known to endow pulmonary tissue with 
structural integrity, whereas elastin plays 
a role in the elastic characteristics of 
the lung 2. Less abundantly present, but 
functionally very important, are a large 
number of glycoproteins, including fi- 
bronectin, laminins, entactin, fibrillins, 
and a variety of proteoglycans. 
 The group of proteoglycans, with their 
characteristic glycosaminoglycan (GAG) 
chains, seems to play a particular role in 
the lung, due to their capacity to bind and 
modulate a myriad of proteins -including 
many effector molecules-, their strategic 
location on cell surfaces and in basement 
membranes, and their huge variability. 
Current research is increasingly focused 
on non-fibrillar components like proteo- 
glycans. In an official statement of the 
American Thoracic Society on future 
research on pulmonary emphysema, it 
was stated that: ‘Future directions should 
explore the specific role of pulmonary 
parenchymal GAGs in maintaining al- 
veolar integrity’ 3. 
 Although little is known about the 
exact roles proteoglycans and GAGs play 
in the lung, their distribution over various 
components, their strategic ultrastructural 
Extracellular matrix
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location 4, and their involvement during 
developmental stages 5 suggest their cru-
cial importance for the architecture and
functioning of the lung. In this review we
will focus on heparan sulfate proteo-
glycans (HSPGs), especially on their su-
gar moiety, the heparan sulfates.  
Proteoglycans constitute a large family of 
glycoproteins, consisting of a core protein 
with highly variable GAG moieties at- 
tached to it. GAGs are long unbranched 
polysaccharides consisting of alternating 
hexosamine and hexuronic acid residues 
(Table 1). Keratan sulfate (KS) is an 
exception since it lacks hexuronic acids. 
Hyaluronic acid (hyaluronan) is the on-
ly GAG that is not attached to a core 
protein. Depending on the nature of their 
backbone, the following classes of GAGs 
can be discerned (see Table 1): heparan 
sulfate (HS)/heparin, chondroitin/der-
matan sulfate (CS/DS), KS and hya-
luronan. Heparin is structurally similar to 
HS, but has a higher degree of N-, and O-
sulfation. The majority of proteoglycans 
in lung tissue carry HS, DS or CS side 
chains. The amount of each type of 
proteoglycan, however, differs in the 
different compartments of the lung. For 
example, in the tracheobronchial tree 
Heparan sulfate proteoglycans
the major species is a large cartilaginous 
CS/KS proteoglycan; the pleural lining 
of the lung contains mainly small DS 
proteoglycans (DSPGs), whereas heparin, 
the GAG component of the proteoglycan 
serglycin, is abundantly present in mast 
cells. In (alveolar) basement membranes 
and on cell surfaces HSPGs are the 
major class. The differences in amount, 
type, and distribution reflect the different 
roles of proteoglycans in distinct lung 
compartments (Figure 1). Basically, 
three major classes of HSPGs can be 
discerned: one class primarily confined to 
basement membranes, one class bound to 
the cell membrane by a GPI-anchor (the 
glypicans), and one class consisting of 
transmembrane proteoglycans (the syn-
decans). 
 Perlecan, agrin, and type XVIII col-
lagen are basement membrane-asso-
ciated HSPGs (Figure 2). Perlecan has 
a large, multi-domain core protein of 
about 467 kDa in humans. The major 
sites for GAG attachment reside in the 
extreme amino terminal domain of the 
perlecan core protein 6. These three sites 
are usually occupied by HS, though CS 
substitution has also been described. Its 
complex core protein structure provides 
the potential to interact with numerous 
proteins. HS degradation of perlecan 
Table 1: Various types of glycosaminoglycans
Gal, D-galactose; GalNAc, N-acetyl-D-galactosamine; GlcA, glucuronic acid; GlcNAc, N-acetyl-D-gluco-
samine; IdoA, L-iduronic acid.
 
Glycosaminoglycan Disaccharide composition Possible modifications 
Chondroitin sulfate 
Dermatan sulfate 
Heparan sulfate/ Heparin 
Keratan sulfate 
Hyaluronic acid 
GlcA(β1,3)-GalNAc(β1,4) 
IdoA(α1,3)/GlcA(β1,3)-GalNAc(β1,4) 
GlcA(β1,4)/IdoA(α1,4)-GlcNAc(α1,4) 
Gal(β1,4)-GlcNAc(β1,3) 
GlcA(β1,3)-GlcNAc(β1,4) 
2-, 4- and 6-O sulfation 
2-, 4-, and 6-O sulfation, C5 epimerization 
N-deacetylation/N-sulfation C5 epimerization, 2-, 3-, and 6-O sulfation 
6-O-sulfation 
- 
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by the action of HS-degrading enzymes 
(e.g., heparanases) has been associated 
with the ability of some metastatic cancer 
cells to penetrate basement membranes 7. 
In the lung, perlecan is associated with 
basement membrane-producing cells and 
is also found in all vascularized and some 
connective tissues (e.g., cartilage).
 Perlecan is able to interact with 
growth factors such as basic fibroblast 
growth factor (FGF-2) via its HS chains, 
a property shared with other HSPGs. 
It can regulate interaction of FGF-2 
with its receptor and thereby modulate 
tissue metabolism. In the lung, FGF-2 
is largely bound by HS (Figure 3) 8, 9. 
The multiple functions of perlecan are 
evident from the tissue disruption that 
occurs in both perlecan-null mice 10, 11, 
and in humans with mutations in the 
perlecan gene where disturbances occur 
in organ development owing to basement 
membrane perturbation 11. Perlecan plays
a major role in maintaining the inte-
grity of basement membranes and the
cartilage matrix, but has no apparently 
critical function in (alveolar) basement 
membrane assembly. Despite the abi-
lity of perlecan to interact with several 
Figure 1. Location of various proteoglycans in 
lung parenchyma. A. Schematic representation 
of various proteoglycans present in the alveolar 
septum. 1) Heparan sulfate (HS) proteoglycan 
associated with epithelial cell basement membrane; 
2) HS proteoglycan associated with endothelial 
cell basement membrane; 3) HS proteoglycan 
associated with endothelial cell surface; 4) fibroblast 
chondroitin sulfate (CS) proteoglycan aggregates 
with hyaluronan; 5) fibroblast cell surface HS 
proteoglycan and CS proteoglycan; 6) collagen 
fibril-associated dermatan sulfate proteoglycan; 
7) heparin proteoglycan-containing granules in 
mast cells; 8) elastin-associated CS proteoglycan.
AE, alveolar epithelium; BM, basement membrane; 
Type I Ep, type I alveolar epithelial cell; Type II Ep, 
type II alveolar epithelial cell; Endo, endothelial 
cell; Fibro, fibroblast; C, collagen; E, elastin 
(adapted from Juul et al, Proteoglycans. In: The 
Lung, Scientific Foundations, Vol I, Crystal RC, 
West JB, Raven Press, NY. 1991;413-420)124.
B, Location of heparan sulfate proteoglycans in 
the blood-air barrier of human alveoli. To visualize 
proteoglycans, cuprolinic blue was used according 
to the critical electrolyte concentration method 124. 
Each electron dense filament (arrows) represents 
a proteoglycan.
Highly sulfated HS-proteoglycans are located 
in the basement membrane of type I alveolar 
epithelial cells, where they appear to be located 
in one plane. In the capillary basement membrane 
HS-proteoglycans are less sulfated and distributed 
in a more random fashion.
A, alveolar airspace; cap, capillary; ecI, type I 
alveolar epithelial cell; en, endothelial cell. Bar, 
0.5 μm (Reproduced and adapted with permission 
from van Kuppevelt et al, 1985).
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 components of the basement membrane, 
basement membranes assemble in the ab-
sence of perlecan and appear morpholo-
gically normal. A likely explanation 
for this finding is that other HSPGs 
substitute for the loss of perlecan. A 
possible candidate could be agrin, which 
is present in most (if not all) basement 
membranes and which is also able to 
bind growth factors.
 Agrin induces clustering of acetyl-
choline receptors and acetylcholine es-
terases at the postsynaptic membrane 
of neuromuscular junctions. It has been 
shown to be distributed in basement 
membranes of numerous cells. The 220-
250 kDa agrin core protein contains two 
GAG attachment sites. In addition to its 
HS chains, agrin also contains O-linked 
glycans in its mucin region and N-linked 
glycans, which bind to other proteins 
including collagen type IV, several iso-
forms of laminin, and tenascin. Agrin 
may interact with carbohydrates, which 
may affect its activity. In the lung, agrin 
has been found in alveolar basement 
membranes 12.
 Collagen XVIII is a basement mem-
brane component with the structural 
properties of both a collagen and a 
proteoglycan. It is in fact the only cur-
rently known collagen that carries HS 
chains 13. Proteolytic cleavage within the 
C-terminal domain releases a fragment, 
endostatin, which has been reported to 
have anti-angiogenesis effects 14.
Figure 2. Highly schematic representation of HSPG core proteins, containing HS and/or CS side chains.
Shown are the four isoforms of syndecan, two (out of six) isoforms of glypican, three isoforms
of CD44 and betaglycan. The three major basement membrane-associated HSPGs, viz: perlecan,
collagen XVIII and agrin are also shown.
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Collagen XVIII is generally present in 
epithelia and endothelia, including the 
basement membranes of the lung, retina, 
epidermis, pia, cardiac and striated 
muscle, kidney, and blood vessels 15, 16. 
 Two main types of cell surface-bound 
proteoglycan core proteins have been 
identified: the glycosylphosphatidylino-
sitol-linked glypicans and secondly the 
transmembrane syndecans (Figure 2). In 
the lung both glypicans and syndecans 
are more densely arranged along the 
alveolar than the capillary surface 17. 
 Whereas glypicans are linked to 
the cell surface, the syndecans are 
a family of highly conserved type
I transmembrane HSPGs that are ex-
pressed in a developmental and cell type-
specific pattern. Syndecans comprise 
a family of molecules consisting of 
four members 18-22. They are highly 
expressed at basolateral surfaces of 
vascular endothelial cells 23, are variably 
expressed by smooth muscle cells, and 
can also be found in all layers of the 
the intima, the media and the adventitia 
24-27. The majority of GAGs added to 
syndecan core proteins are of the HS 
type, but syndecan-1 and syndecan-
4 may also contain CS 28. Biological 
activity, however, depends largely on 
the HS moiety 29. Syndecan isoforms 
are expressed in distinct cell-, tissue- 
and development-specific patterns. Syn-
decan-1 expression has been reported to 
be high in lung airway epithelia and skin 
30, 31. In the lung, matrilysin-mediated 
shedding of syndecan-1 is involved in 
directing neutrophil influx to sites of 
injury 32. 
 CD44 is, like syndecans, a widely 
distributed type I transmembrane glyco-
protein 33, 34 (Figure 2). It can carry 
either CS and/or HS side chains and is 
upregulated on many activated/diseased 
cells. CD44 is also known as a ‘part time’ 
proteoglycan, as its glycanation sites are 
not always occupied with GAG chains. 
Splicing may result in isoforms that 
lack transmembrane and cytoplasmic 
domains, thus yielding secreted, soluble 
CD44 35. In the lung, CD44 is present on 
parenchymal cells like fibroblasts and 
epithelial cells. A role for CD44 in lung 
pathology has also been demonstrated. 
In patients with diffuse panbronchiolitis 
(DPB), a disease characterized by chronic 
inflammation of respiratory bronchioles, 
alveolar macrophage dysfunction may 
result from abnormalities of CD44 
expression which could contribute to the 
pathogenesis of DPB 36. In addition, an 
impressive role for CD44 was reported in 
allergic eosinophilic airway inflammation 
(experimental asthma) 37. 
 Betaglycan, a transmembrane CS/ 
HSPG, is a major TGF-β binding mole-
cule on most cell types 38 (Figure 2). 
The GAG chains of betaglycan are not 
necessary for expression at the cell 
surface, or for the binding of TGF-β 39. 
Binding of betaglycan with FGF increases 
the affinity of FGF’s to cell receptors, 
and protects FGFs from proteolysis 40.
 
HS has important functions in a variety 
of developmental, morphogenetic, and 
pathogenetic processes. The specificities 
of the interactions between HS and its 
protein ligands are thought to be due, at 
least in part, to the fine structure of HS 
characterized by the specific sulfation 
patterns and the hexuronic acid isoform 
residues (Figure 4) 41-44. The divergent 
fine structures of HS are generated in the 
Golgi apparatus through the coordinate 
actions of HS modification enzymes. 
Heparan sulfate biosynthesis
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Biosynthesis of HS begins with the 
addition of xylose to selected serine 
residues in proteoglycan core proteins. 
Subsequently, two Gal units and a GlcA 
residue are added by three distinct 
glycosyltransferases 41, 42. This linkage 
region is common to HS/heparin but also 
to CS chains, and in part explains why 
many HSPGs can also carry CS chains. 
After the formation of the linkage region, 
the HS backbone is synthesized by a set 
of glycosyltransferases belonging to the 
EXT gene family (exostosin proteins 
EXT1, EXT2, EXTL1, EXTL2 and 
EXTL3). The backbone is then modified 
by a semi-ordered series of reactions, 
which generate distinct HS motifs. During 
polymerization of the HS chain, HS N-
deacetylase/N-sulfotransferase (NDST) 
deacetylates and N-sulfates subsets of 
N-acetylglucosamine residues of the 
growing polymer 45, 46, Figure 4. Four 
NDST isoforms have been identified 43, 47, 
48. NDST-1 and the less abundant NDST-
2 are widely expressed in a variety of 
tissues 45, 46, 49, 50, whereas NDST-3 and 
NDST-4 are restrictively expressed. The
subsequent modification step is C-5 
epimerization of GlcA to IdoA by the 
enzyme D-glucuronyl C5-epimerase 50, 51. 
No isoforms of this enzyme are known. 
Next, O-sulfation occurs at various posi-
tions (C-2, C-3, and C-6) by different 
sulfotransferases. For 3-O-sulfation, the 
rarest modification in HS biosynthesis, at 
least seven related sulfotransferases exist 
52, 53. For 6-O-sulfation, three isoenzymes 
are known, whereas 2-O-sulfation is me-
diated by only one enzyme. 
 The HS modification reactions are
generally incomplete, resulting in HS
molecules displaying a domain-type
arrangement of highly modified sac-
charide sequences alternating with re-
gions having a low density of mo-
dification (Figure 4). Information about 
HS domain structures in the lung is 
sparse. HS is very diverse with respect 
to sulfation 54-56, indicating a large 
heterogeneity with respect to domain and 
motif structure. The alveolar basement 
membrane beneath type I cells is highly 
sulfated compared to those beneath 
type II cells 57, 58. This difference is 
Figure 3. Heparan sulfate binds FGF-2 and 
VEGF in human lung tissue. Non-treated (a1–c1) 
and heparinase III–treated (a2–c2) cryosections 
of human lung parenchyma were incubated with 
an antibody to FGF-2 (bFGF) (a, b) or VEGF (c). 
Heparinase III removes HS from the sections. 
Sections b and c were pretreated with 20 μg/ml 
recombinant FGF-2 and VEGF respectively, before 
incubation with an antibody to FGF-2 or VEGF. 
Heparinase III treatment removed endogenous 
FGF-2 (a2), and reduced binding of recombinant 
FGF-2 and recombinant VEGF to sections (b2, 
c2). Scale bar: 50 μm (Reproduced and adapted 
with permission from Smits et al. 2004).
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Figure 4. Biosynthesis of heparan sulfate. In heparan sulfate (HS) biosynthesis N-deacetylase/N-
sulfotransferase (NDST) enzymes are responsible for the first modification step. N-deacetylation and N-
sulfation of GlcNAc, has an important function, since the remaining N-acetylated regions will largely escape 
subsequent modifications. The N-sulfated regions are subject to additional modification steps at various 
positions, including C-5 epimerization of glucuronic acid (GlcA) to IdoA (by C5-epimerase), and O-sulfation. 
The various O-sulfotransferases include: 2-O-sulfotransferase (2-O-sulfation of iduronic acid (IdoA) and 
GlcA); 6-O-sulfotransferase (6-O-sulfation of N-acetyl/-sulfo-glucosamine), and 3-O-sulfotransferase (3-
O-sulfation of N-unsubstituted/sulfo-glucosamine). The formation of the N-unsubstituted glucosamine is 
possibly due to an incomplete N-deacetylation/N-sulfation reaction (Reprinted with permission from Esko 
JD, Selleck JB, 2002). 
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mainly due to the presence of HSPGs as 
shown histochemically by differential 
enzymatic digestions 57, 58. Using phage 
display-derived antibodies against lung 
HS, the location of structurally different 
HS chains has been demonstrated 
(Figure 5) 8. Substrata containing CS 
and heparin with different degrees of 
sulfation modulate the response of al-
veolar type II cells in vitro to growth 
factors including FGF-1, -2 and -7, and 
(highly sulfated) heparin seems to reduce 
responsiveness to FGF’s 59, 60. Highly sul-
fated proteoglycans modified by NDSTs 
are responsible for the spreading of cells 
during transdifferentiation of type II cells 
to mature type I cells 61. 
Heparan sulfate and lung development/
pathology
The generation of knockout mice for 
various proteoglycan core proteins and 
proteins involved in the biosynthesis 
of HS has added significantly to our 
understanding of the physiological role 
of HS 62. Due to their capacity to bind 
a diverse set of proteins (Table 2), HS/
heparin present in the ECM and on cell 
surfaces has been implicated in many 
cellular processes such as angiogenesis, 
cell proliferation and differentiation, 
cell adhesion, metastasis, tumor growth, 
tissue repair, and protein expression.
 Specific HS modifications have been 
linked to binding/modulation of ligands. 
For example, FGF-2 requires N- and 2-
O-sulfates for binding. The 6-O-sulfate 
group is not essential for binding of 
FGF-2, but is critical for activation of the 
FGF-receptor. Activation of antithrombin 
by HS/heparin is mediated by a specific 
pentasaccharide in which an internal 3-O-
sulfate and an adjacent 6-O-sulfate group 
are crucial 23. The necessity for the correct 
complement of enzymes to generate these 
specific HS domains at various stages of 
development is becoming apparent from 
studies of biosynthetic enzyme mutants. 
 Interestingly, mice deficient in one of 
the enzymes involved in HS biosynthesis 
have abnormal phenotypes. Despite 
the fact that the defects observed are 
characteristic of the missing/mutated 
enzyme, significant overlapping lung 
phenotypes have been observed for some 
HS mutants (Table 3). Mouse embryos 
carrying a homozygous deletion of the 
gene Ext1 lack an organized mesoderm 
and extra embryonic tissues, and die at 
the gastrulation stage 63. Inactivation of 
Ext1 abolishes the production of HS, 
illustrating the importance of Ext genes 
in HS synthesis. Loss of Ext2 results in 
early embryonic lethality 64. The lack of 
Ext2 leads to a gastrulation defect and 
abnormalities in the formation of extra-
embryonic structures. 
 NDST-1 deficient mice have under-
sulfated HS in which N-sulfation and 
2-O-sulfation are reduced, but in which 
6-O-sulfation seems normal 65. Null mice 
experience severe respiratory difficulties 
as judged from their gasping breath 
and skin color. They die shortly after 
birth due to respiratory failure caused 
by immaturity of type II pneumocytes, 
which results in insufficient production 
of surfactant 65, 66. 
 The lack of NDST-2 in mice does not 
affect normal life span and fertility, but 
NDST-2 deficient mice display severe 
mast cell defects, caused by a complete 
lack of heparin. Surprisingly, they show 
no obvious HS defects 67, 68. The lack of 
HS defects in NDST-2 deficient mice 
indicates that other isoforms of NDSTs 
are more important in HS biosynthesis or 
that these isoforms are able to compensate 
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for the lack of NDST-2. 
 Mice deficient in NDST-3 are fertile 
and show subtle changes in their behavior 
and in some hematological parameters 
69. In the adult brain, a region-specific 
activity of NDST-3 could be detected 
leading to changes in HS sulfation. 
However, no significant overall changes 
in HS sulfation and no obvious lung 
defects could be detected. In addition, 
mice that are deficient in both NDST-
1 and NDST-3 have a complete lack of 
disulfated disaccharide products 69. 
 Targeted disruption of D-glucuronyl 
C5-epimerase gene results in mouse 
embryos with GlcA but no IdoA residues 
and a highly distorted sulfation pattern, 
including a strong reduction of 2-O-
sulfation 70. Lungs of mutant mice are
immature and poorly inflated with thicke-
ned, cell-rich interalveolar septa. Not sur-
prising, the corresponding phenotype is 
Reprinted with permission from Esko JD, and Selleck JB, 2002
Table 2: Glycosaminoglycan-binding proteins (partial list)
- Chemokines 
 CXC chemokines, CC chemokines 
- Enzymes 
 Elastase 
 Lipoprotein lipase 
Superoxide dismutase 
Thrombin 
- Enzyme inhibitors 
 Antithrombin 
Heparin cofactor II 
Protein C inhibitor 
- Growth factors 
 Epidermal growth factors 
 Fibroblast growth factors 
 Hepatocyte growth factors 
 Platelet-derived growth factors 
 Transforming growth factors 
 Vascular endothelial growth factors 
- Growth factor-binding proteins 
 Follistatin 
 IGF binding proteins 
 TGF β binding proteins 
 FGF receptor 
- Nuclear proteins 
 Histones, transcription factors 
- Morphogens 
 Activin 
 Bone morphogenetic proteins 
 Sonic hedghehog 
 Sprouty peptides 
 Wnts 
- Cell adhesion molecules 
 Selectins, integrins, neural cell adhesion 
 molecules 
- Lipoproteins  
 Low and very low density lipoproteins 
 Apolipoproteins 
- Other proteins 
 Prion proteins 
 Amyloid proteins 
 Fibrin 
 Ion channels 
- Extracellular matrix proteins 
 Collagens, fibrillins 
 Fibronectin, laminin 
 Thrombospondin, vitronectin 
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lethal. 
 Mice homozygous for a gene trap 
mutation that disrupts the gene encoding 
HS 2-O-sulfotransferase (HS2ST) exhibit 
bilateral renal agenesis, resulting from 
a failure of ureteric bud branching and 
mesenchymal condensation. They show 
defects of the eye and skeleton 71, but no 
obvious lung defects.
 HS6ST-1 (HS 6-O-sulfotransferase-
1) deficient mice exhibit increased neo-
natal lethality, decreased growth and 
show aberrant lung morphology 72. In 
another study 73, morphological and 
marker analysis of lungs of null mice at 
birth reveal no obvious changes in cellular 
profile, architecture, or expression of 
differentiation markers. However, adult 
mice show enlargement of the airspaces 
suggesting that 6-O-sulfation of HS is 
essential for homeostasis of alveoli. 
Airspace enlargement was associated 
with fragmented and irregularly de-
posited elastin in alveoli, a feature sug-
gestive of pulmonary emphysema. The 
formation of lung alveoli is known to 
be regulated by Wnt5a, FGF-10, and 
BMP4, which bind to HS/heparin. 
HS6ST-1 is expressed strongly at the tips 
of branching tubules in the developing 
lung 74 and FGF-10 is preferentially 
bound to 6-O-sulfate residues rather than 
2-O-sulfate residues in HS. A deficiency 
in HS6ST-1 is potentially relevant to 
impaired lung development. Decreased 
6-O-sulfation may affect the signaling of 
growth factors and ECM proteins in the 
lung which impact alveolarization. 
 Mice deficient in HS 3-O-sulfo-
transferase-1 (HS3ST-1) are seemingly 
healthy, but develop several unanticipated 
abnormalities. These include spontaneous 
eye degeneration, aberrant cardiovascular 
response to anesthesia, reduced male and 
female fertility, postnatal lethality and 
intrauterine growth retardation 75. 
 Recently, a novel family of glu-
cosamine-6-sulfatases has been iden-
tified 76-79. Sulf1 and Sulf2 are members 
of (extracellular) 6-O-endosulfatases and
remove 6-O-sulfates from HS 76. Homo-
zygous mice with a gene trap disruption 
of the Sulf2 gene display strain-speci-
fic defects in viability, growth and lung 
development. A number of the Sulf2 
homozygotes display lung-related defects 
as can be judged from their breathing 
difficulties and enlarged airspaces 80. It 
Figure 5. Immunostaining for different heparan 
sulfate domains in human lung parenchyma 
using phage display-derived single chain 
antibodies. A: staining with single chain antibody 
EV3C3, which recognizes heparan sulfate 
domains characterized by N- and 2-O-sulfation, 
C-5 epimerization, but which is inhibited by 6-O-
sulfation. B: Phase contrast image of section used 
in a. C: staining with single chain antibody HS4C3, 
which shows high affinity for N-, 2-, 3-, and 6-O- 
sulfated heparan sulfate domains. D: antibody 
staining of section after pre-treatment with heparin-
ase III which removes heparan sulfates.
Note that the two antibodies stain different areas 
in human lung parenchyma, EV3C3 primarily re-
acting with basement membranes in the alveolus, 
HS4C3 primarily reacting with small blood vessels.
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should be noted here, that lung phenotypes 
observed in mice defective in HS bio-
synthetic enzymes are likely the result 
of a disturbed lung development and that 
the airspace enlargements observed may 
be due to defects in (secondary) septation 
that gives rise to formation of alveoli. 
Mutations in the core proteins them- 
selves can also lead to lung defects. 
For example, glypican-3 deficient mice 
exhibit developmental overgrowth, cys-
tic and dysplastic kidneys, and defective 
lung development 81. They often develop 
respiratory infections with high fre-
quency. Interestingly, lungs from null 
mice were found to be disproportionally 
heavy at time of birth, weighing about 
28% more than their normal littermates. 
This disproportionate overgrowth is on-
ly evident in newborn mice and might 
be due to the accumulation of debris 
observed in the lungs after birth. 
 Although many knock out models, 
deficient in enzymes involved in HS 
biosynthesis, have been developed, the 
Given are HS mutants with an obvious lung phenotype. It should be noted that other HS mutants exist, but 
no obvious lung phenotype has been reported. Reproduced with permission.
Table 3: Pulmonary phenotypes in mice lacking a specific HS biosynthetic enzyme 
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lungs are generally overlooked and not 
studied at great length. A more detailed 
analysis of mouse models will very likely 
reveal more subtle phenotypes, some of 
which may be related to lung pathology. 
The construction of conditionally and 
lung-specific knock out models will allow 
for a better understanding of the complex 
in vivo roles of HS in lung pathology.
HS binds and modulates various classes 
of proteins which are involved in the 
pathogenesis of emphysema. These in-
clude proteases and protease inhibitors 
(protease anti-protease hypothesis 82, 83),
enzymes involved in neutralizing reac-
tive oxygen species like superoxide 
dismutase 84 and xanthine oxidase 85, 86,
chemokines (emphysema as a immuno-
logical disorder hypothesis 87), and growth
factors/cytokines (aberrant tissue repair 
hypothesis 88).
 HS forms fulfill many functions that 
may relate them to the pathogenesis of 
emphysema. They:
a)
b)
c)
d)
e)
f)
Alterations in proteoglycan/GAG struc-
ture and/or content have been observed 
in lung tissue derived from both patients 
with emphysema and animal models,
although results tend to be contradictory 
100-104. In urine samples of emphysematous 
patients a decrease of a specific HS epi-
tope has been noticed 105, and in lung tissue 
from patients with severe emphysema a 
diminished staining for HSPG as well 
as for the interstitial proteoglycans de-
corin and biglycan has been reported 
106. HS is prone to depolymerization by 
reactive oxygen and nitrogen species like 
hydroxyl radicals 107, and nitric oxide 108, 
and the level of HS/GAG is compromised 
by toxic levels of oxygen 109.
 HSPGs have also been implicated 
in the pathogenesis of emphysema in 
mammalian models. Specific inhibition 
of proteoglycan synthesis induces em-
physematous lesions in rats 110. In elas-
tase-induced emphysema in rats, HS 
is readily removed from the lungs by 
degradation of the protein core of HSPGs 
111. As a consequence the protective pro-
tease (elastase) inhibiting capacity of HS 
may be lost 96, 97. For elastase-induced 
emphysema in rats, the only long-term 
disturbance was a decrease in the HS/
collagen ratio and the HS/elastin ratio 
112.
Taken together, data indicate that HS 
plays a crucial role in the homeostasis of 
the lung, especially in the parenchymal 
tissue. HS is compromised in emphysema, 
and (given the multiple functions as-
cribed to this GAG) may lead to a major
disturbance in the coordination of ef-
fector molecules ranging from growth 
factors and morphogens to proteases and 
matrix molecules, thus compromising 
orderly tissue repair and regeneration, 
cumulating in the development of em-
physematous lesions. Studies on HS in 
the lung pathology, however, are scarce, 
and primarily due to a lack of appropriate 
Heparan sulfate and pulmonary 
emphysema
are involved in the fibrillogenesis of 
collagen and elastin 89-92 
offer protection against proteolysis of 
collagen and elastin 93, 94 
posses anti-protease activity (e.g., 
anti-elastase, anti-cathepsin) 95-98
bind and modulate growth factors/
cytokines 
have a high water-binding capacity
providing resilience to the alveolar 
wall 99
are able to inhibit neutrophil function
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tools to study them. New tools are now 
entering the field, including antibodies 
defining specific HS domains 8, 113-116, 
sequencing techniques to establish the 
monosaccharide sequence of HS 117, 118, 
and new ways to chemically synthesize 
defined HS oligosaccharides 119. This 
new armamentarium may spark new 
avenues of research into the role of 
GAGs in general, and HS in particular, 
in the lung. Future discoveries may be 
especially rewarding with respect to the 
development of new therapeutics to fight 
emphysema. The therapeutic potential 
of GAGs and HS was already indicated 
at the end of last century when it was 
shown that heparin (= highly sulfated 
HS) and sulfated polysaccharides could 
prevent elastase-induced emphysema in 
mice and hamsters 96, 120-122. Recently, the 
protective role of aerosolized hyaluronan 
against elastase-induced or smoke-in-
duced lung damage including airspace 
enlargement has been reported 123. 
Clearly, the exploration of the intriguing 
field of lung glycobiology has only just 
begun.
In the research towards the ECM of the 
lung and its involvement in the patho-
genesis of emphysema, proteoglycans 
have been studied. However, these stu-
dies primarily focused on the protein
core, largely ignoring the GAG moiety
of the proteoglycans. Investigating the 
role of GAGs has long been hampered 
by the lack of appropriate tools, e.g., 
antibodies. The aim underlying the study 
described in this thesis was to isolate 
HS from human lung, to generate highly 
specific antibodies against human lung 
HS by means of phage display technology, 
as well as to investigate the distribution 
of these HS epitopes in human lung. In 
addition, the involvement of HS in the 
pathogenesis of emphysema has been 
addressed. An overview of the present 
knowledge concerning GAGs in the lung 
is given in Chapter 1. In Chapter 2 a 
description is given of the use of phage 
display technology to generate and select 
antibodies against human GAG epitopes. 
Phage display technology was used to 
select 7 unique antibodies against human 
lung HS, as described in Chapter 3. These 
novel antibodies were used to evaluate 
the expression of distinct HS epitopes in 
human lung tissue. Chapter 4 deals with 
the unraveling of the monosaccharide 
sequence recognized by phage display-
derived antibody, NS4F5. Special at-
tention is given to the characterization 
of the HS sequence which was (GlcNS-
6S-IdoA2S)3. In Chapter 5, lung tissue 
from subjects with microscopical em-
physema was used to demonstrate that
heparanase expression and loss of HS in
the lung are early events in the develop-
ment of emphysema. In Chapter 6, focus 
is on fibrillin-1, a major component of 
the microfibrillar part of elastic fibers, 
another important player in the onset 
of pulmonary emphysema. Chapter 7 
concludes this thesis with a summary as 
well as indications for future research.
Aim and outline of this thesis
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lycosaminoglycans (GAGs) are long unbranched polysaccharides, most of which are linked 
to a core protein to form proteoglycans. Depending on the nature of their backbone, one 
can discern galactosaminoglycans (chondroitin sulfate (CS), and dermatan sulfate (DS)) 
and glucosaminoglycans (heparan sulfate (HS), heparin, hyaluronic acid, and keratan 
sulfate). Modification of the backbone by sulfation, deacetylation, and epimerization results 
in unique sequences within GAG molecules which are instrumental in the binding of a large 
number of proteins. Investigating the exact roles of GAGs has long been hampered by 
the lack of appropriate tools. In recent years, we have successfully implemented phage 
display technology to generate a large panel of antibodies against CS, DS, HS, and heparin 
epitopes. These antibodies provide unique and highly versatile tools to study the topography, 
structure and function of specific GAG domains. In this chapter, we describe the selection, 
characterization, and application of antibodies against specific GAG epitopes. 
G
Antibodies are widely used in the research
on proteoglycans. They have been applied
to evaluate proteoglycan expression pat-
terns in a variety of tissues in health 
and disease, and have also been used 
as (immuno) precipitating agents. Most 
of the antibodies available to date are 
directed against the core protein of 
proteoglycans. Only a few antibodies that 
are reactive with the glycosaminoglycan 
(GAG) moiety have been described 1-
5. However, these were all generated 
using proteoglycans rather than isolated 
GAGs. 
 As stated earlier, investigating the 
biological role of GAGs has long been 
hampered by the lack of appropriate 
tools. Using phage display technology we 
have generated a large panel of epitope-
specific antibodies against heparan sul-
fate (HS), heparin, chondroitin sulfate 
(CS), and dermatan sulfate (DS) 6-10 (Table 
1). Characterization of the GAGs bound 
by the antibodies revealed that specific 
modification patterns are recognized 10, 
11. For instance, one specific antibody 
against HS requires 3-O-sulfates and 
recognizes an epitope that resembles the 
antithrombin-III binding pentasaccharide 
sequence 1. A variety of anti-GAG anti-
bodies was used to study the distribution 
of GAG epitopes in spleen 2, lung 3, 
kidney 15, and skeletal muscle 4. GAG-
specific antibodies were also used to 
study changes in expression pattern in 
diseased versus healthy tissue, especially 
melanoma and psoriasis 8, 17. Next to 
immunohistochemical evaluation, anti-
bodies were applied to analyze the bio-
logical function of GAGs e.g., growth 
factor binding. The endogenous ex-
pression of anti-HS antibodies resulted 
in the functional knockout of specific HS 
epitopes, which was shown to interfere 
with ion housekeeping in skeletal muscle 
cells 5. Our panel of antibodies thus 
provides a unique and highly versatile 
tool to study the topography, structure, 
and function of GAGs. Here, we describe 
the selection, and evaluation of single-
chain variable fragment (scFv) antibodies 
against specific GAG epitopes. 
One of the most successful applications 
of phage display has been the selection 
of specific antibodies from phage display
libraries 19-21. DNA’s encoding antibodies 
Phage display
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are cloned into a suitable vector as a 
fusion to the gene encoding one of the 
phage coat proteins (pIII, pVI, or pVIII). 
Upon assembly in bacteria, the antibody-
coat protein fusion will be part of the 
surface of the phage, thus ‘displaying’ 
the antibody. A phage display library 
is a large collection of phages, each 
displaying an individual antibody. 
Phage display allows for generation of 
antibodies against ‘self antigens’, which 
is favorable because GAGs are largely 
nonimmunogenic.
 The phage display system is illustra-
ted in Figure 1. First, the phage display 
library is incubated with the ‘antigen’ 
(GAGs) immobilized onto a tube. Phages
that display antibodies that are specific 
for the antigen will bind, nonadherent 
phages will be washed away. Phages 
expressing a specific anti-GAG antibody 
can then be recovered from the tube (e.g., 
by altering the pH), and multiplied by 
infection into bacteria. This biopanning 
procedure is repeated several times. Se-
lected phages are then analyzed for anti-
GAG antibodies by ELISA and immuno-
histochemistry (IHC).
 In principle, any phage display 
library can be used. In the protocol 
described here, a human semisynthetic 
library [Library no.1, 6] was used, con-
sisting of > 108 different clones, each 
expressing a unique antibody. The semi-
synthetic Library no.1 contains 50 dif-
ferent V
H 
genes combined with a single-
light chain gene (DPL16). In the library, 
variable parts of the heavy and light 
chains are joined to each other by a 
linker sequence to form so-called scFv. 
All antibodies contain a c-Myc tag for 
identification. Due to the use of an amber 
codon combined with a suppressor 
Escherichia coli (E. coli) strain, one can
easily produce soluble scFv antibodies 
from selected phage clones. 
 To rescue and amplify phages fol-
lowing selection, a helper phage is 
required to allow for phage assembly. 
VCS-M13 is a commonly used helper 
Table 1: Characteristics of different scFv antibodies
Given are the scFv antibody code, VH germ line gene family, DP gene segment number, amino acid sequence 
of the VH complementarity determining region 3 (CDR3), and the class of GAG with which the antibody reacts. 
Selection of the antibodies is described in the indicated reference. GAG, glycosaminoglycan; HS, heparan 
sulfate; CS, chondroitin sulfate; DS, dermatan sulfate. All scFv antibodies recognize specific epitopes as 
based on different staining patterns, and different reactivities toward various HS/CS/DS preparations. 
 
scFv VH DP Gene VH CDR3 Class of GAG Reference 
RB4EA12 
HS4C3 
EV3C3 
HS4E4 
AO4B08 
IO3H10 
LKN1 
MPB49 
3 
3 
3 
3 
3 
1 
1 
3 
32 
38 
42 
38 
47 
7 
25 
38 
RRYALDY 
GRRLKD 
GYRPRF 
HAPLRNTRTNT 
SLRMNGWRAHQ 
AKRLDW 
GIKL 
WRNDRQ 
HS 
HS 
HS 
HS 
HS 
CS 
DS 
- (control) 
(Jenniskens et al., 2000) 
(van Kuppevelt et al., 1998) 
(Smits et al., 2004) 
(Dennissen et al., 2002) 
(Jenniskens et al., 2000) 
(Smetsers et al., 2004) 
(Lensen et al., 2005) 
- 
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Figure 1. Schematic outline of the phage display technique. A library of phage-infected bacteria is grown 
and induced to produce phages expressing (‘displaying’) scFv antibody fragments on their surface (A). 
Phages are isolated (B) and used for selection (‘panning’; C) against glycosaminoglycans (GAGs), which are 
immobilized onto the surface of a selection tube. Non-binding phages are washed away, whereas phages 
displaying antibodies that are reactive with GAGs stay bound to the tube. Thus, the library becomes enriched 
for phages displaying GAG-reactive antibodies. Selected phages are harvested (D), allowed to infect a fresh 
Escherichia coli culture, and used for another round of panning (A-D). Individual clones can be isolated after 
four rounds of panning. 
Insert top left: schematic representation of the phagemid encoding antibody-expressing phages. At the 
bottom a three-dimensional model of a scFv antibody showing the light and heavy chain (ribbon) and the 
CDR3 region is depicted (space filling). CDR3, complementarity determining region 3.
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  in 985 ml H2O; dissolve and autoclave. 
 Cool the solution to 60°C and add 
 500 µl of 20% MgSO4, 0.5 ml of 1%
 B1 (thiamine HCl, filter-sterilized 0.2
 µm) and 5 ml 40% glucose (filter-
 sterilized 0.2 µm). Mix gently and 
 pour into Petri dishes. (Plates are
 stored at 4°C).
0.1M NaOH/1% (w/v) sodium dodecyl-
 sulfate (SDS).
Phosphate-buffered saline (PBS) 
20% (w/v) polyethylene glycol 6000 
 (PEG)/2.5M NaCl
Tris/EDTA (TE) buffer: 10mM Tris-HCl,
 pH 8.0 and 1mM EDTA, pH 8.0
1M Tris-HCl, pH 7.4
2 × TY medium
2 × TY medium containing 100 µg/ml
 ampicillin and 1% glucose
TYE plates: 10 g/l peptone, 5 g/l Bacto-
 yeast extract, 8 g/l NaCl, 15 g/l Bacto- 
 Agar in H2O; dissolve, bring the volume
 to 1 l, and autoclave. Cool the solution
 to 60°C and add 1 ml of 100 mg/ml
 ampicillin and 25 ml of 40% glucose
 to achieve final concentrations of 100
 µg/ml ampicillin and 1% glucose.
 Mix gently and pour into Petri dishes.
 (Plates are stored at 4°C).
Day 1
1. Streak E. coli TG1 cells from a gly-
 cerol stock on a minimal media
 agar plate and incubate o/n at 37°C.
  Do not use antibiotics; E. coli TG1 
 has no antibiotic resistance genes.
Day 2
phage that bears the kanamycin-resistance 
gene, which, along with the ampicillin-
resistance gene carried by compatible 
phagemids, enables the selection of cells 
that contain both the helper phage and the 
phagemid. Helper phages usually have a 
defective origin of replication 7, which 
allows the preferential packaging of the 
phagemid DNA over the helper phage 
DNA and results in a greater output of 
phagemid phage over helper phage. This 
is especially important during selection, 
because only the phagemid contains the 
DNA encoding the antibody of interest.
Bacterial strain: E. coli TG1 suppressor
 strain (K12, supE, hsd∆5, thi, ∆[lac-
 proAB], F’[traD36, proAB+, lacIq, 
 lac-Z∆M15])1
Ampicillin (100 mg/ml)
H-top agar: 10 g/l peptone, 8 g/l NaCl,
 8 g/l Bacto-Agar in H2O; dissolve,
 bring the volume to 1 l with H2O.
 Autoclave and store at 4°C. Melt in a
 microwave before use.
H-bottom plates: 10 g/l peptone, 8 g/l NaCl,
 15 g/l Bacto-Agar in H2O; dissolve, 
 bring the volume to 1 l with H2O and
 autoclave. Mix gently and pour into 
 Petri dishes. (Plates are stored at 4°C).
Kanamycin (25 mg/ml)
Minimal media agar plates: 15 g/l Bacto-
 Agar, 10.5 g/l K2HPO4, 4.5 g/l KH2PO4,
 1 g/l (NH4)2SO4, 0.5 g/l sodium citrate
1 E. coli TG1 is a T-phage-resistant strain that harbors a mutated tRNA gene. The mutated tRNA will suppress the UAG 
amber (stop codon). To allow expression of scFv-pIII fusion protein on the phage tip, the amber codon will be substituted 
by a glutamine.
Preparation of helper phage VCS-M13
Solutions
Materials
Methods
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1. Inoculate 5 ml 2 × TY medium con-
 taining 1% glucose with a single co-
 lony of E. coli TG1 cells from the
 minimal media agar plate and incu-
 bate o/n at 37°C.
Day 3
1. Inoculate 50 ml 2 × TY medium con-
 taining 1% glucose with 500 µl of 
 the o/n culture. Grow the culture, 
 while shaking, at 37°C until an absor-
 bance at 600 nm of 0.4-0.5 is reached.
2. Prepare 10-6, 10-7, and 10-8 dilutions of
 the commercially obtained VCS-M13 
 preparation (usually in the range of
 1 × 1011 plaque-forming units [pfu]/ml
 in 2 × TY medium containing 1%
 glucose. Add 10 µl of these dilutions
 to 200 µl E. coli TG1 cultures (Day 3;
 step 1). 
3. Incubate for 30 min at 37°C, without
 shaking, to allow for infection of
 E. coli cells with helper phage.
4. Add 3 ml of liquefied H-top agar
 (not warmer than 50°C) to the infected 
 culture, mix gently, and pour onto H-
 bottom plates that have been pre-
 warmed to 37°C. Incubate o/n at
 37°C. The aim is to obtain a plate
 from which single VCS-M13 plaques
 can be picked easily (i.e., E. coli co-
 lonies that are growing slower be-
 cause of infection with VCS-M13).
5. Determine the titer of the VCS-M13
 phages from the number of plaques. 
6. Separately, inoculate 5 ml 2 × TY me-
 dium containing 1% glucose with a
 single colony of E. coli TG1 cells
 from the minimal media agar plate 
 (Day 1; step 1) and grow o/n at 37°C.
Day 4
1. Inoculate 50 ml 2 × TY medium con-
 taining 1% glucose with 500 µl 
 of the o/n culture (Day 3; step 5).
 Grow the culture, while shaking, at 
 37°C until an absorbance at 600 nm 
 of 0.4-0.5 is reached. (When necessary,
 the E. coli culture can be kept on ice 
 before infection for a moment. How-
 ever, do not exceed 30 min because
 of the loss of F-pili).
2. Transfer a single VCS-M13 plaque 
 from the H-bottom plate (Day 3; 
 step 4) to 4 ml of the E. coli culture
 (step 1) and incubate, while shaking,
 for 2 h at 37°C (phage infection). 
3. Transfer the infected 4 ml culture to a 
 2-liter Erlenmeyer flask containing
 500 ml of prewarmed 2 × TY medium
 and grow the culture, while shaking,
 for 1 h at 37°C.
4. Add 1.2 ml of 25 mg/ml kanamycin 
 to a final concentration of 60 µg/ml 
 and grow, while shaking, o/n at 37°C.
Day 5
1. Cool the culture (Day 4; step 4) on
 ice for 20 min.
2. Collect the bacteria by centrifugation
 at 5,000g for 10 min at 4°C (after
 centrifugation phages are present in
 the supernatant!).
3. Add 100 ml of ice-cold PEG-NaCl
 to the phage supernatant, mix gently,
 and incubate on ice for 1 h. In this
 step, phages are precipitated.
4. Pellet the phages at 10,000g for 30
 min at 4°C.
5. Resuspend the phage pellet in 40 ml 
 H2O. Transfer the solution to a 50-ml 
 tube and add 8 ml of ice-cold PEG-
 NaCl. Mix well and incubate on ice
 for 20 min.
6. Centrifuge the phage solution at 
 10,000g for 30 min at 4°C. Decant
 the supernatant, centrifuge briefly, and
 remove residual PEG-NaCl with a
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  capillary. 
7.  Resuspend the phage pellet in 2.5 ml 
  TE buffer and centrifuge at 10,000g.
8.  Wet a 0.45 disposable filter with TE 
  buffer and filter the phage solution to 
  remove any remaining bacterial de-
  bris. Note that it can be difficult to
  filter the phage solution and that this
  step may result in the loss of phages
  that remain in the filter. 
9.  Titrate the phages to 10-12 pfu/ml.
10.  Store the phage solution at 4°C (up
  to 5 days).
Panning methodology (Figure 1, Table 
2) involves the physical contact of the 
phage display library with the antigen (in 
this case GAGs), and can be regarded as 
an affinity selection system. In practice, 
a small volume containing the phage 
display library is incubated with the 
antigen immobilized to a tube. Panning 
consists of several rounds of binding 
phages to the immobilized GAGs, a 
defined number of washing steps, and 
elution of the bound phages by altering 
the pH. Eluted phages are subjected 
to another round of panning. During 
each round of panning specific binding 
clones are selected and amplified so they 
predominate after three to four rounds of 
panning. The input of each round should 
be in the range of 1012 phages.
Bacterial strain: E. coli HB2151 non-
 suppressor strain (K12, ara, thi, ∆[lac-
 pro], F’[proAB+, lacIq, Z∆M15]
Bacterial strain: E. coli TG1 suppressor
  strain (K12, supE, hsd∆5, thi, ∆(lac-
 proAB), F’(traD36, proAB+, lacIq,
 lac-Z∆M15))
Glycerol stock of the (semi)-synthetic
 scFv Library no.1 6 (Dr. G. Winter,
 MRC Centre for Protein Engineering, 
 Cambridge, UK), stored at -80°C
VCS-M13 helper phages2 used at a titer
 of 1 × 1012 pfu/ml (Stratagene) ( for
 large amounts see preparation of
 helper phage VCS-M13)
GAGs of interest: 10 mg/ml in H2O
PBS containing 0.1% (v/v) Tween-20
PBS containing 2% (w/v) Marvel (pre-
 pare freshly)
PBS containing 4% (w/v) Marvel (pre-
 pare freshly)
100mM triethlyamine (prepare freshly)
2 × TY containing 100 µg/ml ampicillin
 and 25 µg/ml kanamycin
Several precautions need to be taken 
to avoid carryover of phages during 
the selections. The use of sterile so-
lutions and disposable plastics is high-
ly recommended. Nondisposable plas-
tics should be soaked for 1 h in 2% (v/
v) hypochlorite, followed by thorough 
washing and autoclaving. Glassware 
should be baked for at least 6 h at 180°C. 
Always use aerosol-resistant pipette 
tips (Molecular Bio-Products) when 
working with phages. It is recommended 
to work in a laminar-flow cabinet. Clean 
2 VCS-M13 phages provide phage coat proteins and enzymes that are crucial for rescue of the phages.
Panning methodology
Selection of phages displaying specific 
antibodies against GAGs using panning 
methodology
Materials
Methods
Solutions
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Table 2: Time schedule of experiments described in this chapter
3 M13 phages infect F+ E. coli via sex pili. For optimal infection, E. coli needs to be in the log phase (absorbance of 0.4-0.5 
at 600 nm) at 37°C. When grown to a higher density, sex pili are lost very rapidly. A log phase culture can be held on ice 
for about 30 min. 
 
Day Activity Sections Notes 
Selection of antibodies using panning methodology 
1 Growth of phage library A.1.1-1.6 Inoculate original library or n + 1 generation 
(from section D.3.4); grow o/n at 37°C 
 Coating of selection tubes C.1.1  
 Inoculation of E. coli TG1 A.1.7  
2 Isolation of phages B.1.1-1.8 Phages are used for selection (see section 
C.2.2-2.11) 
 Preparation selection tube C.2.1 To be used for selection (see section C.2.2-
2.9) 
 Round of panning C.2.2-2.11  
3 Calculate titers C.3.1 Store plates; individual clones can be used to 
inoculate master plate (see section E.3.1) 
 Harvest phagemids D.3.2-3.5 Phagemids can be stored at -80°C or used for 
a next round of selection (see section A.1.1-
1.6) 
 Inoculation of master plate E.3.1 Stored as back up and used to inoculate 
induction plate (E.4.1-4.3) 
Screening for antibody-expressing clones 
4 Preparation of induction plate E.4.1-4.2  
 Storage of master plate E.4.3  
 Coat ELISA plate F.4.1 Coating of ELISA plates with the antigen that 
was used for selection 
5 ELISA screening F.5.1-5.10 Identification of active antibody-expressing 
clones 
 
Characterization and large-scale production of antibodies 
 
6 Streak individual clones G.6.1 Streak individual clones from master plate (see 
section E.4.3) 
7 Inoculation of o/n cultures G.7.1  
8 Production and isolation of 
antibodies 
G.8.1-8.8  
 DNA isolation and sequencing H.8.1-8.3 Identification and characterization of individual 
antibodies 
9 Aliquot and store antibodies G.9.1 Storage at 4°C (weeks) or at -20°C (months) 
 
Miscellaneous analytical techniques 
 Immunofluorescence analysis I Characterization of epitope occurrence 
 Direct ELISA analysis J.1 Characterization of epitopes 
 Competition ELISA analysis J.2 Characterization of epitopes 
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the workplace (bench tops, etc.) with 
0.1M NaOH/1% (w/v) SDS before and 
after each working day. Clean pipettes 
and other tools daily by wiping the 
outside with 0.1M NaOH/1% (w/v) 
SDS, followed by a rinse with water.
  For a schematic representation of the 
following steps see Figure 1.
1.1. Inoculate 50 ml of 2 × TY containing
  100 µg/ml ampicillin and 1% glucose 
  with 50 µl from a glycerol stock of 
  the scFv Library no.1 6.
1.2. Grow the culture, while shaking, at 
  37°C until an optical density at 600 
  nm of 0.5 is reached3. (This takes 
  about 2-3 h).
1.3. Transfer 10 ml of the culture to a 
  sterile 50-ml tube and add 50 µl 
  VCS-M13 helper phages4. The ratio 
  between bacteria and helper phages
  must be 1:20 (titer helper phages
  1012 pfu/ml).
1.4. Incubate at 37°C for 30 min without
  shaking (phage infection).
1.5. Centrifuge the infected culture at 
  4,000g for 10 min at room tem-
  perature. Decant the supernatant, and
  resuspend the pellet in 1 ml 2 × TY 
  containing 100 µg/ml ampicillin and 
  25 µg/ml kanamycin. 
1.6. Add the infected bacterial suspension 
  to 300 ml of prewarmed (30°C) 2 
  × TY containing 100 µg/ml ampicillin
  and 25 µg/ml kanamycin (no glu-
  cose5). Incubate o/n, while shaking, 
  at 30°C. This culture will be used in 
  section ‘B. Isolation of phages; step
  1.1.’.
Inoculate 10 ml of 2 × TY with a single
colony of E. coli TG1 from a minimal 
medium plate (do not use antibiotics) 
and grow o/n, while shaking, at 37°C.
This culture will be used in section ‘C: 
Selection of phages binding to GAGs; 
Day 2, step 2.8.’.
1.1. Cool the culture from section ‘A. 
  Growth of antibody phage display
  library; step 1.6.’ on ice for 10 min. 
1.2. Centrifuge the culture at 5,000g for
  15 min at 4°C. After centrifugation, 
  the bacterial pellet can be discarded 
  and the supernatant containing the 
  phages transferred into a sterile
  bucket. 
1.3. Add 60 ml of ice-cold PEG-NaCl
  to the supernatant to precipitate the
  phages6. Mix well by inverting, and
  leave the bucket on ice for 1 h. 
1.4. Pellet the phages at 10,000g for 30 
  min at 4°C. Resuspend the pellet in 40 
  ml of ice-cold sterile H2O. Transfer 
  the phage suspension to a 50-ml tube
  and add 8 ml of ice-cold PEG-NaCl.
4Take the remaining 40 ml of the culture, spin it down, and resuspend the pellet in 1 ml 2 ml 2 × TY. Spread it on TYE 
plates, and grow overnight at 37°C. Harvest the cells in 2 × 5 ml 2 × TY medium. Collect the cells in a 50-ml tube 
and centrifuge for 10 min at 10,000g. Resuspend the pellet in 500 μl of 2 × TY, add 500 μl of 60% glycerol to a final 
concentration of 30%, mix well, divide this stock in 50-μl aliquots, and store at -80°C as a back up for additional selections 
(this stock will be the n + 1 generation).
5 Glucose represses transcription of the scFv-pIII fusion protein through the Lac operon in the phagemid. 
6 In this step, phages are precipitated and concentrated. Given that the TG1 suppression of the amber codon is never 
complete, this step is also necessary for removing any soluble antibodies present in the supernatant. 
(A) Growth of antibody phage display library
(B) Isolation of phages
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  Mix well (as in the preceding step 
  1.3.) and leave on ice for 20 min.
1.5. Centrifuge the phage mixture at
  10,000g for 30 min at 4°C. Decant 
  the supernatant, centrifuge briefly,
  and remove residual PEG-NaCl with
  a capillary.
1.6. Resuspend the phage pellet in 
  2.5 ml PBS and centrifuge the phage
  solution at 10,000g for 5 min.
1.7. Wet a 0.45-µm disposable filter with 
  PBS and carefully filter the phage 
  solution to remove any remaining 
  bacterial debris. Note that it can be
  difficult to filter the phage solution.
1.8. This step may result in loss of
  phages that remain in the filter. 
1.9. Store the phage solution at 4°C
  until use. Phages will be used in
  section ‘C. Selection of phages bin-
  ding to GAGs; Day 2, step 2.2.’.
Day 1
1.1. Coat immunotubes with 3 ml of a 
  10 µg/ml solution of GAG of inte-
  rest and incubate o/n at room
  temperature, while rotating on an
  under-and-over turntable.
 
Day 2
2.1. Decant the GAG solution, wash the 
  tube three times with PBS and block 
  the tube with PBS containing 2% 
  (w/v) Marvel to avoid nonspecific
  binding of phages to the surface of
  the tube. Fill the tube to the edge, 
  cover it with Parafilm, and incubate 
  for at least 2 h at room temperature 
  on an under-and-over turntable. This 
  step should be performed early in the 
  day so the tube will be ready when
  the phages used for biopanning
  are obtained (section B. ‘Isolation of
  phages, step 1.8’).
2.2. Empty the tube and add 2 ml of
  PBS containing 4% Marvel and 2 ml 
  of phage supernatant from step 1.8
  in section ‘B: ‘Isolation of phages’, 
  cover the tube, and incubate for 1 h 
  on an under-and-over turntable at 
  room temperature, followed by stan-
  ding for 1 h.
2.3. Discard the phage suspension and
  wash the tube 20 times with PBS 
  containing 0.1% (v/v) Tween-20. 
  After the last wash, fill the tube 
  with PBS containing 0.1% (v/v) 
  Tween-20 and rotate on an under-and-
  over turntable for 10 min at room
  temperature.
2.4. Empty the tube and wash the tube 
  20 times with PBS. Fill the tube with 
  PBS and rotate on an over-and-under-
  table for 10 min at room temperature.
2.5. Empty the tube and add 1 ml of 
  100mM triethlyamine solution. Co- 
  ver the tube and rotate for 15 min on
  an under-and-over turntable at room
  temperature. In this step, bound pha-
  ges are eluted.
2.6. Add the eluted phages to a 50-ml tube 
  containing 0.5 ml of 1M Tris-HCl, 
  pH 7.4 for neutralization. Addition-
  ally, add 200 µl of 1M Tris-HCl, pH
  7.4 to the remaining phages in the
  immunotube. At this point, phages 
  can be stored at 4°C for a short 
  period (up to 2 days) or used di-
  rectly to infect E. coli TG1 cells.
  The latter is recommended. 
2.7. Add the eluted phages (step 6) to 
  9 ml of exponentially growing E. 
  coli TG1 cells in a 50-ml tube. Add 4 
  ml TG1 culture to the remaining 
  phages in the immunotube (step 6). 
  Incubate both cultures for 30 min at 
  37°C, without shaking, to allow in- 
(C) Selection of phages binding to GAGs
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  fection. 
2.8. Exponentionally growing TG1 cul-
  ture is prepared as follows: Inoculate 
  50 ml of 2 × TY with 0.5 ml of the 
  o/n culture from section ‘A. ‘Growth
  of antibody phage display library; 
  step 1.7.’. Grow the culture, while 
  shaking, at 37°C until an absorbance 
  at 600 nm of 0.4-0.5 is reached (this 
  takes about 90 min). It is recom-
  mended to inoculate an additional 
  50 ml of 2 × TY with 0.5 ml of the 
  overnight culture 30 and 60 min after 
  the first inoculation and use the cul-
  ture with an absorbance of 0.4-0.5
  for infection.
2.9. Pool both infected E. coli TG1 cul- 
  tures (9 ml and 4 ml from step 
  2.8.) and take 100 µl of the pooled 
  cultures to make serial dilutions (102, 
  104, 106, 108) in 2 × TY to calculate 
  the titer. Plate 100 µl of the dilutions 
  on TYE plates and grow o/n at 37°C. 
  Centrifuge the infected TG1 culture
  for 10 min at 10,000g at room 
  temperature (do not refrigerate!). Re-
  suspend the cells in 2 ml 2 ×
  TY, spread on TYE plates and
  incubate o/n at 37°C.
Day 4
3.1. Count colonies and calculate the 
  titer from the dilutions. An increase 
  in titer is expected after each selec-
  tion round, indicating enrichment
  of binding clones. Store plates with
  separate colonies, since individual
  clones will be used in section ‘E.
  Production of master plate and induc-
  tion plate of phage infected clones;
  Day 3, step 3.1.’.
3.2. Add 5 ml 2 × TY medium to the TYE 
  plates and scrape the bacterial cells 
  from the plate with a glass spreader.
  Collect the bacteria in a 50-ml tube
  and centrifuge at 5,000g for 10 min
  at room temperature. 
3.3. Decant the supernatant and resuspend
  the bacterial pellet in 2 ml 2 × TY
  medium.
3.4. For a next round of selection, take 
  50 µl of the bacterial suspension and 
  use it to inoculate 50 ml 2 × TY con-
  taining 100 µg/ml ampicillin and 1%
  (w/v) glucose as in section ‘A. Growth
  of antibody phage display library; 
  step 1.1.’. Repeat this selection pro-
  cedure for another three selection
  rounds (all steps of this section).
3.5. Add 1 ml of ice-cold 60% glycerol
  to the remaining cells, aliquot in 50
  µl fractions, snap-freeze in liquid
  nitrogen, and store at -80°C7.
To assess whether the panning experi-
ment was successful, individual clones 
need to be selected and analyzed. 
This section describes a procedure to 
identify antibody-expressing clones after
panning. An easy and fast method to 
test the selected clones for production 
of antibodies directed against GAGs is
ELISA. Antibody-containing superna-
tants obtained from isopropyl-β-D-thio-
7 Glycerol stocks are used as a backup. When a subsequent selection found fails, use the glycerol stock for a new round 
of selection.
(D) Harvesting of selected phagemids
Screening for clones expressing anti-
GAG antibodies
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galactosidase (IPTG)-induced cultures 
can be used for this purpose. Clones 
with desired specificity in ELISA can 
be further analyzed by DNA sequencing 
to identify different clones (e.g., with 
unique CDR3 sequences). Clones of 
interest can then be used for large-scale 
production and purification.
Sterile 96-well flat-bottom assay plates
  with high-binding surface (ELISA
  plate, Greiner) round-bottom
Cellstar plates (master block) (Greiner) 
p-Nitrophenyl phosphate disodium salt,
  hexahydrate (MP Biomedicals)
1M diethanolamine, pH 9.8. Store in the
  dark at room temperature.
GAGs of interest 10 mg/ml in H2O
1mM IPTG in H2O (prepare freshly)
10mM IPTG in 2 × TY
PBST: 0.05 ml/l Tween-20 in PBS
Secondary antibody solution: Mouse 
  anti-c-Myc antibody (9E10, hybri-
  doma culture supernatant8) diluted 
  1:10 with PBST containing 2% (w/v)
  bovine serum albumin (BSA)
Tertiary antibody solution: Alkaline 
  phosphatase-conjugated rabbit anti-
  mouse IgG (DAKO) diluted 1:2,000 
  with PBST containing 2% (w/v) 
  BSA 
Substrate solution: Add 1 mg PNPP/ml
  to 1M diethanolamine solution (pre-
  pare freshly). 
Washing solution: PBS containing 0.1%
  (v/v) Tween-20
Day 3
3.1. Pick individual bacterial clones with 
  sterile toothpicks from the serial 
  dilution plates of the last two selec-
  tion rounds (round 3 and 4) (section
  ‘C. Selection of phages binding to
  GAGs; Day 3, step 3.1.’), and
  inoculate individual wells of a 96-
  well master block, filled with
  500 µl of 2 × TY containing 100
  µg/ml ampicillin and 1% glucose.
  Repeat this for 94 individual clones. 
  Include a negative control (medium 
  without bacterial clones) and a 
  positive control (a clone that reacts 
  with the antigen). When no positive 
  clone is available, leave the well 
  empty and use a commercially avail-
  able antibody for further analysis.
  Secure the lid with tape and grow
  o/n, while shaking, at 37°C. 
Day 4
4.1. Transfer 10 µl bacterial culture 
  (Day 1, step 1) to the corresponding 
  wells of a secondary sterile mas-
  ter block containing 1 ml 2 × TY 
8 The hybridoma cell line (9E10 [anti-c-Myc]) is available from the American Type Culture Collection (ATCC). Alternatively, 
polyclonal rabbit anti-c-Myc antibody (A14, Santa Cruz Biotechnology) or purified 9E10 (Sigma) can be used.
9 Glucose (0.1%) is added to suppress the expression of scFv antibodies until a sufficient number of bacteria is produced 
for large-scale production of the antibody. The total amount of glucose will be fully metabolized at an absorbance of 0.9 
at 600 nm. 
10 Grow the culture in the induction plate for 3 h at 37°C while shaking. Bacterial growth should be clearly visible before 
adding IPTG. 
(E) Production of master plate and induction 
plate of phage-infected clones
Solutions
Methods
Materials
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  tape, and grow at 37°C, while sha-
  king, for 3 h10. Do not exceed 200
  rpm to prevent contamination.
4.2. When bacterial growth is clearly 
  visible in the induction plate, an 
  absorbance at 600 nm of about 0.9 is 
  reached. For induction, add 100 µl 
  of 10mM IPTG in 2 × TY to each 
  well of the induction plate to 
  reach a final concentration of 1mM
  IPTG. Incubate the plate, while 
  gently shaking (do not exceed 200
  rpm to prevent contamination) o/n
  at 30°C to induce the production
  of anti-GAG antibodies. 
4.3. Fill a master block with 200 µl of 
  the o/n culture and add 200 µl of ice-
  cold 60% glycerol to all wells to a 
  final concentration of 30% (use a
  multichannel pipetter). Mix well, and
  store the plate immediately at -80°C.
  This plate will be the master plate
  and is used as a backup.
Day 5
5.1. Centrifuge the induction plate 
  (Day 2; step 2) for 30 min at
  5,000g to pellet bacteria. The sup- 
  ernatant containing antibodies will
  be used to screen for positive 
  clones as described in the fol-
  lowing section.
Figure 2. (A) Schematic representation of plasmid pUC119-HV, harboring the DNA encoding scFv 
antibody HS4C3 (pUC119-HV-HS4C3). (B) HS4C3-coding sequence cloned into plasmid pUC119-HV 
(NcoI-NotI cloning). Depicted are: Amp, ampicillin resistance-encoding gene; P LacZ, LacZ promoter; pelB, 
signal peptide of bacterial pectate lyase that targets antibodies to the periplasmic space; (G4S)3-linker, a 15 
amino acid linker sequence connecting the VH and VL domains; His-tag, eight histidine residues used for 
protein purification; VSV-tag, peptide epitope used for immunodetection. Sequences encoding VH and VL 
complementarity determining regions (CDRs) are shaded. Also indicated are the nucleotide sequences of 
polymerase chain reaction (PCR) primers that can be used for sequencing (pUC/M13-s and PelBseq-s).
containing 100 µg/ml ampicillin and 
0.1% glucose9. This plate will be the
induction plate. Secure the lid with
Phage display-derived human antibodies
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Day 4
4.1. Coat wells from an ELISA plate 
  with 100 µl of a 10 µg/ml GAG
  solution. Incubate o/n at 4°C. This
  step can be performed on Day 2 of
  the previous section.
Day 5
5.1. Discard the GAG solution and 
  wash the plate six times with PBST.
5.2. Block the plate with 200 µl of
  2% (w/v) BSA in PBST for 90
  min at room temperature. 
5.3. Empty the plate and add 100 µl cul-
  ture supernatant from the induction 
  plate (section ‘E. Production of mas-
  ter plate and induction plate of 
  phage-infected clones; Day 5, step 
  5.1.’) containing soluble antibodies
  to the corresponding wells of the
  ELISA plate. Incubate for 2 h at
  room temperature11.
5.4. Discard the culture supernatant and
  wash the plate six times with PBST.
5.5. Add 100 µl of the secondary anti-
  body solution to each well and incu- 
  bate for 1 h at room temperature.
5.6. Discard the secondary antibody solu-
  tion and wash the plate six times
  with PBST.
5.7. Add 100 µl of the tertiary antibody
  solution to each well and incubate
  for 1 h at room temperature.
5.8. Discard the tertiary antibody solu-
  tion and wash the plate six times with 
  PBST. This step is followed by a 
  single wash with 100 µl of 1M di-
  ethanolamine solution to reduce 
  background signals.
5.9. Add 100 µl of substrate solution 
  to each well and incubate in the
  dark at room temperature until co- 
  lor development is clearly visible. 
  Read the absorbance on an ELISA
  reader at 405 nm.
To obtain large amounts of soluble 
antibodies, periplasmic fractions of bac-
teria expressing the antibodies are
used. Upon induction with IPTG, scFv
chains are expressed with the N-terminal 
pelB bacterial leader sequence that 
targets the chains to the periplasm, 
where the pelB sequence is cleaved off 
by the enzyme signal peptidase. Within 
the periplasm, appropriate oxidizing 
conditions allow the antibody to fold and 
form functional scFv antibodies. Soluble 
scFv antibodies are obtained from the 
bacterial periplasm, through the addition 
of borate buffer, which selectivity re- 
leases periplasmic proteins. Antibodies 
contained in this crude periplasmic 
fraction can be purified by various ways 
(e.g., by metal chelate chromatography 
using a His tag). However, the pHEN-1 
vector into which the library is cloned 
(Figure 2) yields scFv antibodies with a
c-Myc tag. To circumvent high back-
ground signals in IHC on, for example, 
tumor tissue (which express c-Myc), scFv 
antibodies are subcloned into pUC119-
His-VSV (Figure 2; Raats, Department
of Biochemistry [NWI], Nijmegen Centre 
for Molecular Life Sciences, Radboud 
11 Include negative controls (i.e., supernatant without scFv antibodies) and positive controls (if available).
(F) ELISA screening for bacterial clones 
expressing anti-GAG antibodies
(G) Large scale production of periplasmic 
fractions containing soluble scFv antibodies
Methods
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  bate o/n at 37°C.
Day 7
7.1. Inoculate 20 ml 2 × TY containing 
  100 µg/ml ampicillin and 1% (w/v) 
  glucose with a single colony from
  a fresh streak of an antibody-expres-
  sing clone. Incubate o/n, while sha-
  king, at 37°C. Plates can be stored
  at 4°C for up to 1 month.
Day 8
8.1. Inoculate 1 l of 2 × TY containing
  100 µg/ml ampicillin and 0.1% (w/v)
  glucose with 10 ml of the o/n 
  bacterial culture and incubate, while
  shaking, at 37°C until an absor-
  bance at 600 nm of 0.5-0.8 is
  reached. This takes about 2.5 to 3.0 h. 
8.2. As a backup for additional anti-
  body production, a glycerol stock
  is prepared. Add 500 µl of 60% 
  glycerol to 500 µl of the o/n culture. 
  Mix well, freeze in liquid nitrogen, 
  and store at -80ºC; 1.5 ml of the 
  remaining o/n culture is used for 
  DNA Miniprep and sequencing as
  described in the section ‘Sequence 
  analysis of selected clones’.
8.3. To the 1 l of induction culture add 1 
  ml of 1M IPTG to a final con-
  centration of 1mM IPTG and incu-
  bate the culture, while shaking, for
  3 h at 30°C.
8.4. Cool the culture on ice for 20 min.
8.5. Collect the bacteria by centrifugation 
  at 5,000g for 10 min at 4°C. Decant 
  the supernatant, and add 10 ml of 
  ice-cold borate buffer to the bacterial
  pellet. Borate buffer dissolves the 
  glycocalix. scFv antibodies, which 
  are present in the periplasmic space,
  become available and can be readily 
  isolated.
University Nijmegen, Nijmegen, The 
Netherlands). This vector contains both 
a His- and VSV tag for purification and 
detection. Both the pHEN and the pUC119 
vector contain β-lactamase (ampicillin 
selection) and a LacZ promoter upstream 
of the antibody gene of interest (IPTG 
induction of antibody expression). 
EDTA-free protease inhibitor cocktail
  tablets (Roche Diagnostics)
Glycerol stock of bacteria producing 
  anti-GAG antibody, stored at -80°C
Dialysis membrane (Medicell Interna-
  tional, molecular weight cut-off <
  20 kDa)
Ampicillin (100 mg/ml)
0.5M Boric acid
Borate buffer: Adjust 0.5M boric acid to
  pH 8.0 with 0.5M sodium borate. 
  Store at room temperature. Before 
  use, add 1 EDTA-free protease in-
  hibitor tablet, and 1.6 ml of 5M
  NaCl to 16 ml of the borate buffer, 
  and adjust the volume to 40 ml
  with H2O
LB medium
LB medium containing 1% glucose and
 100 µg/ml ampicillin
0.5M Sodium borate
TYE plates
2 × TY containing 100 µg/ml ampicillin
  and 0.1% glucose
2 × TY containing 100 µg/ml ampicillin
  and 1% glucose
Day 6
6.1. Streak individual clones that express
  GAG binding antibodies from a mas-
  ter plate on TYE plates and incu-
Materials
Solutions
Methods
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8.6. Resuspend the pellet by vortexing 
  and pipetting vigorously. Transfer 
  the mixture to a 50-ml tube and 
  centrifuge at 10,000g for 30 min at 
  4°C. The supernatant is the peri-
  plasmic fraction containing the solu-
  ble scFv antibodies.
8.7. Filter periplasmic fractions through
  a 0.45-µm disposable filter.
8.8. Dialyze the periplasmic fraction o/n 
  against PBS at 4°C.
Day 9
9.1. Divide the periplasmic fraction in 
  aliquots (1 ml). Store at 4°C for direct 
  use or freeze and store at -20°C to 
  -80°C12.
 
For DNA sequence analysis, purified 
phagemid DNA from an o/n culture of 
the selected clones is used, which can 
easily be isolated by a commercially 
available small-scale plasmid preparation 
kit. Sequence analysis of the antibody-
producing clones is performed with one 
of the oligonucleotide primers given in 
the following subsection or any other 
suitable primer. The sequence can then 
be analyzed using the alignment program 
IgBLAST, which can be found on the 
Internet at http://www.ncbi.nlm.hih.gov/
igblast/. V
H
 CDR3 sequences are es-
pecially useful to identify individual 
clones. 
Plasmid DNA isolation kit (e.g., QIA-
  prep Spin Miniprep Kit, QIAGEN)
Sequencing kit (e.g., ABI Prism)
Sequencing primers (see Figure 2 for
  details and location on vector)
Forlinkseq: 5’ -GCC ACC TCC GCC
  TGA ACC- 3’ (sense)
PelBseq: 5’ -CCG CTG GAT TGT TAT
  TAC TC- 3’ (anti-sense)
 
o/n culture of a selected bacterial clone 
  grown at 37 ºC.
8.1. Take 1.5 ml of the o/n culture (large- 
  scale production of periplasmic frac-
   tions containing soluble scFv anti-
  bodies; Day 8, step 8.1.) and centri-
  fuge 5 min at 5,000g.
8.2. Decant the supernatant and use the
  bacterial pellet for isolation of plas-
  mid DNA according to the manu-
  facturers’ protocol. 
8.3. Mix suitable amounts of Miniprep 
  DNA and sequencing primer and
  submit for sequencing according to 
  the manufacturers’ protocol.
We have generated a large number of 
unique scFv antibodies that are specific 
for unique epitopes on GAG chains. Table 
1 shows a selection of the scFv antibodies 
obtained. Note that all antibodies are
12 The stability of scFv antibodies is highly variable. Whereas some antibodies can be stored at 4°C for weeks to months, 
others stay immunoreactive for only a couple of days. Most antibodies can be stored at -80°C for years. Bacterial superna-
tants containing scFv antibodies can be used for ELISA, but are often not suitable for immunohistochemistry. Periplasmic 
fractions, containing scFv antibodies, which are more concentrated, are suitable for both. For immunoprecipitation or 
addition to cell cultures, antibodies may be purified using Protein A (in case of antibodies belonging to the VH3 family) or 
metal chelating column chromatography.
13 E.C. is the Enzyme Commission number.
(H) Sequence analysis of selected clones
Materials
Solution
Methods
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different with respect to their CDR3.
To investigate GAG specificity of the
scFv antibodies, cryosections can be in-
cubated overnight with the glycosidases 
heparinase I (0.04 IU/ml in 50mM 
NaAc/50mM Ca(Ac)2, pH 7.0 at 37°C) 
(E.C. 4.2.2.7)13, heparinase II (0.04 IU/
ml in 50mM NaPO4, pH 7.1 at 37°C), 
heparinase III (0.04 IU/ml in 50mM 
NaAc/50mM Ca(Ac)2, pH 7.0 at 37°C) 
(E.C. 4.2.2.8), or a mix of these enzymes, 
to digest HS/heparin. CS and DS can 
be digested from cryosections by o/n 
incubation with the chondroitin lyases 
chondroitinase AC, which digests CS (1 
IU/ml in 25mM Tris-HCl, pH 7.5 at 37°C), 
chondroitinase ABC, which digests both 
CS and DS (1 IU/ml in 25mM Tris-HCl, 
pH 8.0 at 37°C), or chondroitinase B, 
which digests DS (1 IU/ml in 25mM 
Tris-HCl, pH 7.5 at 37°C). As a control, 
digestion buffer without the enzyme 
can be used. Digested cryosections are 
incubated with mouse anti-HS stub IgG 
antibody 3G10 to check for heparinase 
pretreatment or with mouse anti-CS/
DS stub IgG antibody 2B6 to check for 
chondroitinase pretreatment. 
Coverslips
2-5 µm tissue cryosections on glass slides
Chondroitinase ABC, AC, B (Seikagaku)
Heparinase I, II, III (IBEX)
GAG digestion buffers:
Figure 3. Immunostaining of normal rat kidney cryosections with six different scFv antibodies. 
Cryosections were incubated with anti-heparan sulfate (HS) antibodies RB4EA12 (A), HS4C3 (B), AO4B08 
(C), anti-chondroitin sulfate (CS) antibody IO3H10 (D), anti-dermatan sulfate (DS) antibody LKN1 (E), and 
negative control antibody MPB49 (F). G, glomerulus. Note differential staining patterns. Scale bar, 50 μm.
(I) Evaluation of specificity of anti-GAG 
antibodies by immunofluorescence
Materials
Solutions
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- Heparinase I, III digestion buffer
 50mM NaAc and 50mM Ca(Ac)2,
 pH 7.0
- Heparinase II digestion buffer   
 50mM NaPO4, pH 7.1
- Chondroitinase AC,B digestion buffer
 25mM Tris-HCl, pH 7.5
- Chondroitinase ABC digestion buffer
 25mM Tris-HCl, pH 8.0
Mouse anti-HS stub IgG antibody 3G10
 (Seikagaku)
Mouse anti-CS/DS stub IgG antibody 2B6
 (Seikagaku)
Mowiol solution (Calbiochem): (10% 
 (w/v) in 0.1M Tris-HCl, pH 8.5/25% 
  (v/v) glycerol/2.5% (w/v) NaN3) 
Primary antibody solution: periplasmic 
  fraction diluted in PBST containing 
  2% (w/v) BSA, such that the antibody 
  gives maximal specific fluorescence 
  and minimal background staining.
Secondary antibody solution: Mouse anti-
  c-Myc antibody (9E10, hybridoma
  culture supernatant [See footnote8])
  or mouse anti-VSV antibody (P5D4,
  hybridoma culture supernatant14) di-
  luted 1:10 with 2% (w/v) BSA in 
  PBST.
Tertiary antibody solution: Alexa-488-
  conjugated anti-mouse IgG antibody
Figure 4. Specificity of anti-glycosaminoglycan antibodies. Normal rat kidney cryosections were treated 
with heparinase III, chondroitinase B, or chondroitinase ABC. Next, cryosections were stained using anti-
heparan sulfate (HS) antibody HS4C3, anti-chondroitin sulfate (CS) antibody IO3H10, or anti-dermatan 
sulfate (DS) antibody LKN1. Scale bar, 50 μm.
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To evaluate the specificity of the scFv
antibodies, cryosections can be pre-
incubated with the glycosidases in the
desired buffer for 2 h at the optimal
temperature (see earlier discussion). 
Cryosections are washed with PBST and 
blocked with 2% (w/v) BSA in PBST 
as in step 4. Proceed with the above 
procedure (begin at step 5). For staining 
patterns, see Figure 4.
To analyze which chemical groups in
HS/heparin or CS/DS are involved in 
antibody recognition, reactivity with a 
number of test molecules can be evaluated 
by additional ELISA experiments: (1) 
direct ELISA in which wells of microtiter 
plates are coated with the test molecules, 
or by (2) competition ELISA in which the 
scFv antibodies and test molecules are 
simultaneously incubated in wells of a 
microtiter plate coated with the molecule 
of interest. 
See section ‘F. ELISA screening of bac-
terial clones expressing anti-GAG anti-
bodies’.
Day 1
1.  Coat wells from an ELISA plate with
  100 µl of a 10 µg/ml GAG solution. 
  Incubate o/n at 4°C. 
  (Molecular Probes) diluted 1:250
  with 2% (w/v) BSA in PBST.
1.  Air-dry the cryosections for 30 min 
  before use, to ensure attachment to
  microslide surface and to preserve 
  the structure.
2.  Rehydrate the cryosections with PBS 
  for 5 min.
3.  Block free binding sites with 2%
  (w/v) BSA in PBST for 20 min.
4.  Incubate cryosections with the pri-
  mary antibody solution for 45 min.
5.  Remove the primary antibody solu-
  tion and wash three times 5 min with
  PBST.
6.  Incubate cryosections with secondary
  antibody solution for 30 min.
7.  Remove secondary antibody solution
  and wash three times 5 min with 
  PBST.
8.  Incubate cryosections with tertiary
  antibody solution for 30 min.
9.  Remove tertiary antibody solution 
  and wash three times 5 min with
  PBST.
10.  Fix cryosections in 96% ethanol for  
  10 seconds.
11.  Air-dry the sections and use Mowiol 
  solution for embedding; store at -
  20°C.
12.  Analyze staining patterns by fluores-
  cence microscopy15. Figure 3 is an 
  example of staining pattern on renal  
  cryosections using scFv antibodies.
14 The hybridoma cell line (P5D4 [anti-VSV]) is available from the American Type Culture Collection (ATCC). Alternatively, 
polyclonal rabbit anti-VSV-G (Sigma) can be used.
15 Stained  tissue sections can be kept for up to 3 years at 4°C. The fluorescent tag (Alexa-488) is very stable, and 
fading of the signal hardly occurs. Store stained sections at -20°C. Background staining can often be eliminated by 
additional blocking steps with BSA or with 1-5% (v/v) serum from the same species in which the tertiary antibody is raised.
(J) Characterization of scFv antibodies by 
ELISA
(J1) Direct ELISA
Methods
Methods
Materials
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3.  Discard the 2% (w/v) BSA in PBST
  and add 100 µl of primary anti-
  body solution (periplasmic fraction
  diluted 1:5 with 2% (w/v) BSA in
  PBST) together with the test mole-
  cules (serially diluted) to the plate.
  Incubate for 2 h at room temperature. 
4.  Proceed as in the section ‘ELISA
  screening for bacterial clones ex-
  pressing anti-GAG antibodies; Day
  2, step 4’.
5.  Analyze the absorbance values to 
  determine apparent affinities/ specifi-
  city towards various GAGs.
This work was financially supported by
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fic Research (NWO), grant 902-27-292 
(to J.F.M.L., and T.J.M.W.), the Dutch 
Cancer Society (KWF), grant 2002-2762 
(to G.B.t.D), and the International Human 
Frontier Science Program Organization 
(HFSP), grant RGP0062/2004-C101 (to 
G.J.J.). The authors express their grati-
tude to Dr. G. Winter (Cambridge 
University, Cambridge, UK) for pro-
viding the phage display library. They 
thank Dr. J.M.H. Raats (Department 
of Biochemistry, Faculty of Sciences, 
Nijmegen, The Netherlands) for provi-
ding the pUC119-His-VSV vector, and 
IBEX Technologies (Montreal, PQ, 
Canada) for providing recombinant 
heparinase III derived from Flavo-
bacterium heparinum. 
Day 2
1.  Discard the GAG solution and wash
  the plate six times with PBST.
2.  Block the plate with 200 µl of 2%
  (w/v) BSA in PBST for 90 min at 
  room temperature. 
3.  Empty the plate and add 100 µl
  of primary antibody solution (peri-
  plasmic fraction diluted 1:5 with 2% 
  (w/v) BSA in PBST) to the plate.
  Incubate for 2 h at room temperature. 
4.  Proceed as in section ‘F. ELISA 
  screening for bacterial clones ex-
  pressing anti-GAG antibodies; Day 
  5 step 5.4’.
5.  Analyze the absorbance values to 
  determine apparent affinities/specifi-
  city towards various GAGs.
See section ‘F. ELISA screening for bac-
terial clones expressing anti-GAG anti-
bodies’.
Day 1
1.  Coat wells from an ELISA plate 
  with 100 µl of a 10 µg/ml GAG 
  solution. Incubate o/n at 4°C. 
Day 2
1.  Discard the GAG solution and wash 
  the plate six times with PBST.
2.  Block the plate with 200 µl of 2%
  2% (w/v) BSA in PBST for 90 min
  at room temperature. 
(J2) Competition ELISA
Acknowledgements
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eparan sulfates (HS), a class of glycosaminoglycans, are long linear complex polysac-
charides covalently attached to a protein core. The HS molecules are made up of repeating 
disaccharides onto which modification patterns are superimposed. This results in a large 
structural heterogeneity and forms the basis of specific interactions of HS towards a vast 
array of proteins, including growth factors and proteases. To study HS heterogeneity in the 
lung, we used phage display technology to select seven antibodies against human lung HS. 
Antibodies reacted with HS/heparin, but not with other glycosaminoglycans or polyanions. 
Sulfate groups were essential for antibody binding. The amino acid sequence of the 
antibodies was established, the complementarity determining region 3 of the heavy chain 
containing basic amino acids. The antibodies defined HS epitopes with a characteristic tissue 
distribution. Antibody EV3A1 primarily stained macrophages. Other antibodies primarily 
stained basement membranes, but with different preference towards type of basement 
membrane. Antibody EV3C3 was the only antibody which clearly reacted with bronchiolar 
epithelial cells. In human lung parenchyma bFGF and VEGF were largely bound by HS. 
Some antibodies blocked a bFGF-binding site of HS, and one antibody blocked a VEGF-
binding site of heparin. Taken together, these data suggest a specific role for HS epitopes 
in human lung. The antibodies obtained may be valuable tools to study HS in pulmonary 
diseases. 
H
Heparan sulfates (HS) are members of 
the glycosaminoglycan (GAG) family,
consisting of repeating disaccharide 
units onto which modification patterns
are superimposed. HS bind and mo-
dulate a myriad of molecules, including
growth factors, cytokines, proteases, anti-
proteases, matrix molecules and viral and 
bacterial proteins 1, 2. This large number 
of interactions suggests an extensive 
structural variation within HS. The struc-
tural diversity of HS is brought about 
by specific chain modifications during 
the biosynthesis of HS, including de-
acetylation, sulfation and epimerisation. 
The addition of e.g., sulfate groups leads 
to generation of specific motifs that make 
HS highly versatile, protein-binding, cell 
regulators 3-5. HS proteoglycans (HSPGs) 
are predominantly present on cell surfaces 
and in the extracellular matrix.
 Little is known about the roles pro-
teoglycans and GAGs play in the lung.
However, their distribution over various 
lung components 6, their strategic ultra-
structural location 7, and their changes 
during developmental stages 8 suggest 
that they are of crucial importance to 
the architecture and functioning of the 
lung. Due to their location in basement 
membranes and on cell surfaces, HSPGs 
deserve special attention. 
 The importance of specific HS modifi-
cations for lung functioning has been
demonstrated in mice lacking N-deacety-
lase/N-sulfotransferase-1 (NDST-1), an 
enzyme involved in the deacetylation 
and sulfation of glucosamine residues in 
HS. NDST-1-/- mice develop respiratory 
distress syndrome and die shortly after 
birth of respiratory failure 9, 10. This 
effect has been attributed to immature 
type II pneumocytes, resulting in short-
age of lung surfactant. Sulfation is a 
major determinant of the response of 
alveolar type II cells to growth factors 11. 
Growth factors like FGF’s are retained 
by HS. Electron microscopical studies 
Introduction
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using cationic probes indicate that HS 
in the basement membranes of alveolar 
type I and type II cells and of alveolar 
endothelial cells are differentially sul-
fated 12, 13. Sulfated proteoglycans play 
a central role in the modulation of 
the extracellular matrix of pulmonary 
fibroblasts, and HSPGs are involved in 
neutrophil trafficking to the alveolar 
space 14. 
 Studies of HSPGs have mainly been 
focused on the protein core, whereas 
research on HS in the lung has been 
limited to the estimation of total HS 
content. Detailed structural analysis of HS 
domains have not been performed, simply 
because appropriate tools were lacking. 
Only a few antibodies that recognize HS 
epitopes have been generated, primarily 
because of the nonimmunogenic nature 
of HS. To circumvent this, we adapted 
the phage display technology to obtain 
specific antibodies against HS 15, 16.
 In this study, we report on the isolation, 
characterization, and application of single 
chain antibodies selected against HS 
isolated from human lung. We provide 
evidence for the existence of several, 
differentially distributed HS epitopes in 
human lung, and show that binding of 
FGF-2 and VEGF to the alveolar matrix 
of human lung is mediated via HS. The 
antibodies may be very instrumental in 
elucidation of the role of HS domains in 
health and disease. 
Lung specimens were obtained from 
patients undergoing lobectomy or pneu-
monectomy for a localized malignant 
pulmonary process, at the University 
Lung Centre Nijmegen or the Rijnstate 
Hospital Arnhem, the Netherlands. A 
human semi-synthetic antibody phage
display library 17, (now officially named 
synthetic scFv Library no.1) was gen-
erously provided by Dr. G. Winter, 
Cambridge University, Cambridge, Uni-
ted Kingdom). This library contains 
50 different V
H
 genes with a synthetic 
random complementarity determining 
region 3 (CDR3) segments, which are 
4-12 amino acid residues in length. The 
heavy chains are combined with a single 
light chain gene (DPL16). The library 
contains over 108 different clones and all 
antibodies contain a c-Myc tag. 
 All chemicals used were purchased 
from Merck (Darmstadt, Germany) un-
less stated otherwise. Bacterial medium
(2 × TY) was from Gibco BRL (Paisley, 
Scotland); chemically modified heparan 
sulfate kit, chemically modified heparin 
kit, anti-chondroitin sulfate (CS)/der-
matan sulfate (DS) ‘stub’ antibody 
(2B6), anti-HS ‘stub’ antibody (3G10) 
and chondroitin 4, 6-disulfate from 
squid cartilage were from Seikagaku 
Kogyo (Tokyo, Japan). Heparin from 
porcine intestinal mucosa, HS from 
bovine kidney and from porcine intes-
tinal mucosa, chondroitin 4-sulfate from 
whale cartilage, chondroitin 6-sulfate 
from shark cartilage, hyaluronate from 
human umbilical cord, DNA from calf 
thymus, dextran sulfate, sodium azide, 
bovine serum albumin (fraction V), 
chondroitinase ABC (Flavobacterium 
heparinum), and rabbit anti-rat FGF-2 
were from Sigma (St Louis, MO); 
Microlon 96-well microtiter plates were 
from Greiner (Frickenhausen, Germany); 
polystyrene Maxisorp Immunotubes 
were from Nunc (Roskilde, Denmark); 
mouse anti-c-Myc monoclonal IgG (clone 
9E10) and mouse anti-VSV monoclonal 
IgG (clone P5D4) were from Boehringer
Mannheim (Mannheim, Germany); rab-
Experimental methods
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buffer, pH 6.5, containing 2mM EDTA, 
2mM cysteine, and 10 U papain were 
added and digestion was performed for 
16 h at 65°C. The digest was centrifuged 
(16,000g for 20 min at 4°C) and the 
supernatant containing the GAGs was 
subjected to mild alkaline borohydride 
digestion (0.5M NaOH/0.1M NaBH4 at 
4°C) to remove residual peptides from 
the GAGs. After overnight digestion, 
the mixture was neutralized by addition 
of 6M HCl. Proteins were precipitated 
for 30 min at 0°C by addition of 100% 
(wt/vol) trichloroacetic acid to a final 
concentration of 15%. Precipitated pro-
teins were removed by centrifugation 
(16,000g for 20 min at 4°C), and GAGs 
were precipitated by addition of 5 vol 
of 100% ethanol to the supernatant and 
incubation overnight at -20°C. After 
centrifugation (16,000g for 30 min at 
4°C), the pelleted GAGs were washed 
with 70% ethanol, dried, and dissolved 
in MilliQ. To obtain GAG preparations 
which contained only HS, chondroitinase 
ABC, which digests chondroitin sulfate 
and dermatan sulfate, was added (1 IU/100 
mg of GAG in 25mM Tris-HCl, pH 8.0) 
and incubation was performed for 16 h 
at 37°C. The efficacy of chondroitinase 
ABC treatment was evaluated by agarose 
gel electrophoresis 18. HS were further 
purified using DEAE Sepharose column 
chromatography 18, using 0.2M, 0.5M, 
1.0M and 2.0M NaCl in 10mM Tris-
HCl elution steps, pH 6.8. The 0.5M and 
1.0M HS fractions were pooled, ethanol-
precipitated, and residual salt removed 
by a 70% (vol/vol) ethanol wash. HS 
preparations were dissolved in MilliQ, 
checked for purity (Figure 1) and stored 
at 4°C.
bit anti-c-Myc polyclonal IgG (A-14) 
was from Santa Cruz Biotechnology 
(Santa Cruz, CA); alkaline phosphatase-
conjugated rabbit anti-mouse IgG, 
mouse anti-human mast cell tryptase 
(clone AA1), and mouse anti-human 
CD68 (clone KP1), were from Dakopatts 
(Glostrup, Denmark); Alexa 488-con-
jugated goat anti-mouse IgG and Alexa
594-conjugated goat anti-mouse IgG 
were from Molecular Probes (Eugene, 
OR); Mowiol (4-88) was from Cal-
biochem (La Jolla, CA); Plasmid DNA 
isolation kit was from Qiagen (Hilden, 
Germany); and ABI Prism Big Dye 
Terminator Cycle Sequencing Ready 
Reaction Kit was from PE Applied 
Biosystems (Norwalk, CT). Hematoxylin 
was from Fluka Biochemika (Buchs, 
Switzerland). Mouse anti-human VEGF 
(ab1316) clone VG1) was from Abcam 
(Cambridge, UK). Human recombinant 
(hr) VEGF165 and rat recombinant (rr) 
FGF-2, cloned in prokaryotic vector 
pQE16, were a gift from the Department 
of Pathology, University Hospital Nij-
megen, Nijmegen, The Netherlands. All 
experiments were performed at ambient 
temperature (22°C), unless stated other-
wise. 
Lung tissue was collected from 8 indivi-
duals, 5 were male, and 3 were female. 
Small lung specimens were taken from 
resected lung lobes, not showing any 
sign of the underlying disease for which 
the patient underwent surgery (mostly 
lung cancer) or obstruction pneumonia. 
Subjects (54 ± 7; mean age ± SD) had 
spirometric values in the normal range. 
Per gram (wet weight) of human lung 
tissue, 4 ml 50mM sodium phosphate 
Isolation of heparan sulfate from human 
lung tissue 
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 (IPTG, final concentration 1mM). Plates 
were centrifuged, and the supernatant 
containing soluble antibodies was ap-
plied to wells of polystyrene microtiter 
plates previously coated with HS. Bound 
antibodies were detected using mouse 
anti-c-Myc, followed by incubation 
with alkaline phosphatase-conjugated 
rabbit anti-mouse IgG. Alkaline phos-
phatase activity was measured using 
p-nitrophenyl phosphate as a substrate. 
Absorbance was measured at 405 nm. 
To establish the CDR3 and V
H
 gene 
DNA segments, antibody expressing 
clones were sequenced using PelB-seq 
(5’-CCGCTGGATTGTTATTACTC-
3’) (located within the PelB leader se-
quence), and For Link-seq (5’-GCCACC-
TCCGCCTGAACC-3’) (located in the
linker region between the V
H
 and the 
V
L
 genes). For this purpose, double-
stranded DNA was isolated using stan-
dard procedures. 
To obtain large amounts of soluble 
antibodies, periplasmic fractions from 
infected bacteria were isolated 15. Briefly, 
bacteria were grown at 37°C until 
an optical density (OD600) of 0.5 was 
reached. Induction was effectuated by 
the addition of IPTG. After incubation at 
30°C for 3 h, the culture was centrifuged, 
and the pellet was resuspended in 
200mM sodium borate buffer (pH 8.0) 
containing 160mM NaCl, and an ethy-
lenediaminetetraacetic acid (EDTA)-free
protease inhibitor cocktail (1mM). After 
centrifugation at 5,000g for 30 min at 
4°C, the supernatant (representing the 
periplasmic fraction containing the anti-
bodies) was filtered through a 0.45 µm 
filter, dialyzed overnight at 4°C versus 
PBS, and stored at -20°C.
Phage display-derived antibodies were 
obtained as described 15 using four rounds 
of panning against HS (0.5M and 1.0M 
fraction). Briefly, antibody-expressing 
phages were added to HS-coated tubes, 
and bound phages were eluted at high 
pH to allow for the infection of E. coli 
TG1 cells. After overnight amplification, 
phages were rescued by the addition of 
helper phage and used for further rounds 
of selections. 
Screening for bacteria expressing anti-
HS antibodies was as described 15. 
Briefly, single colonies picked from 
the last two rounds of selection were 
grown in 96-well polystyrene plates until 
bacterial growth was visible. Antibody 
production was induced by the addition 
of isopropyl-β-D-thiogalactopyranoside 
Selection of anti-GAG antibodies 
Figure 1. Agarose gel electrophoresis of hu-
man lung HS used for biopanning. The gel 
was run in 50mM Ba(Ac)2 pH 5.0 and stained 
by a combined azure A-silver procedure. M, 
marker; lane 1: total lung GAG; lanes 2 and 3: 
human lung HS after DEAE sepharose column 
chromatography (eluting at 0.5M NaCl [2], and 
1.0M NaCl [3] followed by chondroitinase ABC 
digestion). HS, heparan sulfate; DS, dermatan 
sulfate; CS, chondroitin sulfate. 
Screening for bacteria expressing antibodies 
against glycosaminoglycans
Large scale preparation of antibodies
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Affinity of the antibodies to various 
molecules was evaluated by ELISA as 
described 15. Briefly, wells were coated 
with the molecules concerned by incu-
bation with 100 µl of a 10 µg/ml solution 
in wells of a 96-well microtiter plate for 
16 h at 4°C. The wells were rinsed with 
PBS containing 0.1% (vol/vol) Tween-
20 (PBST) and blocked with 2% BSA in 
PBS containing 0.05% (vol/vol) Tween-
20. Antibodies were added and allowed 
to bind for 90 min. Bound antibodies 
were detected by incubation with 10-fold 
diluted mouse anti-c-Myc monoclonal 
antibody 9E10, followed by incubation 
with 1:1,000 diluted alkaline-phospha-
tase conjugated rabbit anti-mouse IgG. 
Plates were rinsed six times with PBST 
following each incubation. Enzyme ac-
tivity was detected using 100 µl 1 mg
p-nitrophenyl phosphate/ml 1M diethan-
olethanolamine/0.5mM MgCl2, pH 9.8, 
as a substrate. Absorbance was read at 
405 nm. All assays were performed at 
least 3 times and representative results 
are shown. As a control, wells were 
incubated with an irrelevant antibody 
TSC01 (CDR3 sequence LGFHS, V
H
3 
family, germline segment DP40). 
 To evaluate which chemical groups 
are important for recognition of the 
antibodies, an ELISA with modified 
HS/heparin preparations (from porcine 
intestine) was performed, including 
heparins that were desulfated and N-
sulfated, desulfated and N-acetylated, N-
desulfated and N-acetylated, and various 
HS preparations. Periplasmic fractions 
containing antibodies were incubated 
for 90 min in 96-well microtiter plates 
previously coated with modified heparin/
HS preparations. The plates were rinsed 
with PBST and ELISA was performed as 
described above. 
Human lung cryosections (5 µm) were 
fixed in 4% paraformaldehyde. After 
rinsing in PBS for 10 min, cryosections 
were incubated in H2O2 solution (0.3% 
in PBS, pH 7.3) to quench endogenous 
peroxidase activity. Subsequently, cryo-
sections were washed for 10 min in PBS, 
blocked with PBS containing 0.05% (vol/
vol) Tween-20 and 2% (wt/vol) BSA for 
10 min, and incubated with 2-fold diluted 
antibodies containing 3% normal horse 
serum for 45 min. Bound antibodies were 
detected by incubation with 1:10 diluted 
mouse anti-c-Myc monoclonal antibody 
9E10 containing 3% normal horse serum 
for 45 min. After washing with PBST (2 
× 10 min), cryosections were incubated 
with biotinylated anti-mouse IgG con-
taining 3% normal horse serum, for 45 
min, washed with PBST (2 × 10 min), 
and incubated with Vectastain Elite 
ABC-kit (Vector, Burlingame, CA) for 45 
min. Sections were rinsed in PBST and 
incubated with 3,3’-diaminobenzidine 
(DAB) solution to identify bound anti-
body. After a final wash in PBS, sections 
were counterstained with Mayers’ hema-
toxylin and mounted with Entellan 
(Merck, Darmstadt, Germany). As a con-
trol, cryosections were incubated with an 
irrelevant antibody TSC01. 
 To evaluate the specificity of the 
antibodies, cryosections were digested 
with the glycosidases heparinase III, 
heparinase I (both digest HS) 0.04 IU/
ml in 50mM NaAc/50mM Ca(Ac)2, 
pH 7.0 or chondroitinase ABC (digests 
chondroitin sulfate and dermatan sulfate) 
0.02 U/ml in 25mM Tris-HCl, pH 8.0, (2 
h at 37°C, refreshing the enzyme after 
Characterization of antibodies by ELISA
Characterization of antibodies and localization 
of HS epitopes by immunohistochemistry
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1 h). As a control, cryosections were 
incubated in reaction buffer without 
enzyme. After washing three times with 
PBS and blocking for 30 min with PBS 
containing 0.05% (vol/vol) Tween-20 
and 2% (wt/vol) BSA, cryosections were 
incubated with antibodies and processed 
for immunohistochemistry as described 
above. The efficiency of heparinase III 
and chondroitinase ABC treatment was 
evaluated by incubation of cryosections 
with antibodies against GAG-‘stubs’, 
generated by the glycosidases. For HS 
stubs the antibody 3G10 was used. For 
chondroitin sulfate stubs the antibody 
2B6 was used. All tests were performed 
at least 3 times. 
 To evaluate whether the antibodies 
react with heparin or mast cells in situ, 
human lung cryosections were rehydra-
ted, blocked with PBS containing 0.05% 
(vol/vol) Tween-20 and 2% (wt/vol) BSA 
for 30 min, and incubated with 2-fold 
diluted antibodies for 90 min. Bound 
antibodies were detected using 1:100 
diluted anti-c-Myc rabbit polyclonal
anti-body A-14 and goat anti-rabbit IgG 
Alexa 488, each for 60 min. For detection 
of mast cell tryptase, 1:500 diluted mouse 
anti-human mast cell tryptase and goat 
anti-mouse IgG Alexa 594 were included 
in the incubations. Macrophages were 
detected by 1:500 diluted CD68, and goat 
anti-mouse IgG Alexa 594. After each 
incubation, cryosections were washed, 
fixed in 100% methanol, air-dried, and 
embedded in Mowiol (10% (wt/vol) in 
0.1M Tris-HCl, pH 8.5/25% (vol/vol) 
glycerol/2.5% (wt/vol) NaN3). As a con-
trol, cryosections were incubated with an 
irrelevant antibody TSC01. 
To study whether the HS epitope defined 
by the antibodies is involved in the bin-
ding of FGF-2 and/or VEGF, polystyrene 
microtiter plates were coated with HS 
from bovine kidney or heparin from 
porcine intestinal mucosa. Subsequently, 
100 μl of a solution containing FGF-2 19 
or VEGF165 (0.3 μg/ml PBS, containing 
0.05% (vol/vol) Tween-20 and 2% (wt/
vol) BSA) was applied for 60 min to 
wells of the polystyrene microtiter plate. 
At these amounts, a maximum number of 
FGF-2 or VEGF165-binding sites on HS 
and heparin are occupied, as determined 
using anti-growth factor antibodies. 
After washing, antibodies were applied. 
The amount of antibodies was chosen 
such that, in an ELISA without growth 
factors, 50% staining was obtained, 
100% being the value obtained using 
saturating amounts of antibody. This 
set-up was chosen to sensitively detect 
a reduction of HS-bound antibodies by 
growth factors. Bound antibodies were 
detected as described. 
 
A human synthetic phage library con-
taining phages expressing antibodies 
was biopanned against HS isolated 
from human lung. After four rounds of 
panning, seven antibodies were selected 
(Table 1). The antibodies were different 
with respect to their amino acid sequence 
of the complementarity-determining re-
gion 3 and/or V
H
 gene.
Using ELISA, antibodies were shown to 
be reactive for the lung HS preparation 
as well as for heparin, a highly sulfated 
Inhibition of antibody binding to heparin and 
HS by FGF-2 and VEGF 
Results
Selection of anti-HS antibodies
Characterization of anti-HS antibodies 
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form of HS. HS from other sources was 
also recognized, except for EV3A1, 
which only reacted with heparin (Table 
2). None of the antibodies was reactive 
with other GAGs such as dermatan sul-
fate and chondroitin 4-sulfate, chondroi-
tin 6-sulfate, hyaluronic acid, keratan 
sulfate and K5 (similar to the HS 
precursor polysaccharide), nor with other 
polyanionic molecules such as dextran
sulfate and DNA.
To determine which chemical groups 
are important for recognition, we tested 
all seven antibodies for reactivity with 
chemically modified heparin and HS 
preparations (Table 2). 
 None of the antibodies reacted with 
K5 capsular polysaccharide from E. 
coli (which is similar to the HS pre-
cursor polysaccharide), indicating that 
additional modifications are essential for 
binding. Except for antibodies EV4D12 
and EV4D4, none of the antibodies 
reacted with heparin that was completely 
desulfated/N-acetylated, desulfated but 
N-sulfated heparin, or N-desulfated/N-
acetylated, indicating that N- and O-
sulfate groups are essential. Only anti-
body EV4D12 reacted, although weakly, 
with heparin that was completely de-
sulfated and N-sulfated, suggesting that 
N-sulfation is of major importance for 
the binding of this antibody. Antibody 
EV4D6 was the only antibody which 
partially recognized N-desulfated and 
N-acetylated heparin (but not HS), 
indicating that the presence of N-sulfate 
groups is not absolutely essential for 
binding. 
Table 1: Characteristics of anti-HS antibodies 
Given are the antibody code, amino acid sequence 
of the VH complementarity-determining region 
3 (CDR3), VH family and the germline segment 
(DP numbering). CDR3 sequences are shown in 
single-letter amino acid code. VH families and DP 
segments were deduced from the V BASE using 
DNAPLOT alignment (http://www.mrc-cpe.cam.
ac.uk/imt-doc/restricted/DNAPLOT.html) by apply-
ing the full-length VH sequences of the anti-HS 
antibody clones (nomenclature according to  Tom-
linson and coworkers 40). 
*Antibodies EV3B2 and EV3C3 have been partially 
described 15.
Figure 2. Immunostaining for HS epitopes defined by anti-HS antibodies. Nontreated and heparinase 
III-treated cryosections of human lung were incubated with periplasmic fractions containing antibody EV3C3 
(a), EV4D12 (b), EV3D6 (c), EV3A1 (d), or anti-heparan sulfate stub antibody (3G10) (e). Bound antibodies 
were visualized by incubation with anti-c-Myc mouse monoclonal antibody 9E10, followed by biotinylated 
anti-mouse IgG. Sections were counterstained with Mayers’ hematoxylin. Untreated tissue (a1-d1, a2-d2) 
showed HS epitopes differentially distributed throughout parenchymal tissue (for details see text). Staining 
was lost or strongly decreased after heparinase III-treatment (a3-d3), indicating the HS-nature of the 
epitopes. Staining of heparan sulfate stubs in heparinase III-treated tissue showed alveolar HS to be present 
in alveolar and capillary basement membranes (e2-e3). Alveolar macrophages are negative (arrow in e2). 
Scale bars, 20 μm.
Analysis of HS epitopes recognized by 
the antibodies 
Antibody CDR3 sequence VH family Germline segment 
EV3A1 GKRRRQ VH-3 DP-42 
EV3B2* GKMKLNR VH-3 DP-38 
EV3C3* GYRPRF VH-3 DP-42 
EV3D6 WMHLRVRH VH-1 DP-5 
EV4D6 GARPRAN VH-3 DP-38 
EV4D12 HAPLRNTRTNT VH-3 DP-38 
EV4F8 GMRPRL VH-3 DP-38 
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To study the location of the HS sac-
charides defined by the antibodies, 
we performed immunohistochemistry 
using cryosections of human lung. Each 
antibody showed a defined pattern of 
reactivity (Table 3, Figure 2: shown 
are the antibodies EV3C3 (a), EV4D12 
(b), EV3D6 (c), EV3A1 (d), and anti-
stub antibody 3G10 (e)). All antibodies, 
except for EV3A1 and EV3D6, primarily 
stained basement membranes of alveoli, 
bronchioli and blood vessels. The anti-
bodies differed in preference toward 
different types of basement membranes. 
EV3D6 was the only antibody which was 
only reactive with basement membranes 
of bronchioli and blood vessels (Figure 2, 
c1-c2). Basement membranes of alveoli 
were not recognized by EV3D6. For the 
other antibodies, staining intensity of 
basement membranes of blood vessel 
endothelium, bronchioles, and capillaries 
was identical, or stronger compared to 
alveolar basement membranes. Base-
ment membranes of smooth muscle cells 
of blood vessels and bronchioli were 
recognized by the antibodies EV3C3, 
EV4D12 (Figure 2, a1-a2, b1-b2), and 
antibody EV3B2 (not shown), whereas 
the other antibodies were completely 
negative. Antibody EV3A1 was pri-
marily reactive with macrophages (Fi-
gure 3c and 3d). It stained granules of 
uneven size, likely lysosomes. It was not 
reactive with mast cells (Figure 3a and 
Table 2: Reactivity of anti-HS antibodies with modified HS and heparin molecules
Periplasmic fractions of the antibodies were applied to various GAG preparations immobilized on microtiter 
plates. Bound antibodies were detected using anti-c-Myc mouse monoclonal antibody 9E10, followed by 
alkaline phosphatase-conjugated rabbit anti-mouse IgG, after which enzymatic activity was measured using 
p-nitrophenyl phosphate as a substrate. Substrate affinity: ++, very strong; +, strong; +/-, moderate; -, absent 
(n = 3).
*Similar to the HS precursor polysaccharide.
Localization of HS epitopes in human lung 
 
Test substance 
Antibody code 
EV
3A
1 
EV
3B
2 
EV
3C
3 
EV
3D
6 
EV
4D
6 
EV
4D
12
 
EV
4F
8 
Heparin, porcine intestinal mucosa + ++ + ++ ++ + ++ 
Heparin, N-desulfated and N-acetylated - - - - +/- - - 
Heparin, completely desulfated and N-sulfated - - - - - +/- - 
Heparin, completely desulfated and N-acetylated - - - - - - - 
HS (bovine kidney) - + + + + + + 
HS (intestinal mucosa) - + +/- +/- + + + 
HS, N-desulfated and N-acetylated - - - - - - - 
K5 (capsular polysaccharide from E. coli)* - - - - - - - 
Heparan Sulfate Heterogeneity in Human Lung
61
C
h
ap
te
r 
3
EV3C3 and EV3F8 (data not shown). 
Thus, the staining patterns of anti-HS 
antibodies show a unique distribution of 
HS epitopes in human lung. 
 To ascertain HS specificity of the 
antibodies, cryosections of human lung 
tissue were treated with heparinase III,
heparinase I, or chondroitinase ABC, 
before incubation with the antibody. 
Staining was absent or strongly decreased 
after treatment with heparinase III 
(Figure 2, a3-d3), whereas treatment 
with chondroitinase ABC had no effect 
Periplasmic fractions of bacteria expressing anti-HS antibodies were applied to cryosections of human 
lung. Bound antibodies were visualized by incubation with anti-c-Myc mouse monoclonal antibody 9E10, 
followed by biotinylated anti-mouse IgG. Sections were counterstained with Mayers’ hematoxylin. Staining: 
++, strong; +, moderate; +/-, weak; -, absent (n = 3).
Table 3: Immunostaining for HS epitopes defined by anti-HS antibodies
3b). EV3C3 was the only antibody which 
clearly stained the epithelial cells of 
bronchioli (Figure 4a); other antibodies 
(e.g., EV4D12, Figure 4b) were negative 
in this respect. Note that EV3C3, but not 
EV4D12, shows a distinct intracellular 
staining in bronchiolar epithelium. Nu-
clei of bronchiolar cells appeared to be
reactive with EV3C3 (Figure 4a, insert). 
Macrophages were recognized by all 
antibodies, except for EV3D6 and 
EV4D6 (data not shown). Mast cells were 
recognized by the antibodies EV3B2, 
Structure 
Antibody code 
EV
3A
1 
EV
3B
2 
EV
3C
3 
EV
3D
6 
EV
4D
6 
EV
4D
12
 
EV
4F
8 
Alveoli        
Basement membrane epithelium - +/- + - +/- +/- +/- 
Basement membrane capillaries - + ++ - + ++ + 
Bronchioli        
Epithelial cells - - + - - - - 
Basement membrane epithelial cells + + ++ + + ++ + 
Basement membrane smooth muscle cells - + + - - +/- - 
Blood vessels        
Basement membrane endothelium + + ++ + + ++ ++ 
Basement membrane smooth muscle cells - +/- + - - +/- - 
Mast cells - + + - - - + 
Macrophages ++ + + - - + +/- 
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(data not shown). For antibody EV3A1 
staining of macrophages was not abo-
lished by treatment with heparinase 
III, nor with heparinase I. For antibody 
EV3C3 some staining at discrete, but 
unidentified, places in the alveolar wall
still remained after treatment with he-
parinase III (Figure 2, a3). After treatment 
with heparinase I, however, staining was 
completely lost. 
To study if antibody-defined HS sac-
charides were involved in growth factor 
binding, the inhibition of antibody bin-
ding to HS/heparin by FGF-2 and VEGF 
was studied. Using FGF-2, binding of 
antibody EV3C3 to HS was blocked 
by 22 ± 2%, EV3B2 by 14 ± 4%, and 
EV4F8 by 19 ± 2% (values are mean 
± SD, n = 4). In case of heparin, only 
antibody EV3A1 was blocked by 39 ± 
3%. For VEGF, only binding of antibody 
EV3A1 to heparin could be slightly 
inhibited (11 ± 1%). No effect of VEGF 
was observed for the other antibodies. 
In tissue, endogenous FGF-2 could be 
detected at sites of basement membranes 
(Figure 5, a1), and staining was removed 
after heparinase III-treatment (Figure 5, 
a2). After applying recombinant FGF-2, 
most basement membranes were stained 
(Figure 5, b1), and staining was decreased 
after heparinase III-treatment (Figure 
5, b2). No endogenous VEGF could be 
detected. Recombinant VEGF165 added 
to the sections was located in basement 
membranes of alveoli, blood vessels, 
bronchioli and macrophages (Figure 
5, c1). Heparinase III digestion greatly 
Figure 3. Staining of macrophages by antibody 
EV3A1. Cryosections of human lung were 
incubated with periplasmic fractions of antibody 
EV3A1 (a, c). Bound antibodies were visualized 
by incubation with rabbit polyclonal anti-c-Myc 
IgG, followed by Alexa 488-conjugated goat anti-
rabbit IgG. Tryptase, identifying mast cells, was 
visualized using mouse anti-human mast cell 
tryptase, followed by Alexa 594-conjugated goat 
anti-mouse IgG (b). Macrophages were visualized 
using mouse anti-human CD68, followed by Alexa 
594-conjugated goat anti-mouse IgG (d). Note that 
EV3A1 reacted strongly with macrophages, but 
not mast cells. Scale bar, 50 μm.
Figure 4. Staining of bronchiolar epithelium by 
antibody EV3C3. Cryosections were incubated 
with antibody EV3C3 (a) and EV4D12 (b). Bound 
antibodies were visualized by incubation with anti-
c-Myc mouse monoclonal antibody 9E10, followed 
by biotinylated anti-mouse IgG. Sections were 
counterstained with Mayers’ hematoxylin. Note 
that EV3C3, but not EV4D12, shows a distinct 
intracellular staining in the bronchiolar epithelium, 
nuclei appearing to be positive (insert). Single 
arrows, epithelial cells of bronchioli; double arrows 
in a, detached epithelial cells. Scale bars, 10 μm.
Inhibition of antibody binding by FGF-2 and 
VEGF 
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abolished VEGF binding to sections 
(Figure 5, c2).
In this study we describe the selection 
of seven antibodies against human lung 
HS from a semi-synthetic phage display 
library. Phage display has proven to be a 
very useful technique to select antibodies 
against poorly immunogenic molecules, 
such as HS. All antibodies selected 
in this study recognize different HS 
epitopes, as indicated by their staining 
patterns and reactivity toward various 
HS preparations. For all antibodies, the 
CDR3 region of the heavy chain, which 
is of prime importance for the specificity 
and affinity of the antibodies, contained 
two or more basic amino acid residues 
likely involved in binding to negatively 
charged HS. HS-binding consensus 
sites contain basic amino acids, e.g., 
XBBXBX (B, basic amino acid residue; 
X, any amino acid residue 20). Three out 
of seven antibodies bear the sequence 
‘GX1RPRX2’ (X1: any amino acid; X2: 
hydrophobic amino acid). We suggest 
that this sequence forms a potential 
GAG-binding site. 
 Of seven antibodies selected against
lung HS, two (EV4D12 and EV4F8) are 
identical to antibodies selected against HS 
from bovine kidney and human skeletal 
muscle 15, 16. Their CDR3 sequences are 
HAPLRNTRTNT and GMRPRL, and it 
indicates that common HS saccharides 
are present in these organs. The position 
of sulfate groups is of major importance 
for the binding of the antibodies. The 
requirement of both N- and O-sulfate 
groups for epitope recognition was indi-
cated by chemically modified heparins. 
Overall desulfation completely abolished 
recognition by all antibodies. N-resul-
fation could not restore the heparin-
antibody interaction, except (partly) 
for EV4D12. N-desulfation abolished 
reactivity with all antibodies, except 
EV4D6. Because CS as well as DS were 
not bound by any of the antibodies, 
sulfation patterns specific for HS are 
likely to be important in the structure of 
the epitopes involved in binding. For two 
antibodies (EV3A1 and EV3C3), staining 
Figure 5. Localization of bFGF and VEGF in 
human lung. Non-treated (a1-c1) and heparinase 
III-treated (a2-c2) cryosections of human lung 
were incubated with an antibody to bFGF (a, b) 
or VEGF (c). Sections b and c were pretreated 
with 20 μg/ml bFGF or VEGF prior to incubation 
with the antibody to bFGF or VEGF. Heparinase 
III treatment removed endogenous bFGF (a2), 
and reduced binding of recombinant bFGF and 
recombinant VEGF to sections (b2, c2). After 
digestion with heparinase III endogenous bFGF 
could not be detected (a2). Staining of sections 
treated with heparinase III prior to incubation with 
bFGF or VEGF was markedly decreased (b2 and 
c2). Scale bar, 50 μm.
Discussion
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could not be completely abolished using 
heparinase III-treatment. For EV3A1, 
treatment with heparinase III abolished 
staining of basement membranes, but not 
of macrophages (Figure 2, d3). Treatment 
with heparinase I also did not remove 
staining. Staining for HS/heparin stubs, 
generated by heparinases, was positive 
after treatment with heparinase I, but 
not III, indicating that the HS/heparin 
in macrophages is not a substrate for 
heparinase III and therefore probably 
not bound to a core protein (heparinase 
III cleaves HS in a region near the core 
protein, and HS is then washed away from 
the tissue section). This situation may 
be analogues to that of heparin in mast 
cells. In mast cells heparin is not bound 
to a core protein (it is cleaved off by an 
endogenous endoglucuronidase) and also 
cannot be washed out after treatment 
with heparin-ase I, probably because of 
a tight binding of heparin (fragments) to 
positively charged molecules (histamine, 
proteases). Also, 3-O-sulfation of glucos-
amine residues inhibits cleavage of he-
parin at that site 21, and heparin with a 
high degree of 3-O-sulfation may be 
more resistant to heparinase I digestion 
compared with heparin which is less 3-
O-sulfated. 
 For antibody EV3C3, heparinase III 
abolished basement membrane staining
but not staining at some regions in the 
alveolar wall. Heparinase I, however, 
abolished all staining. Heparinase III
cleaves primarily at unsulfated hexuro-
nic acid residues, especially if there 
are relatively few sulfate groups on the
adjacent residues. In contrast, heparin-
ase I prefers highly sulfated regions
including sulfated iduronic acid resi-
dues. Therefore, we suggest that EV3C3 
recognizes highly sulfated regions in 
HS. Possibly, although speculative, free 
EV3C3-positive HS, not bound to a 
core protein, stick to positively charged 
areas in the alveolar wall and can only be 
removed by more extensive digestion by 
heparinase I.
 Our results implicate that in human 
lung at least seven different HS epitopes 
are present. Already in the early seventies 
it was recognized that pulmonary HS are 
exceptionally diverse with respect to 
sulfation 22-24. The biosynthesis of HS 
allows for a large number of different 
epitopes. First a precursor polysaccha-
ride is formed, which is subsequently 
subjected to a number of modifications 
25. Regions where the precursor molecule 
is not modified consist of D-glucuronic 
acid-N-acetyl-glucosamine (GlcA-Glc-
NAc) repeats and are known as N-
acetylated (NA) domains. These act as 
spacers between the highly modified and 
sulfated domains (S-domains). In these 
S-domains, extensive modifications oc-
cur, especially additions of sulfate groups 
and epimerisation of GlcA to IdoA. The 
bifunctional enzyme N-deacetylase/N-
sulfotransferase (NDST) catalyzes the 
first modification. Mice deficient in 
NDST-1, but not -2, die shortly after 
birth due to respiratory failure caused 
by immaturity of type II pneumocytes 
which results in insufficient production 
of surfactant 9-10. This indicates that 
NDST-1, but not 2, is essential for the 
maturation of type II pneumocytes, and 
implies the importance of specific sulfate 
patterns in HS. NDST-1 deficient mice 
have undersulfated HS in which N-
sulfation and 2-O-sulfation are reduced, 
but in which 6-O-sulfation is normal 9, 
26. The antibodies identified in this study 
recognize specific sulfation patterns and
may be valuable tools to study HS sac-
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charides in health and disease.
A well recognized feature of HS/heparin 
is the binding of growth factors. FGF-
2 could (partially) prevent three (out of 
seven) antibodies to bind to HS. This 
suggests that a number of antibodies are 
not recognizing domains in HS/heparin 
involved in binding FGF-2/VEGF. The 
three antibodies that were blocked cover 
the sites to which FGF-2 binds in sections. 
Interestingly, these three antibodies are 
the only ones reactive with mast cells (see 
Table 3). In case of VEGF, only antibody 
EV3A1 could be partially inhibited by 
VEGF from binding to heparin, and this 
antibody did not completely cover the 
structures reactive with exogenously 
applied VEGF. The binding of growth 
factors to immobilized HS in ELISA 
may be quite weak. It should be noticed 
that in tissue, HS chains are clustered on 
a core protein in a way that is probably 
not possible in microtiter plates. In tissue, 
therefore, a multivalency effect may 
be expected which results is a stronger 
binding of growth factors compared to 
that seen in ELISA. In this respect it is 
notable that for example for glypican-
1 (a HS-proteoglycan) a Kd of 0.12nM 
has been found for VEGF165, which is 
considerably lower than what is generally 
found for HS 27. 
 The staining patterns of the antibodies 
raise curiosity about the function of the 
distinct HS epitopes involved in human 
lung. Antibody EV3A1 showed a quite 
different staining pattern compared with 
the other antibodies as it reacted strongly 
with macrophages. Frevert and coworkers 
28 showed positive staining for HS on the 
cell surface of alveolar macrophages. 
Macrophages are distributed throughout 
connective tissues and participate in both 
defense- and injury-related processes 29. 
They are thought to play a central role 
in the fibroproliferative response, and 
studies indicate that they produce FGF-
2 30 and generate an abundant amount of 
VEGF 31. Interestingly, EV3A1 was the
only antibody that could compete with
VEGF for HS. In lung the role of VEGF, 
which is bound by HS, has recently at-
tracted much attention. In rats, a blockade 
of the VEGF receptor results in lung 
alveolar cell apoptosis and emphysema 
32, 33. In humans, lung tissue from patients 
with emphysema contains less VEGF 
compared with controls. Also, lower 
levels of VEGF in sputum correlate well 
with lower FEV1 and DLco levels 
34. 
 Proteoglycans and GAGs may have 
a specific role in the pathogenesis of 
pulmonary diseases. Next to binding and 
modulation of growth factors/cytokines, 
GAGs (especially HS) can function as 
strong inhibitors of neutrophil elastase 
35-37, and may thus influence the protease/
antiprotease balance. Alterations in HS 
would have consequences for the pro-
tective HSPG barrier of the alveolus 7. 
In the urine of patients with emphysema, 
a decreased content of the HS epitope 
JM403 was found together with a normal 
content of HS 38, suggesting a structural 
alteration in or an altered processing of 
HS molecules in the lungs of emphyse-
matous patients. Studies on chemically 
and enzymatically modified HS indicate 
that the JM403 epitope contains one or 
more N-unsubstituted glucosamine and 
D-glucuronic acid units, and is located 
in a region of the HS chain composed 
of mixed N-sulfated and N-acetylated 
disaccharide units 39. This is an example 
of a structural alteration in HS associated 
with a pulmonary disease. The availability 
of seven HS epitope-specific antibodies 
further allows to identify changes in the
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fine structure of HS associated with pul-
monary conditions. 
 In conclusion, using phage display 
technology seven antibodies were se-
lected against HS from human lung. 
Antibodies recognize different epitopes 
and some of them compete with growth 
factor for binding to HS. The binding of 
bFGF and VEGF to the alveolar matrix 
of human lung is likely to be mediated 
via HS. The availability of anti-lung HS 
antibodies and their encoding DNAs 
may provide valuable tools to study more 
accurately alterations in HS in health and 
disease.
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eparan sulfate (HS) regulates the activity of various ligands and is involved in molecular 
recognition on the cell surface and in the extracellular matrix (ECM). Specific binding of 
HS to ligands depends on sulfation patterns of HS. Tissue and cellular location of specific 
HS domains have been suggested by immunohistochemistry. However, the location and 
function of specific HS saccharide sequences have not been reported. In this study, we 
selected a novel phage display-derived antibody and established the saccharide sequence 
of its epitope using a combination of biosynthetic HS oligosaccharide libraries, tissues from 
mice defective in HS biosynthetic enzymes, and a panel of chemically modified heparins. 
The HS sequence was (GlcNS6S-IdoA2S)3 and this highly sulfated sequence was, next to 
heparin-containing mast cells, only present in a small subset of HS. Blocking this specific HS 
domain resulted in reduced cell proliferation and enhanced sensitivity to apoptosis, but had 
no effect on cell adhesion. This is the first time that immuno-blockage reveals the cellular 
importance of a specific HS sequence.
H
Heparan sulfate proteoglycans (HSPGs),
major components of the cell surface and 
the ECM, are involved in a variety of
biological phenomena, including cell ad-
hesion, proliferation, and differentiation. 
Due to their high negative charge, HS 
chains interact with a variety of proteins, 
including growth factors/morphogens and 
their receptors, chemokines, and extra-
cellular matrix proteins. HS-protein inter-
actions vary with regard to specificity, and 
may depend on charge density in addition 
to strict sequence motifs of HS.
 The interaction of heparin and HS 
with FGFs and their receptors (FGFR) 
has been characterized in great detail. 
Specific HS structures are predominantly 
determined by the regulated positioning 
of N-, 2-, 6-, and 3-O-sulfate groups along
HS chains 1. For example, FGF-2 re-
quires both N- and 2-O-sulfate groups 
for binding to HS. The 6-O-sulfate group 
is not essential for binding to FGF-2, 
but is critical for activation of the FGFR 
2. In contrast, binding of hepatocyte 
growth factor, platelet-derived growth 
factor, lipoprotein lipase, and herpes 
simplex virus glycoprotein C to HS are 
all dependent on 6-O-sulfation 3. The 
activation of antithrombin III by HS/
heparin is mediated by a specific penta-
saccharide in which a 3-O-sulfate group
is crucial. Thus, the biological functions
of HSPGs are controlled by biosynthetic 
events that define HS structures.
 Antibodies reactive with HS have been 
developed and have proven valuable tools 
to locate HS epitopes in cells and tissues 
4-8. From the phage display-derived anti-
HS antibodies available, some chemical 
HS modifications crucial for antibody 
binding have been identified, however, 
the exact saccharide sequence(s) of the 
epitope remains elusive 8, 9. This impedes 
the assignment of specific HS domains/
sequences to cell biological phenomena. 
 Here, we report on the selection, char-
acterization and application of a novel 
phage display-derived antibody, NS4F5.
The antibody reacted with a specific 
stretch of highly sulfated GlcNS6S-
IdoA2S disaccharides, which was very 
restrictively located in tissues. To study 
the cell biological relevance of this HS 
domain, we used the antibody as blocking 
agent and showed that it is involved in 
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cell proliferation and apoptosis, but not 
in cell adhesion. Our study provides new 
insights into the function of a specific 
HS domain and shows that specific 
blockage of a saccharide sequence 
results in altered cellular behavior.
ScFv antibodies 
Periplasmic fractions of infected bacteria 
were isolated as described 4. Bacteria 
were grown and induced by IPTG to 
produce antibodies. Periplasmic frac-
tions, containing antibodies, were iso-
lated, dialyzed against PBS, and stored 
at –20°C.
Tissues and cells
Rats (Wistar, male, 8 weeks old) were 
obtained from the Central Animal 
Laboratory (RUNMC, Nijmegen, The 
Netherlands).
Hsepi+/- and Hsepi-/- mouse embryos (18.5 
d.p.c.) were from Dr. J-p. Li (Uppsala, 
Sweden), Hs2st+/- and Hs2st-/- mouse em-
bryos (18.5 d.p.c.) were from Dr. C. 
Merry (Manchester, UK). Human lung 
epithelial cells (A549; ATTC, Rockville, 
MD) were cultured in F-12K Nutrient 
Mixture (Kaighn’s modification) (Gibco, 
Life Technologies, Inc., Grand Island, 
NY), supplemented with 10% FCS (PAA 
Laboratories GmbH, Pasching, Austria). 
CHO-K1 and CHO-pgsF-17 cells were
cultured in Ham’s F-12 medium sup-
plemented with 10% FCS. 
Antibody treatment
Cells were incubated for 24 h after 
passage before further manipulation. 
Medium was removed and replaced 
with 1% FCS or containing antibodies 
(10 or 50 μg/ml) in medium with 1% 
FCS. Cells were incubated 16 h for 
immunohistochemistry. As controls, cells 
were incubated with irrelevant antibody 
(MPB49) which is > 95% identical to 
most antibodies used, but does not bind 
any GAG.
Polysaccharides
For characteristics of polysaccharides, 
see Table 1.
Oligosaccharides
Specific activity of 3H-end-labeled pro-
ducts was ~7.5 × 106 cpm/nmol. Heparin 
was chemically O-desulfated to eliminate 
all 6-O-sulfate and about half of the 2-
O-sulfate groups, and was subjected 
to partial deaminative cleavage at low 
pH followed by end-labeling through 
reduction with NaB3H4. 
3H-end-labeled 
8-mer (~1.4 × 106 cpm/nmol) was re-
covered and separated into subfractions 
with defined numbers of 2-O-sulfates. 
Subfractions were separately incubated 
with mastocytoma microsomal enzymes 
in the presence of (unlabeled) PAPS, pri-
marily de novo attaching sulfate groups
in 6-O-position.
Binding assays
Affinity chromatography was performed 
on columns with 1 mg antibody coup-
led to 0.5 mg Protein-A-beads in 50mM
Tris/HCl, pH 7.4. Radiolabeled polysac-
charide samples were eluted with a 
stepwise gradient of 0.15M - 2M NaCl in 
50mM Tris/HCl, pH 7.4. Polysaccharide 
samples compared for antibody binding 
were applied in similar amounts, based 
on specific radioactivity determined by 
colorimetric analysis. Heparin oligo-
saccharides and oligosaccharide libraries
were separated by affinity chroma-
tography, as described 9.  
Experimental methods
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0.5mM MgCl2 (pH 9.8) as a substrate. 
Absorbance was read at 405 nm. 
Characterization of NS4F5 oligosaccharide 
epitopes 
For sequencing of epitope motifs, selec-
ted library octasaccharides were affinity 
purified on an NS4F5 column. Binding 
and nonbinding fragments were se-
parately pooled, desalted, dried, and
sequenced 6. Samples were subjected 
to partial HNO2 cleavage by 2mM 
NaNO2 in 20mM HCl and stopped after
different time points (0-60 min). Ali-
quots were pooled, and a fraction of 
the pool analyzed by anion-exchange 
chromatography directly while a fraction 
was subjected to enzymatic digestion with 
recombinant IdoA2S-sulfatase. Digests 
were analyzed on a Propac column and 
sequence information was obtained by 
detecting shifts in the elution positions 
Table 1: Characteristics of K5 polysaccharide derivatives and modified heparin
K5 is the non-sulfated precursor polysaccharide of HS/heparin derived from E. coli; the modified 
heparin preparations and HS are from porcine intestinal mucosa. HS, heparan sulfate; (Glc)NAc, N-
acetyl(glucosamine); (Glc)NS, N-sulfated(glucosamine); GlcA, D-glucuronic acid; IdoA, L-iduronic acid; OS, 
O-sulfate.
Reactivity of antibodies with K5 poly-
saccharide derivatives and modified 
heparin preparations (Table 1) was 
evaluated by ELISA. Wells of microtiter 
plates (Greiner, Frickenhausen, Ger-
many) were coated as described 5. 
After blocking with PBS containing 3% 
(wt/vol) BSA and 1% (vol/vol) Tween-
20 for 1 h, anti-HS antibodies (in PBS 
containing 1% (wt/vol) BSA and 0.1% 
(vol/vol) Tween-20) were added for 1.5 h. 
As a control, antibody MPB49 was used. 
Bound antibodies were detected using 
mouse IgG anti-VSV tag antibody P5D4 
(1:10; Boehringer Mannheim, Mann-
heim, Germany), followed by incuba-
tion with alkaline phosphatase-conjugated 
rabbit anti-mouse IgG (1:2000; Dako, 
Glostrup, Denmark), both for 1 h. En-
zyme activity was detected using 100 
μl 1 mg p-nitrophenyl phosphate (ICN,
Aurora, OH)/ml 1M diethanolamine
Test molecule Characteristics Source 
K5 (GlcNAc-GlcA)n 20 Glycores (Milano, Italy) 
NdAcNS K5  N-deacetylated/N-sulfated K5 20 Glycores (Milano, Italy) 
epiNdAcNS K5 epimerized N-deactylated/N-sulfated K5 Glycores (Milano, Italy) 
OS K5 (low)  low O-sulfated K5: 90% GlcNAc6OS, 10% GlcNAc 20 Glycores (Milano, Italy) 
NdAcNS/OS K5 (low)  N-deacetylated/N-sulfated/low O-sulfated K5: 90% GlcNS6OS, 10% GlcNS 20 Glycores (Milano, Italy) 
NdAcNS/OS K5 (high)  N-deacetylated/N-sulfated/high O-sulfated K5: 100% GlcNS6OS; 70% GlcA2,3OS, 30% GlcA2OS 
or GlcA3OS 20 
Glycores (Milano, Italy) 
heparin  11.3% NAc, 88.7% NS, 69% 2OS, 79% 6OS G. Ronzoni Institute (Milan, Italy) 
CdSNAc heparin completely desulfated/N-acetylated heparin Seikagaku (Tokyo, Japan) 
CdSNS heparin completely desulfated/N-sulfated heparin Seikagaku (Tokyo, Japan) 
NdSNAc heparin N-desulfated/N-acetylated heparin: 100% NAc, 0% NS, 69% 2OS, 79% 6OS G. Ronzoni Institute (Milan, Italy) 
2OdS heparin 2-O-desulfated heparin: 13% NAc, 87% NS, 0% 2OS, 79% 6OS G. Ronzoni Institute (Milan, Italy) 
partially 6OdS heparin 6-O-desulfated heparin: 13% NAc, 87% NS, 67% 2OS, 23% 6OS G. Ronzoni Institute (Milan, Italy) 
OdS heparin O-desulfated heparin Neoparin (Alameda, CA) 
carboxyl-reduced heparin uronic acid COOH-reduced heparin Neoparin (Alameda, CA) 
HS  Celsus (Cincinnati, OH) 
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 least three times. Sections were examined 
using a Leica CTR6000 microscope. 
Immuno-electron microscopy
Tissue was fixed for 3 h in Somogyi 
solution containing 4% (vol/vol) for-
maldehyde and 0.05% (vol/vol) glutar-
aldehyde in 0.1M phosphate buffer 
(PB). Sections (200 μm) were cut and 
incubated in increasing amounts of 
glycerol (10-20-30%) in PB for 30 min. 
Sections were oriented on Thermanox 
(LAB-TEK DVI., Miles Laboratories 
Inc., Naperville) and frozen in liquid 
propane. Freeze substitution was per-
formed as described 7. Ultra-thin lowi-
cryl HM20 resin sections were cut on a 
Reichert Ultracut-E and mounted on one-
hole nickel grids coated with a formvar 
film. Sections were pre-incubated in 
PBS containing 0.2% BSA and 0.05% 
cold fish skin gelatin (PBG). Sections 
were incubated overnight at 4°C in 
drops of PBG containing antibodies 
and washed for 20 min in PBG. Bound 
antibodies were visualized using anti-
VSV tag antibody P5D4 and goat anti-
mouse IgG labeled with gold spheres (10 
nm, Aurion, Wageningen, Netherlands). 
Sections were washed in PBS and post-
fixed with 2.5% (vol/vol) glutaraldehyde 
in PBS for 5 min. After washing with 
distilled water, sections were contrasted 
with uranyl acetate and studied using a 
Jeol TEM 1010 electron microscope. 
Cell proliferation assay
Human lung epithelial cells were in-
cubated at 37°C with or without purified 
scFv antibodies. Incubation was for 4 
days in a humidified atmosphere. Cell 
proliferation was assessed by measuring 
the mitochondrial dehydrogenase activity
using the tetrazolium salt 4-[3-(4-iodo-
of the enzyme-treated fragments.
Immunohistochemistry
Sections (4 μm) were air-dried and 
blocked with PBS containing 2% (wt/
vol) BSA and 0.05% (vol/vol) Tween-20 
(blocking buffer) for 20 min. Sections 
were incubated with anti-HS antibodies 
in blocking buffer for 1 h. As a control, 
antibody MPB49 was used. Bound anti-
bodies were detected by incubation 
with mouse anti-VSV tag antibody 
P5D4 (1:10), followed by Alexa 488-
conjugated goat anti-mouse IgG (1:200; 
Molecular Probes, Eugene, OR), both for 
45 min. After each incubation, sections 
were washed three times 5 min with PBS 
containing 0.1% (vol/vol) Tween-20. 
Sections were fixed in 100% (vol/vol) 
ethanol for 10 s, air-dried, and embedded 
in 10% (wt/vol) Mowiol.
 To evaluate antibody specificity, 
sections were digested with the glyco-
sidases heparin lyase III (digests HS) 
0.04 IU/ml in 50mM NaAc/50mM 
Ca(Ac)2, pH 7.0 or chondroitinase ABC 
(digests CS and dermatan sulfate) 0.02 
U/ml in 25mM Tris-HCl, pH 8.0, (2 h at 
37°C, refreshing the enzyme after 1 h). 
As a control, sections were incubated 
in reaction buffer without enzyme. 
After washing three times with PBS 
and blocking for 30 min, sections were 
incubated with anti-HS antibodies and 
processed for immunohistochemistry as 
above. The efficiency of heparin lyase 
III-, and chondroitinase ABC-treatment 
was evaluated by incubation of sections 
with antibodies against GAG-‘stubs’ 
generated by the glycosidases. For HS 
stubs the antibody 3G10 (Seikagaku, 
Tokyo, Japan) was used. For CS stubs the 
antibody 2B6 (Seikagaku, Tokyo, Japan) 
was used. All tests were performed at 
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phenyl)-2-(4-nitrophenyl)-2H-5-tetra-
zolio]-1,3-benzene disulphonate (WST-
1) (Boehringer Mannheim, Germany), 
according to the manufacturer’s proto-
col. 
Adhesion assay
Flatbottom 96-well plates (Greiner, 
Frickenhausen, Germany) were coated 
with 100 µl of type I collagen (Symatese, 
Chaponost, France) for 60 min and 
washed three times with PBS. Cells were 
labeled with Calcein-AM (Molecular 
Probes, Eugene, OR) in PBS for 30 
min at 37°C in the dark while shaking. 
Labeled cells were incubated with 
scFv antibodies (50 μg/ml) in medium 
supplemented with 1% FCS for 30 min 
and allowed to adhere for 45 min. Non-
adherent cells were removed. Attached 
cells were lysed and fluorescence was
quantified in a cytofluorometer (Per-
septive Biosystems). Adhesion was ex-
pressed as the mean percentage (± SD) 
of bound cells from four wells relative to 
untreated cells.
Detection of apoptosis in human lung epithelial 
cells after treatment with scFv antibodies 
Cells were treated with scFv antibodies 
(50 µg/ml) for 16 h, washed with PBS, 
fixed in ice cold methanol for 10 min, 
washed three times with PBS, and 
blocked with blockingbuffer for 10 
min. Permeabilization and TUNEL la-
beling were performed according to the 
manufacturer’s instructions (In Situ Cell 
Death Detection kit; Roche), and cells 
were incubated with DAPI 0.5 μg/ml 
for 1 min. Cells were washed with PBS, 
rinsed with ice cold methanol, air dried 
and embedded in Mowiol. 
In addition to the TUNEL assay, apoptosis 
was detected using an M30 CytoDEATH 
antibody that detects a caspase cleavage 
site in cytokeratin 18 (CK-18) and labels 
apoptotic epithelial cells instead of viable 
or necrotic cells 8. To detect caspase 
cleavage, cells were treated with scFv 
antibodies (50 µg/ml) for 16 h. After 
blocking, cells were incubated with M30 
antibody for 1 h. Cells were washed with 
PBS and incubated with goat anti-mouse 
IgG Alexa 488 for 1 h. Cells were washed 
with PBS and incubated with 0.5 µg/ml 
DAPI. Cells were washed with PBS, air- 
dried, fixed with ice cold methanol and 
embedded with Mowiol. 
Statistical analysis
Four independent experiments were 
subjected to statistical analysis. Results 
were expressed as mean ± SD. Data 
were analyzed using Student’s t-test, as 
appropriate. P < 0.05 was considered 
significant for all tests.
Selection of scFv antibody NS4F5 
Four rounds of panning were performed 
against glycosaminoglycans (GAGs) iso-
lated from human lung tissue, using 
the semi-synthetic scFv library no.1 9. 
Panning resulted in an increase of phage 
titer from 3 × 104 colony-forming units in 
the first round to 2 × 108 colony-forming 
units in the fourth round. Supernatants 
containing antibodies of clones obtained 
after the third and fourth selection 
were initially tested for reactivity with 
various GAGs. Of the clones reactive 
with heparin/HS, one clone produced an 
antibody (NS4F5) with a very selective
reactivity towards (modified) heparin 
preparations and a restrictive staining 
pattern (see below). Therefore, this anti-
body was selected for further analysis. 
Results
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Antibody NS4F5 belongs to the V
H
3 
family, has a DP53 germline gene seg-
ment, and contains a heavy chain comp-
lementarity-determining region 3 amino 
acid sequence of SGRKGRMR. 
Characterization of the HS epitope defined 
by antibody NS4F5
The NS4F5 epitope has a requirement for N-, 
2-O- and 6-O-sulfation and epimerization To 
identify the epitope defined by antibody 
NS4F5 and characterize its structure in 
detail different approaches were taken. 
Figure 1. Characterization of the 
NS4F5 epitope by ELISA and 
immunohistochemistry. (A) ELISA. 
Antibody NS4F5 was applied to various 
immobilized GAG preparations. Bound 
antibodies were detected using mouse 
anti-VSV-tag IgG antibody P5D4, fol-
lowed by alkaline phosphatase–con-
jugated rabbit anti-mouse IgG. Enzyma-
tic activity was measured using p-
nitrophenyl phosphate as a substrate. 
Bars represent the mean reactivity ± 
SD (n = 4) of the antibodies in percent 
relative to the reactivity with heparin. (B) 
Immunohistochemistry. Cryosections of
heterozygous and homozygous knock-
out embryos deficient for 2-O-sulfo-
transferase (Hs2st+/-, Hs2st-/-), and C5-
epimerase (Hsepi+/-, Hsepi-/-) were 
stained with antibody NS4F5. Bound 
antibodies were detected using mouse 
anti-VSV-tag IgG antibody P5D4, fol-
lowed by Alexa 488-conjugated goat 
anti-rabbit IgG. CHO K1 (wild type) and 
pgsF-17 (Hs2st-/-) cells were also used. 
Scale bar, 50 μm. 
Initially, a large set of (modified) heparin 
and E. coli cell wall polysaccharide K5 
and other GAG preparations was analyzed 
for their reactivity with the antibody. 
NS4F5 reacted strongly with heparin 
(Figure 1A), but not with other classes of 
GAGs including HS, chondroitin sulfate, 
dermatan sulfate, and hyaluronate (not 
shown). N-sulfation was an essential 
modification since N-desulfated heparin 
did not react with the antibody. In 
addition, 2-O- and 6-O-sulfation were 
crucial because 2-O-desulfated, as well 
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as partially 6-O-desulfated heparin were 
not reactive. Epimerization was also an 
essential modification since none of the 
K5 preparations tested (the E. coli K5 cell 
wall polysaccharide is the non-sulfated, 
non-epimerized precursor polysaccharide 
of heparin/HS) was reactive, including 
highly N- and O-sulfated K5. To sub-
stantiate the data obtained by ELISA, 
immunohistochemistry was performed 
using embryonic tissues from mice de-
fective in heparin/HS biosynthetic en-
zymes (Figure 1B). Antibody NS4F5 
did not stain tissues from mice lacking, 
2-O-sulfotransferase [Hs2st-/-] 10, or epi-
merase [Hsepi-/-] 11, further indicating 
that 2-O-sulfation and epimerization are 
essential modifications. In addition, a 
cell line lacking 2-O-sulfotransferase 
[CHO pgsf-17] 12 was negative. 
The NS4F5 epitope has a defined saccharide 
sequence: (GlcNS6S-IdoA2S)3 To further 
define the epitope and establish its sac-
charide sequence we turned to heparin-
derived oligosaccharide libraries (Figure 
2). Using a library containing 3H-end-
labeled heparin fragments ranging from 
4-12 monosaccharides, it was established 
by immunoaffinity that the minimal 
length for binding was an 8-mer, and that 
longer oligosaccharides did not increase 
binding affinity (Figure 2A). The binding 
heparin 8-mer eluted as a homogeneous 
oligosaccharide from an anion exchange 
column (Figure 2B upper panel) in 
contrast to the non-bound fraction 
which contained a broad spectrum of 
less charged oligosaccharides (data not 
shown). Cleavage of the bound, end-
labeled 8-mer by (partial) nitrous acid 
digestion at low pH (selective for N-
sulfated residues) resulted in three ad-
ditional fragments corresponding to end-
labeled di-, tetra-, and hexasaccharides. 
Comparison of the elution characteristics 
of these saccharides with those of stan-
dards with known sequences elu-
cidated the saccharide sequence of the 
fragments and, by combination, the 
parent oligosaccharide. The disaccharide 
corresponded to IdoA2S-anManol6S (2-
O-sulfated iduronic acid - 6-O-sulfated 
anhydromannitol; note that nitrous acid 
treatment and subsequent reduction 
converts the reducing N-sulfated gluco-
samine to an anhydromannitol). The 
tetrasaccharide corresponded to IdoA2S-
GlcNS6S-IdoA2S-anManol6S (GlcNS6S 
= N- and 6-O-sulfated glucosamine), the 
hexasaccharide to IdoA2S-GlcNS6S-
IdoA2S-GlcNS6S-IdoA2S-anManol6S, 
and the octasaccharide, i.e., the original 
octasaccharide bound by the antibody, 
to IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-
IdoA2S-GlcNS6S-IdoA2S-anManol6S. 
To substantiate these data, a biosynthetic 
heparin library was used, consisting 
of fully N-sulfated, epimerized octa-
saccharides with various numbers of 
2-O- and/or 6-O-sulfation (Figure 2C). 
Only the highest sulfated octasaccharide 
present in the library, harboring three 
2-O-sulfated iduronic acids and three 
N- and 6-O-sulfated glucosamines, was 
able to bind to the antibody (note that 
during the preparation of the library the 
glucosamine at the reducing end has been 
converted to an anhydromannitol which 
will not be 6-O-sulfated). Therefore, and 
given the notion that IdoA2S residues are 
clustered in the heparin octasaccharide 
library (unpublished observation), the
binding octasaccharide had two mono-
saccharide-sequence possibilities: 
IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-
IdoA2S-GlcNS6S-IdoA-anManol and 
IdoA-GlcNS6S-IdoA2S-GlcNS6S-
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IdoA2S-GlcNS6S-IdoA2S-anManol. 
The latter sequence is more likely since 
the library has been constructed by par-
tial nitrous acid that preferentially 
cleaves at sites of non-sulfated iduronic 
acid residues (unpublished observation). 
Combined, data show that the epitope 
defined by antibody NS4F5 contains 
three N-sulfates, three 2-O-sulfates 
and three 6-O-sulfate groups. Taken 
into account the data obtained from 
the oligosaccharide libraries it can be 
deduced that antibody NS4F5 defines 
the sequence (GlcNS6S-IdoA2S)3. 3-O-
by anion-exchange HPLC on a Propac column, using a linear salt gradient for elution (---). (C) Reactivity 
of immobilized antibody NS4F5 with heparin-derived, 3H-end- labeled octasaccharide libraries with defined 
numbers of 2-O- and variable numbers of 6-O-sulfate groups using a stepwise increasing salt gradient as 
indicated (---). The left panel shows affinity separation of oligosaccharides with two 2-O-sulfate groups and 
zero, one, two, or three added 6-O-sulfate groups, respectively. The right panel displays corresponding 
patterns for octasaccharides containing three 2-O-sulfate groups. Note that only the highest sulfated 
octasaccharides harboring three 2-O-sulfated iduronic acids and three N- and 6-O-sulfated glucosamines 
are able to bind the antibody.
Figure 2. Sequence analysis of the NS4F5 
epitope. (A) Affinity chromatography on antibody 
NS4F5-loaded columns using size defined, 3H-
end-labeled heparin oligosaccharides (4-12-
mer) and a 12-mer oligosaccharide preparation 
affinity selected on antithrombin III (12-mer 
HA). (B) Fractionation of NS4F5-affinity purified 
octasaccharides (as in A) before (upper panel) or 
after partial deaminative cleavage (lower panel) 
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sulfation, a rare modification in heparin, 
is of no importance since 3-O-sulfate 
containing 12-mers (the antithrombin 
III high affinity fraction ‘heparin 12-
mer HA’, Figure 2A) do not bind any 
better than oligosaccharides without this 
modification.
The NS4F5-defined sequence (GlcNS6S-
IdoA2S)3 is present in HS and has a restric-
ted tissue distribution In rat renal tissue 
antibody NS4F5 only stains the medullar 
part and not the cortex (Figure 3). This 
is highly unusual since all anti-HS 
antibodies studied so far strongly reacted 
with the cortical region, which includes 
the glomerulus 4, 16, 17. Treatment of renal 
sections with heparin lyase III, which 
removes HS from the tissue section, 
abolished staining indicating that the 
(GlcNS6S-IdoA2S)3 sequence is present 
in HS, be it only in a subset of HS. To 
identify the renal tubules positive for 
antibody NS4F5, we performed co-
localization studies with an antibody 
raised against aquaporin-1 (AQP-1), 
a marker for proximal tubules and 
descending thin limbs of the loops of 
Henle. Staining for the NS4F5 epitope 
was restricted to the descending thin 
limbs (Figure 3D, asterisk) and to small 
blood vessels (Figure 3D, arrows). In the 
Figure 3. Restricted location of the antibody NS4F5-defined heparan sulfate domain in rat kidney. 
A, B Cortical area. C. Cortical-medullary area. D-F. Medullary area. D-F Identification of antibody NS4F5-
reactive structures by colocalization. Medullary areas were incubated with antibody NS4F5 (D, green) and 
with an antibody against aquaporin-1 (E, AQP), a marker for descending thin limbs of the Loops of Henle 
and proximal tubules (red). F: overlay. Note that the specific HS domain is only present in descending thin 
limbs and some small blood vessels. Scale bars, 50 μm. 
G, Glomerulus 
Asterisks in D, ascending thin limbs of the loops of Henle; arrows in D, ascending thick limbs of the loops of 
Henle; arrow heads in D, descending thin limbs of the loops of Henle
Arrows in E, proximal tubules; arrow heads in E, descending thin limbs of the loops of Henle
Arrow in F, small blood vessel
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descending thin limbs, water is passively 
absorbed from the tubular lumen and 
highly sulfated HS may play a role in this 
process since it will be osmotic active (by 
binding sodium ions), thereby providing 
the osmotic conditions associated with 
water uptake. In the lung, only heparin-
containing mast cells were positive (Fig- 
ure 4, M), the staining being confined 
to the heparin-containing granules. Stri-
kingly, basement membranes –a rich 
source of HS– were completely negative 
Figure 4. Immuno-electron microscopical localization of the antibody NS4F5 epitope in human lung. 
For experimental details, see text. Only heparin-containing granules in mast cells (M) are clearly positive. 
Note that basement membranes (arrows), a rich source of HS, are completely negative. Bar in A represents 
15 μm; bar in B, 5 μm. 
Figure 5. Immunolocalization of the epitope recognized by antibody NS4F5 in rat intestine. Cryosections 
of rat intestine were incubated with the NS4F5 antibody (A) or with anti-HS antibody HS4C3 (B). Bound 
antibodies were visualized by incubation with anti-VSV mouse monoclonal antibody P5D4, followed by Alexa 
488-conjugated goat anti-mouse IgG. Capillaries of the villi are clearly positive (A, arrows), along with mast 
cells (A, arrow head) Basement membranes of epithelia were negative (compare with basement membrane 
staining using anti-HS antibody HS4C3). Scale bar, 50 μm.
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5). The basement membrane of the 
epithelia was negative (compare with 
the staining of the basement membrane 
Figure 7. Immunoblocking using antibody NS4F5 antibody reduces cell proliferation. Human lung 
epithelial cells were incubated with or without the NS4F5 antibody (10 and 50 µg/ml) for 16 h. Proliferation 
was measured at 450 nm using the WST-1 assay (see Experimental Methods). Values are expressed as 
means ± SD, n = 5). Note that the effect of the NS4F5 antibody is dose dependent. As a control, cells were 
incubated with an irrelevant antibody MPB49. *, P < 0.05
Figure 6. Expression of 
NS4F5 epitopes by human 
lung epithelial cells. Human 
lung epithelial cells were 
stained with antibody NS4F5 
(A) or anti-CS antibody IO3-
H10 (C). Bound antibodies 
were detected using mouse 
monoclonal antibody P5D4 
followed by Alexa 488-con-
jugated goat anti-rabbit IgG. 
Human lung epithelial cells 
produce NS4F5 epitopes (A) 
which can be removed by 
heparin lyase III-treatment (B), 
indicating the epitope to be present in HS. Note that heparin lyase III-treatment had no effect on CS (C, 
D). Scale bar, 50 μm.
(Figure 4, arrows). In the intestine, the
capillaries of the villi were clearly po-
sitive, along with mast cells (Figure 
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using anti-HS antibody HS4C3). Com-
bined, immunohistochemical data show
that the specific NS4F5-defined HS do-
main is present in heparin (mast
cells) and a small subset of HS. 
Figure 8. Immuno blocking using antibody NS4F5 induces morphologic changes consistent with 
apoptosis. Human lung epithelial cells were treated with purified NS4F5 (A, D), irrelevant antibody MPB49 
(B, E) or anti-HS antibody HS4C3 (C, F). Cells were fixed and concomitantly stained with M30 antibody (A-C) 
which recognizes caspase-cleaved cytokeratin 18 (CK-18) in the cytoplasm of epithelial cells, or with TUNEL 
(D-F) which labels DNA strand breaks (‘nicks’) generated by apoptosis. DAPI was used to identify nuclei. 
The arrows in A identify caspase-cleaved CK-18 in the cytoplasm of epithelial cells, whereas arrows in D 
identify TUNEL positive cells. Cells treated with the control antibody show normal nuclei (G), whereas cells 
treated with antibody NS4F5 cells show nuclear condensation (H, arrow). Scale bar, 50 μm.
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Blocking of NS4F5 epitopes decreased cell 
proliferation and stimulated apoptosis but 
had no influence on cell adhesion 
HSPGs have many roles in cell physiology 
13. To study the effect of blockage of the 
NS4F5 epitope on cellular behavior, 
human lung epithelial cells were used. 
These cells produce the NS4F5 epitope 
(Figure 6A), which can be removed by 
heparin lyase III-treatment (Figure 6B), 
indicating that the epitope is present in 
HS. Note that heparin lyase III has no 
effect on CS detected by an anti-CS 
antibody (Figure 6, C and D).
Dose dependent effect of antibody NS4F5 
on cell proliferation 
To study the effect of the NS4F5 epitope 
on cell proliferation, human lung epi-
thelial cells were treated with purified 
NS4F5 antibody and the proliferation 
analyzed (Figure 7). Treatment of cells 
with 10 µg antibody/ml resulted in a 
reduced cell proliferation to 76.6% ± 
7.7%. Treatment with 50 µg/ml further 
reduced proliferation to 51.4% ± 7.8%. 
The irrelevant phage display-derived 
antibody MPB49 14 had no effect on cell 
proliferation.
Effect of antibody NS4F5 on apoptosis 
To determine whether the NS4F5 
epitope plays a role in apoptosis, human 
lung epithelial cells were treated with 
purified NS4F5 antibody. As controls, 
the irrelevant antibody MPB49 and 
anti-HS antibody HS4CS, which has 
a different specificity than antibody 
NS4F5 9 were used. After treatment with 
NS4F5, a number of cells were positive 
for immunostaining with antibody M30 
(Figure 8A), which detects caspase-
cleaved CK-18 and which is a marker for 
the process of apoptosis. Staining was 
observed in the cytoplasm and exhibited 
a discrete punctuate distribution (Figure 
8A, arrows). In addition, nuclear con-
densation was observed (Figure 8H). 
NS4F5-treated cells were also positive 
for the TUNEL staining (Figure 8D), 
which detects 3’-OH DNA ends nuclei, 
further indicating that blockage with 
NS4F5 induced apoptosis. Cells treated 
with purified irrelevant antibody MPB49
(Figure 8, B and E), and with anti-HS 
antibody HS4C3 (Figure 8, C and F) did 
not show signs of apoptosis. 
Figure 9. Immunoblocking using antibody 
NS4F5 has no effect on cell adhesion. Calcein-
AM labeled human lung epithelial cells were 
incubated for 60 min with or without, purified 
antibody NS4F5, MPB49 or HS4C3 (50 µg/ml) 
or heparin lyase III (HepIII), and plated in wells 
pre-coated with type I collagen. After washing 
off non-adherent cells, phase contrast images of 
remaining adherent cells were taken (A, without 
heparin lyase III; B, with heparin lyase III), or cells 
were lysed and fluorescence was quantified using 
a cytofluorometer (C). Values are expressed as 
means ± SD, n = 5). Note that adhesion is HS 
dependent, but that antibody NS4F5 has no effect 
on cell adhesion, in contrast to antibody HS4C3. 
*, P < 0.05
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To study the effect of NS4F5 epitopes on 
cellular adhesion, Calcein-AM-labeled 
human lung epithelial cells were treated 
without (Figure 9A) and with (Figure 9B) 
heparin lyase III or with purified NS4F5 
antibody, and allowed to attach to type I 
collagen-coated wells. As controls, cells 
were incubated with purified irrelevant 
antibody MPB49 or with purified anti-
HS antibody HS4C3. Digestion of HS by 
heparin lyase III decreased the number 
of adherent cells to 8.9 ± 1.6% (Figure 
9C). Antibody HS4C3 had a similar 
effect (12.3 ± 3.4%). Antibody NS4F5, 
however, did not have any effect on 
cell adhesion. These data indicated that, 
although cell adhesion is HS dependent, 
the HS epitope recognized by antibody 
NS4F5 does not play a major role. 
In this study, we describe the selection, 
characterization and application of the 
novel phage display-derived anti-HS 
antibody NS4F5. This antibody defines 
a specific stretch of highly sulfated di-
saccharides (GlcNS6S-IdoA2S)3, which
is common in heparin 15, but very rare 
in HS, and has a restrictively location in 
tissues. Antibody NS4F5 was used as a 
blocking agent to study the cell biological 
relevance of such a highly sulfated HS 
domain, and it was demonstrated that the 
defined HS sequence is involved in cell 
proliferation and apoptosis, but not in cell 
adhesion. These findings provide new 
insights into the function of a specific HS 
domain and strengthen the importance of 
HS sequences (or very high HS charge 
densities), 16 in cellular behavior.
 The chemical heterogeneity of HS, 
coupled with the lack of appropriate 
tools to study the fine structure of HS has 
seriously limited the investigations into
the roles of HS in cell biological 
phenomena. Using phage display tech-
nology, we have generated a large panel 
of epitope-specific antibodies against 
HS 4, 5, 22-25. Although these antibodies 
are unique in their preference for spe-
cific modification patterns on HS mole-
cules (for example 2-O-sulfation, 6-O-
sulfation, 3-O-sulfation and/or epimeri-
zation) 4, 7, 8, the exact saccharide se-
quence remains elusive. Antibody 
NS4F5 is the first antibody of which 
the epitope could be described in terms 
of a saccharide sequence. For this a 
number of tools were used including 
chemo-enzymatically prepared heparin 
oligosaccharide libraries, chemically mo-
dified heparin preparations and tissues 
from mice defective in HS biosynthetic 
enzymes. Knowing the specificity of 
antibody NS4F5 makes it a powerful tool 
to investigate the role of HS domains in 
cell biological phenomena.
 HS-protein interactions have re-
cently attracted much interest and it 
is now widely recognized that HS is a 
modulator of protein function 13. HS-
protein interactions vary with regard to 
specificity, and often seem to depend 
on specific HS domains, the degree of 
sulfation being of major importance 1, 26 
For instance, the binding of both FGF-2 
and VEGF depends on the sulfation state 
of HS, as does for instance the process of 
tumor cell proliferation 27-29, 17.
 Blocking of HS domains recognized 
by antibody NS4F5 induced cell apoptosis 
and inhibited cell proliferation, but had 
no effect on cell attachment. Another 
anti-HS antibody (HS4C3), however, did 
affect cell attachment, but had no effect 
on the process of apoptosis. Clearly, 
different HS domains can mediate 
Discussion
Effect of antibody NS4F5 on cell adhesion 
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different cellular responses. The cell 
biological function of the highly sulfated 
HS domain defined by the antibody is 
in line with previous work on the effect 
of sulfation on cellular behavior. HS 
6-O-endosulfatase, an enzyme which 
removes 6-O-sulfate groups from (high-
ly) sulfated HS domains, resulted in 
decreased proliferation and increased 
apoptosis of breast cancer cells 31. 
Likewise, highly sulfated HS fragments, 
derived from a melanoma cell line and 
prepared by heparin lyase III digestion, 
decreased cell proliferation and increased 
apoptosis whereas low sulfated HS 
fragments, prepared by heparin lyase 
I had the opposite effect 18. Finally, 
apoptosis was noticed in blood vessels 
of mice with a targeted deletion of the 
HS biosynthetic enzyme N-deacetylase/
N-sulfotransferase 1 which results in a 
lower degree of HS sulfation33. Thus, 
highly sulfated HS domains generally 
promote cell proliferation and inhibit 
apoptosis. This study pin-points these 
effects to a specific HS domain (IdoA2S-
GlcNS6S)3 defined by antibody NS4F5 
and strongly suggests a role for (IdoA2S-
GlcNS6S)3 sequences in critically im-
portant pathways of cellular growth 
control. Such specific HS domains may 
be main targets for the development of 
novel therapeutic approaches. Some 
analogy may be drawn here with the drug 
fondaparinux, a synthetic heparin-based 
pentasaccharide that binds and activates 
anti-thrombin III, thereby reducing blood
clot formation. The development of
fondaparinux was based on the iden-
tification of the active domain within 
heparin responsible for its anticoagulant 
characteristics 19. Our findings may be 
generalizable to pathologies that are de-
pendent on HS/heparin-mediated path-
ways and may have implications for
the development of therapeutic interven-
tions. Sequence analysis of other anti-
body-defined HS domains and analysis
of their cell biological function, may thus 
provide a window to develop defined 
oligosaccharides with therapeutic poten-
tial. 
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ationale Emphysema, together with chronic bronchitis, forms chronic obstructive pulmonary 
disease (COPD) which is worldwide an important and increasing cause of morbidity 
and mortality. At the time of clinical diagnosis, the process of parenchymal destruction -
characteristic for emphysema- is already in an advanced state, and this seriously hampers 
the identification of early molecular alterations. Methods Using immunohistochemistry, a 
survey of early changes in the extracellular matrix was performed in lungs from subjects 
without clinically evident emphysema, but with early signs of emphysema as morphologically 
established by the destructive index, the most sensitive parameter for emphysema. The 
changes found in human lungs were mimicked in genetically modified mice and it was 
studied if the changes could induce the formation of emphysematous lesions. Results In 
men, an increase in destructive index correlated with an increase in heparanase and a 
specific decrease in heparan sulfate proteoglycans (both side chain and core protein). 
Alterations in other matrix components like elastin, collagens and laminin were not found. 
Importantly, overexpressing of heparanase in transgenic mice, accompanied by loss of 
heparan sulfate, initiated the development of emphysematous lesions, which became more 
severe with increasing age, resembling the human situation. Conclusions Heparanase 
overexpression and loss of heparan sulfate are crucial and early events in the development 
of emphysema. Inhibitors of heparanase activity may be evaluated as potential drugs to 
slow down the process of emphysema. 
R
Pulmonary emphysema is defined as ‘a 
condition of the lung characterized by 
abnormal permanent enlargement of air-
spaces distal to the terminal bronchioles, 
accompanied by the destruction of their 
walls, and without obvious fibrosis’ 1. 
Emphysema is a disabling progressive 
disease that takes many years to develop, 
cigarette smoking being a main risk 
factor. Together with chronic bronchitis, it 
constitutes chronic obstructive pulmonary 
disease (COPD), which affects over 16 
million people in the United States and 
who’s prevalence has risen by 41% since 
1982 2. COPD is the fifth leading cause 
of death worldwide and an increase in its 
prevalence and mortality are expected in 
the coming decades 3.
 The pathogenesis of emphysema re-
mains elusive. A major problem in re-
search to early pathogenic events of em-
physema is the time span between initia-
tion and clinical manifestation. At the
time of clinical diagnosis the process of 
parenchymal destruction is already in an 
advanced state, precluding identification 
of early molecular events. Morphological 
analysis of lung parenchyma allows for 
early identification of emphysematous 
lesions. This especially holds for the 
destructive index (DI), which is a measure 
for early parenchymal destruction and 
has a high sensitivity towards mild 
forms of emphysema 4. The DI is a more 
sensitive parameter in comparison to 
the mean linear intercept (MLI), which 
is a parameter for airspace enlargement 
and which is generally used for mor-
phometrical analysis of emphysema.
 Except for the well-characterized α1 
anti-trypsin deficiency, which accounts 
for about 1% of the cases of emphysema, 
the etiology and pathogenesis of em-
physema are not understood. Several 
hypotheses have been proposed, and 
they include the protease/anti-protease 
Introduction
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concept 5, the oxidant/anti-oxidant theory 
6, aberrant tissue repair 7, malfunctioning 
of the extracellular matrix (ECM) 8, and 
emphysema as an immunological disorder 
9. The prevailing hypothesis involves a 
protease/anti-protease imbalance in the
lung. Due to chronic cigarette smoke 
exposure, an influx of inflammatory 
cells releases proteases that overwhelm 
anti-proteolytic defenses 10, resulting 
in degradation of the ECM. Most at-
tention has focused on elastin as the 
main target of destruction, especially 
since loss of elasticity is a hallmark of 
emphysema. However, little is known 
about destruction of individual ECM 
components at the early onset of em-
physema. Currently, research interest 
is changing from the abundant fibrillar 
components like elastin and collagen 
to the more regulatory molecules in 
the ECM like glycosaminoglycans, 
including heparan sulfate (HS). In 
an official statement of the American 
Thoracic Society on future research on 
pulmonary emphysema it was stated that: 
‘Future directions should explore the 
specific role of pulmonary parenchymal 
glycosaminoglycans in maintaining al-
veolar integrity’ 11.
 Here, we evaluated ECM components 
in lung specimens and found that over-
expression of heparanase and loss of HS 
(proteoglycans) were associated with the 
initial stages of emphysema in men, and 
could initiate emphysematous lesions in 
mice.
All chemicals were purchased from Merck 
(Darmstadt, Germany), unless stated 
otherwise. Alexa 594-conjugated goat 
anti-rabbit IgG, Alexa 488-conjugated 
goat anti-mouse IgM (µ chain), and Alexa 
594-conjugated goat anti-mouse IgG2b 
were from Molecular Probes (Eugene, 
OR). FITC-conjugated donkey anti-goat 
IgG, mouse anti-elastin (clone BA-4), 
and rabbit anti-laminin were from Sigma 
Immuno Chemicals (St. Louis, MO). 
Rabbit anti-type I collagen was from 
Chemicon International, Inc. (Temecula, 
CA). Goat anti-type IV collagen was 
from Southern Biotechnology Associates 
(Birmingham, AL). Mouse anti-human 
heparanase 1 (clone HP3/17) was from
Insight Biopharmaceuticals Ltd. (Reho-
vat, Israel). Mowiol (4-88) was obtained 
from Calbiochem (La Jolla, CA). 
Aminoethyl carbazole (red) substrate 
kit was from Zymed Laboratories Inc. 
(San Fransisco, CA). Mouse monoconal 
antibody 6B6, directed against decorin, 
a dermatan sulfate proteoglycan, was 
from Seikagaku (Tokyo, Japan). Goat 
polyclonal antibody Bl31 12 was directed 
against the core protein of agrin (a HS 
proteoglycan). Mouse monoclonal anti-
body JM72 13 was directed against do-
main AGR10 of the core protein of agrin. 
Mouse monoclonal anti-HS antibody 
JM403 was directed against a HS domain 
containing glucuronic acid-rich sequen-
ces with N-unsubstituted glucosamine 
units 14, 15. All incubations were performed 
at ambient temperature (22°C) unless 
stated otherwise. 
Lung specimens were obtained from 
patients undergoing lobectomy or pneu-
monectomy for a localized malignant 
pulmonary process at the University Lung 
Centre Nijmegen or the Rijnstate Hospital 
Arnhem, the Netherlands. Specimens (1 
cm3) were taken from resected lung lobes, 
not showing any sign of the underlying 
Experimental methods
Human lung specimens 
Chemicals and antibodies
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tions were blinded and scored indepen-
dently by two observers.
The degree of emphysema was evaluated 
by the DI, using a microscopic point 
count technique 4. Microscopic fields de-
void of large bronchi(oli), vessels, col-
lapsed tissue, or extensive fibrosis were 
selected. From each lung specimen, an 
average of 5 different sections was used, 
and representative non-overlapping fields 
were selected. Alveolar, and duct spaces 
lying underneath the counting points were 
evaluated for the presence of destruction. 
Destruction was defined on base of one or 
more of the following criteria: [1] at least 
two alveolar wall defects, [2] at least two 
intraluminal parenchymal rags in alveolar 
ducts, [3] clearly abnormal morphology, 
or [4] classic emphysematous changes 4. 
The percentage of all the points falling 
into the several categories of destroyed 
airspaces was computed to reveal the 
DI. In general, 750 counting points were 
analyzed per specimen. 
Enlargement of the airspaces was 
determined by the MLI measurement 
technique, which represents the average 
size of alveoli originally described by
Dunnill 18. To determine the MLI, the
same images as described above were 
used. A transparent sheet with 10 hori-
zontal and 11 vertical lines was laid 
over the images, and intercepts of al-
veolar walls with these lines were coun-
ted. Values were corrected for tissue 
shrinkage by measuring the dimensions 
before and after histological processing. 
The correction factor was 0.832, in ac-
disease for which the patient underwent 
surgery. Subjects were studied according 
to guidelines of the Committee of Me-
dical Ethics of the Radboud University 
Nijmegen Medical Centre, and gave 
informed consent. Lung function tests 
were performed before surgery. Static 
and dynamic lung function tests were 
performed with a wet spirometer and 
with a closed circuit helium-dilution 
method (Pulmonet III, Sensormedics, 
Bilthoven, The Netherlands). Diffusion 
capacity for carbon monoxide per liter/
lung (alveolar) volume (DL,CO/VA) was 
measured with the single breath-holding 
carbon monoxide method (Sensormedics 
2450), and was corrected for actual 
hemoglobin. Measurements were per-
formed at least 12 h after smoking. Pre-
dicted spirometric values were derived 
from the ERS standards. Both smokers 
and ex-smokers were included and pa-
tient groups were comparable with res-
pect to age and pack years (Table 1). 
None of the patients could be classified 
as having COPD according to the GOLD 
criteria 16.   
Each specimen (about 1 cm3) was cut 
into pieces of equal size. One part was 
immersed in PBS (pH 7.2), inflated 
under vacuum (13kPa) for 20 min using 
a routine water stream-driven device 
(water aspirator) to restore alveolar di-
mensions 17, frozen in liquid nitrogen, 
and stored at -80°C. This part was used 
for immunohistochemistry (see below). 
The other part was similarly inflated in 
PBS containing 4% formalin and further 
processed for paraffin embedding. From 
this part, sections (5 µm) were cut and 
hematoxylin-eosin stained, and used for
morphological characterization. All sec-
Morphological characterization of lung
specimens
Parenchymal destruction
Airspace enlargement
Tissue processing 
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ted with the anti-heparanase 1 antibody 
for 60 min. Sections were washed in
in TBS, and incubated with 1000-fold 
diluted peroxidase labeled goat anti-
mouse for 60 min. Sections were washed 
in PBS for 5 min, rinsed in NaAc buffer, 
and peroxidase activity was detected 
using aminoethyl carbazole (red) sub-
strate kit. Sections were rinsed in water, 
counterstained with hematoxylin, washed
with running tap water for 10 min, and 
with demineralized water for 5 min, and 
embedded in Kaiser’s gelatin. As con-
trols, primary or conjugated antibodies 
were omitted. Digital images were pro-
cessed using Adobe Photoshop 7.0 soft-
ware. Lung sections were randomly co-
ded, and immunoreactivity was scored 
independently using semi-quantitative 
criteria (-, no reactivity; +/-, weak reac-
tivity; +, strong reactivity; ++ very strong 
reactivity) by two observers. 
Animals 
Homozyous transgenic mice overexpres-
sing mammalian heparanase were gene-
cordance with data from Weibel 19.
 
Cryosections (5 µm) were rehydrated 
for 10 min in PBS, blocked in PBS 
containing 2% (wt/vol) BSA for 20 min, 
and incubated with the primary antibody 
for 60 min. Following each incubation, 
cryosections were washed in PBS (3 
times 5 min). Antibody JM72 was used 
at 1:250 dilution, anti-heparanase 1 anti-
body was used at 1:200 dilution, anti-
type I collagen, antibody Bl31, antibody 
JM403, and all secondary antibodies were 
used at 1:100 dilution. All other primary 
antibodies were used at 1:50 dilution.
Cryosections were fixed in 96% ethanol, 
air-dried, and embedded in Mowiol (10% 
(wt/vol) in 0.1M Tris-HCl, pH 8.5/25% 
(vol/vol) glycerol/2.5% (wt/vol) NaN3). 
Additionally, heparanase expression was 
detected using aminoethyl carbazole 
(red) substrate kit. Briefly, sections were
rehydrated for 10 min in tris-buffered 
saline (TBS), blocked in TBS containing 
1% (wt/vol) BSA for 30 min, and incuba-
Table 1: Characteristics of study groups
Ex, ex-smokers, not smoking for at least one year; C, current smokers; DI, Destructive Index; MLI, Mean 
Linear Intercept; KCO, diffusion capacity for CO.
*All values are presented as means ± SD, with ranges in parentheses. 
Immunohistochemistry 
 
 
Normal* (n = 7) 
(DI < 30%) 
Slightly affected* (n = 9) 
(DI 30 - 80%) 
Moderately affected* (n = 7) 
(DI > 80%) 
 
Age (yr) 
 
53±9 (47-63) 
 
59±9 (50-76) 
 
57±8 (54-75) 
Male/female 6/1 8/1 7/0 
Smoking (Ex/C) 3/4 2/7 2/5 
Pack-years 26±9 (15-45) 37±19 (20-84) 37±15 (12-55) 
KCO, % pred 85±23 (59-132) 77±21 (45-106) 73±18 (59-108) 
DI, % 21±8 (11-29) 56±8 (41-65) 85±4 (80-90) 
MLI, mm 0.28±0.03 (0.23-0.34) 0.29±0.03 (0.24-0.35) 0.37±0.08 (0.29-0.49) 
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rated as described 20. In brief, full-length 
human heparanase cDNA was subcloned 
into pCAGGS plasmid at EcoRI-XbaI 
sites under constitutive control of the 
chicken β-actin promoter. The plasmid was 
digested with SalI-PstI and the resulting 
linear fragment was microinjected to 
fertilized eggs of C57BL/6 × Balb/c
origin to produce transgenic mice over-
expressing the heparanase cDNA. Of the 
forty-two pups four were positive human 
heparanase founder transgenic mice as 
identified by tail tip genotyping. Founder 
mice were mated with C57BL/6 mice 
to create F1 mice and those were mated 
among themselves to create F2 mice. 
Homozygous F2 mice from each of the 
four founder lines were identified by 
Southern blot analysis and quantitative 
PCR. Expression of the heparanase 
protein in the four founder lines was 
verified by Western blot analysis of tissues 
derived from F2 homozygous heparanase 
transgenic mice. Homogenized tissue 
samples were subjected to SDS-PAGE,
and heparanase was identified with an 
antibody specifically directed against 
the human enzyme. Heparanase over-
expression was found in the lungs of 
all founder lines. Lung specimens were 
processed as described above.
Results were subjected to statistical ana-
lysis using Spearman’s coefficient of rank 
correlation, and the Mann-Whitney U test
for multiple comparisons. Data were 
analyzed with the Statistical Package for 
the Social Sciences 12.01 (SPSS Inc., 
Chicago, IL), and GraphPad Prism®, 
version 4.0 (GraphPad Software Inc., San
Diego, CA) computer programs. Statis-
tical significance was regarded when P < 
0.05. 
Lung specimens from 23 subjects were
morphologically characterized for em-
physematous lesions using the DI as a
marker for early parenchymal destruction 
and the MLI as a marker for airspace 
enlargement (Table 1) 21. Based on the
DI and MLI, three groups were created: 
(a), normal tissue (DI < 30%, MLI 
normal); (b), slightly affected lung 
tissue (DI 30 - 80%, MLI normal) and 
(c), moderately affected lung tissue (DI 
> 80%, MLI increased). Please note 
that for normal, unaffected lungs of 
non-smoking individuals in the fifth-
sixth decade of life, the DI is between 
0 - 30% 4. Using the lung specimens we 
evaluated early changes in the ECM of 
lung parenchyma.  
Figure 1. Scatter plots showing the relation between staining for extracellular matrix (ECM) 
components and the destructive index (DI). Morphologically analyzed sections of subjects without 
clinically evident emphysema and with normal (DI < 30%, MLI normal), slightly affected (DI 30 - 80%, MLI 
normal), or moderately affected (DI > 80%, MLI increased) lung parenchyma were incubated with antibodies 
against heparan sulfate (HS; A), heparanase (B), elastin (C), decorin (D), type IV collagen (E), and laminin 
(F). Immunoreactivity was scored using semi-quantitative criteria (-, no reactivity; +/-, weak reactivity; +, 
strong reactivity; +/+, very strong reactivity). Note that staining intensity for HS decreased with increasing 
DI, whereas staining for heparanase increased with increasing DI. There were no differences in staining for 
other ECM components like elastin, decorin, type IV collagen, and laminin between the three groups. 
*, P < 0.05; **, P < 0.01; ***, P < 0.005; NS, not significant
Results
Morphological data 
Statistical analysis 
Heparanase and HS in emphysema
93
C
h
ap
te
r 
5
Heparanase and HS in emphysema
94
C
h
ap
te
r 
5
Figure 2. Immunostaining for matrix components in human lung tissue. Morphologically analyzed 
human lung tissue with Destructive Index (DI) < 30% and normal MLI (A, D, G, J, and M), DI 30 - 80% 
but normal MLI (B, E, H, K, and N), and DI > 80%, increased MLI (C, F, I, L, and O) were incubated 
with antibodies against the alveolar basement membrane components heparan sulfate (HS; (A-C)), agrin 
(antibody JM72 (D-F), and antibody Bl31 (GI), type IV collagen (J-L), and laminin (M-O). Note the diminished 
and discontinuous immunoreactivity for HS (B-C), and agrin (JM72, E-F, and Bl31, H-I) in lung tissue with 
DI 30 - 80%, and DI > 80% compared to strong and continuous immunoreactivity for HS (A), and agrin (D 
and G) in lung tissue with DI<30%. Staining for other basement membrane associated components (type IV 
collagen (J-L) and laminin (M-O) remained unaltered. Scale bars, 50 μm.
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A set of antibodies which recognize 
specific ECM components was used to 
evaluate the lung specimens. HS was 
abundantly present in normal lung tissue 
(DI < 30%, MLI normal) in alveolar 
walls as well as in peribronchiolar 
and perivascular areas (Figure 1A, Fi-
gure 2A, and Figure 4D). However, 
in slightly affected tissue, with a DI 
30 - 80%, but with a normal MLI, a 
reduced and discontinuous staining for 
HS was observed in alveolar basement 
membranes, as well as in peribronchiolar 
and perivascular areas (Figures 1A, 2B, 
and 4E). In moderately affected tissue (DI 
> 80%, MLI increased), the reduction of 
HS in alveolar basement membranes was 
more pronounced (Figure 2C and 4F), 
whereas capillaries remained strong-
ly positive (Figure 2C). Staining for the 
basement membrane components type 
IV collagen and laminin, and for the 
interstitial matrix components elastin and 
decorin (a dermatan sulfate proteoglycan) 
did not reveal any differences in staining 
among the three groups (Figure 1, C-F 
and Figure 2, J-O). The same was true 
for type I collagen (data not shown). In 
normal human lung tissue heparanase 
expression could not be detected (Figure 
1B and Figure 4A). However, heparanase 
expression was markedly increased in 
slightly as well as moderately affected 
lung tissue (Figure 1B and Figure 4, 
B and C). Heparanase expression was 
found in alveolar and peribronchiolar
areas (primarily associated with epithelial 
cells), and in perivascular areas. Co-
localization studies demonstrated that 
heparanase expression was associated 
with reduced or lack of HS expression, 
which strongly suggests that heparanase 
is involved in cleavage of HS (data not 
shown). 
 Staining for the core protein of agrin, 
a major HS proteoglycan, revealed a 
continuous basement membrane staining 
in alveolar tissue, and in bronchiolar and 
vascular areas in normal tissue (Figure 
2, D and G). Discontinuous and reduced 
staining was observed in slightly affected 
tissue (Figure 2, E and H), and was more 
prominent in moderately affected tisssue 
(Figure 2, F and I). However, staining of 
capillaries remained strongly positive in 
tissues of all three groups (Figure 2, F and 
I). We next investigated whether HS and 
the core protein of the HS proteoglycan 
agrin were affected simultaneously or in 
sequence. In normal lung tissue, HS side 
chains and the agrin core protein always 
colocalized, but in slightly affected 
lung tissue the core protein could be 
identified at places where HS was absent, 
suggesting that HS is degraded prior to 
the core protein (data not shown). 
Since our data suggest a role for 
heparanase in emphysema, lungs of
transgenic mice overexpressing mam-
malian heparanase were studied at dif-
ferent ages from 3 months up to 3 years. 
We used the MLI as a measure for 
airspace enlargement (Figure 3). The MLI 
increased 1.6-fold (1.59 ± 0.13 versus 
0.97 ± 0.07; P < 0.0001, n = 6) in heparana-
se overexpressing mice at 3 months of 
age, and increased up to 2.2-fold (2.61 ± 
0.13 versus 1.17 ± 0.06; P < 0.0001, n = 
6) in 3-year old mice (Figure 3). In wild 
type mice, no heparanase expression in 
lung tissue could be detected (Figure 4G), 
in contrast to heparanase overexpressing
Reduced heparan sulfate and increased 
heparanase expression are associated with 
early signs of parenchymal destruction 
Heparanase overexpression induces
emphysematous lesions in mice 
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mice (Figure 4H), in which the expression 
was located throughout the lung. HS 
expression was greatly reduced in the 
lungs of heparanase overexpressing mice 
(Figure 4J) as compared to lungs of wild 
type mice (Figure 4I). Staining patterns 
for other basement membrane specific 
components like the core protein of agrin 
(Figure 4, K and L) and laminin (Figure 
4, M and N), and interstitial components 
such as elastin (data not shown) and 
collagen (type IV collagen Figure 4, O 
and P) did not differ between wild type 
and heparanase overexpressing mice.
Figure 3. Overexpression of heparanase initiates emphysematous lesions in mice. A, Mean Linear 
Intercept (MLI) values (mean ± SD, n = 6) of lungs of wild type (WT) and heparanase overexpressing mice 
(hpa-tg mice) at different ages. ***, P < 0.0001. B, hematoxylin-eosin stained sections of lungs from wild 
type and hpa-tg mice at different ages. In heparanase overexpressing mice enlargement of airspaces was 
already seen in lungs of 3 months old mice, and increased with age. Scale bar, 50 μm.
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Figure 4. Overexpression of heparanase 
is associated with loss of heparan sulfate 
(HS). A-F: morphologically analyzed sections of 
subjects without clinically evident emphysema 
and with normal (DI < 30%, MLI normal A, D), 
slightly affected (DI 30 - 80%, MLI normal B, 
E), or moderately affected (DI > 80%, increased 
MLI C, F) lung parenchyma were incubated with 
antibodies against human heparanase (A-C) or HS 
(D-F). Heparanase expression increased with DI in
alveolar basement membranes (arrows), peri-
vascular areas (arrowheads), and peribronchiolar 
areas (not shown) whereas HS decreased. Scale 
bars, 50 μm.
Lung tissue from wild type mice (G-O), and 
transgenic mice overexpressing heparanase were 
stained with antibodies against heparanase (G, 
H), HS (I, J), agrin core protein (K, L), laminin (M, 
N), and type IV collagen (O, P). Note the increase 
in heparanase and loss of HS in transgenic mice. 
Staining for other matrix components was not 
affected. Scale bar, 50 μm.
DI, destructive index
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The two main findings of this study are 
the close association of a decreased HS/
increased heparanase expression with
early parenchymal destruction in human
lung tissue, and the initiation of em-
physematous lesions by heparanase 
overexpression in mice. Both data 
suggest a central role for HS/heparanase 
in the pathogenesis of emphysema.
 HS is increasingly considered as 
a regulatory polysaccharide, binding 
and modulating a number of effector 
molecules and ECM components. It 
has been coined ‘master regulator of 
interactions’. HS interacts with various 
classes of proteins that are involved in 
the pathogenesis of emphysema. These 
include proteases/protease inhibitors 5, 
enzymes involved in neutralizing reactive 
oxygen species like superoxide dismutase 
22 and xanthine oxidase 6, 23, chemokines 
24, and growth factors/cytokines 7. In 
addition, HS proteoglycans interact with 
basement membrane components, which 
is necessary for basement membrane 
barrier integrity in pulmonary tissue. 
Diminished presence of HS and agrin in 
the lungs may therefore affect basement 
membrane integrity. In animal models, 
HS proteoglycans have been implicated 
in the pathogenesis of emphysema. 
Specific inhibition of proteoglycan syn-
thesis induces emphysematous lesions in 
rats 25. In elastase-induced emphysema 
in rats, HS is readily removed from 
the lung by degradation of the protein 
core of the HS proteoglycans 8, and as 
a consequence the protective protease 
(elastase) inhibiting capacity of HS 26 is 
lost. Elastase-induced emphysema can 
be prevented by administration of HS 26. 
The only long-lasting change (one year) 
observed in elastase-induced emphysema 
is a decrease in the ratio HS/collagen and 
HS/elastin 27. HS can be depolymerized 
by reactive oxygen and nitrogen species 
28, both present in cigarette smoke, 
and expression of heparanase can be 
induced by reactive oxygen species 29. 
Rats exposed to cigarette smoke show a 
decrease in HS content in the lung 30. In 
lungs of human emphysematous patients 
alterations in glycosaminoglycans, in-
cluding HS, have also been observed 
31, 32, but the results are contradictory. 
A structurally altered HS has been 
found in urine samples of patients with 
emphysema 33 and a diminished HS 
staining has been reported in alveolar 
lung tissue from patients with clinically 
diagnosed mild and severe emphysema 
34. A diminished peribronchiolar staining 
for the interstitial proteoglycan decorin 
has been observed in this patient group 
34, but in our study, using patients 
without clinical emphysema, we did 
not find a reduced staining, perhaps 
because our specimens were at a very 
early stage of tissue destruction. This 
furthermore underscores the importance 
of characterization of the tissue studied. 
 Loss of HS staining already occurred 
at the initial stage of tissue destruction, 
when the MLI was not increased. 
Therefore a number of HS dependent 
phenomena such as vascular endothelial 
growth factor signaling may be affected 
early on, and this may be relevant in 
emphysematogenesis. Blockade of the
vascular endothelial growth factor re-
ceptor results in the development of 
emphysematous lesions in rats 35, and 
vascular endothelial growth factor and 
related proteins have been associated 
with the pathogenesis of emphysema 
36. In lung, vascular endothelial growth
factor and a number of other growth
Discussion
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factors are bound by HS 37. HS is
degraded from the lungs ECM prior 
to the core protein and this suggests a 
sequential breakdown of the alveolar 
wall and puts emphasis on heparanase. 
Degradation of HS may leave the core 
protein unprotected from e.g., proteases, 
resulting in their breakdown. Core 
proteins are vulnerable to proteolytic 
digestion 38, and may therefore be prime 
targets for excess of proteolytic activity 
when HS is removed 39.
 In conclusion, our results provide 
for the first time a clear link between 
heparanase and emphysema. Heparanase 
is overexpressed in human lung pa-
renchyma at an early stage of tissue 
destruction. Also, overexpression of 
heparanase in mice causes emphyse-
matous lesions, which become more 
severe in time as they do in humans. 
Increased heparanase expression may 
therefore be a crucial early pathogenic 
event in emphysema, and may be a 
promising pharmacological target.
Heparanase has been identified in a 
variety of cells including endothelial 
cells, platelets, mast cells, neutrophils, 
macrophages and T and B lymphocytes 
40. Currently, a number of heparanase 
inhibitors such as PI-88 are in clinical trials 
for their capacity to inhibit angiogenesis 
and metastasis 41. Heparanase may be 
an attractive pharmacological target be-
cause it appears that only one form of 
heparanase is present, in contrast to e.g., 
the family of matrix metalloproteinases. 
Understanding the role of heparanase and 
HS in the onset of emphysema may lead 
to new therapeutic approaches to control 
this disease.
The authors wish to express their gra-
titude to the staff and members of the 
Department of Lung Diseases, University 
Lung Center Nijmegen, and Canisius-
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arenchymal destruction, airspace enlargement, and loss of elasticity are hallmarks of pul-
monary emphysema. Although the basic mechanism is unknown, there is a consensus 
that malfunctioning of the extracellular matrix is a major contributor to the pathogenesis of 
emphysema. In this study, we analyzed the expression of the elastic fiber protein fibrillin-1 in 
a large number (n = 69) of human lung specimens with early-onset emphysema. Specimens 
were morphologically characterized by the Destructive Index, the Mean Linear Intercept, 
and the Panel Grading. We observed a strong correlation (P < 0.001) of aberrant fibrillin-1 
staining with the degree of destruction of lung parenchyma (r = 0.71), airspace enlargement 
(r = 0.47), and emphysema-related morphological abnormalities (r = 0.69). There were no 
obvious correlations with age and smoking behavior. Staining for three other extracellular 
matrix components (type I collagen, type IV collagen, and laminin) was not affected. The 
aberrant fibrillin-1 staining observed in this study is similar to that observed in Marfan 
syndrome, a syndrome caused by mutations in the gene encoding fibrillin-1. Strikingly, 
emphysema is noticed in a number of Marfan patients. This, together with the notion that 
disruption of the fibrillin-1 gene in mice results in emphysematous lesions, makes fibrillin-1 
a strong candidate to be involved in the etiology and pathogenesis of emphysema.
P
Pulmonary emphysema is a progressive 
lung disease that is defined by an abnormal 
permanent enlargement of airspaces dis-
tal to the terminal bronchioles, ac-
companied by destruction of their walls 
and without obvious fibrosis 1. The pre-
vailing theory is that emphysema develops
through an imbalance between the pro-
teolytic activity, due to proteases released
from inflammatory cells, and the anti-
proteolytic defense of the lung. This 
protease/anti-protease imbalance results 
in the destruction of lung extracellular 
matrix (ECM) and eventually leads to 
emphysema 2. Another theory is the 
oxidant/anti-oxidant concept, which pos-
tulates that an excess of oxidants and free 
radicals in the lung directly promotes 
tissue damage and emphysema 3. Firm 
evidence for either of these concepts 
is lacking and consequently the patho-
genesis of emphysema is still an area of 
intense investigation.
 The pathogenesis of emphysema is 
characterized by the loss of elasticity. The 
network of elastic fibers is an important 
structural element in lung parenchyma 
and is, to a major extent, responsible for 
the elastic recoil properties of the lung 4, 
5. Elastic fibers are composed of 10-12 
nm microfibrils located in and around 
amorphous elastin 6-8. Elastin, the major 
component of elastic fibers, has attracted 
much attention in emphysema research. 
However, evidence that associates elastin
to the pathology of emphysema is lacking,
although an amino-acid substitution in
the elastin gene has been associated with
chronic obstructive pulmonary diseases
(COPDs), which include emphysema, 
in one family 9. Therefore, other mole-
cules present in the elastic fiber may
play important roles in the process of 
emphysema.
 Fibrillin-1 is the major component 
of the microfibrillar part of the elastic 
fibers, although many other components, 
including fibulins 10-12, microfibril-asso-
ciated glycoproteins 13-15, and emilins 16-18,
are present. A number of observations 
Introduction
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have associated fibrillin-1 with develop-
mental emphysema. In man, develop-
mental emphysema has been noticed 
in patients with Marfan syndrome, an 
autosomal disorder caused by mutations 
in the gene encoding fibrillin-1 19-27. In 
mice, disruption of the fibrillin-1 gene 
results in developmental emphysema. 
The tight skin mouse, characterized 
by tandem duplication of 30–40 kb in 
the gene encoding fibrillin-1, develops 
emphysematous lesions that are in many 
ways similar to those observed in humans 
28-32. In addition, mice harboring a tar-
geted deletion of 6 kb of the fibrillin-1 
gene also display emphysematous lesions 
33. Both Marfan syndrome and the two 
mouse models share a mutated form of 
fibrillin-1 that gives rise to developmental 
emphysema. It is, however, unknown if 
fibrillin-1 also plays a role in the onset of 
adult emphysema.
 This study reports on the role of 
fibrillin-1 in early-onset emphysema in 
adult humans. A major problem in the 
research into the onset of emphysema 
is the large time span between the 
initiation of the degenerative disease 
process and its clinical manifestations. 
At the time of clinical diagnosis, the 
process of parenchymal destruction is 
already in an advanced state, impeding 
the identification of initiating molecular 
events. Detailed morphological analysis 
of lung parenchyma allows for early 
identification of emphysema, especially 
since the definition of emphysema is 
based on morphological parameters. 
Therefore, we used lung specimens from 
patients without clinical emphysema 
but with microscopical emphysema, as 
defined by destruction of the alveolar 
wall and enlargement of the airspaces 34. 
On the basis of our data, a new concept 
for the onset of emphysema is proposed.
Lung specimens were obtained from 
patients undergoing a lobectomy or 
pneumonectomy, for a localized malig-
nant process, at the University Lung 
Center Nijmegen. All subjects were 
studied according to the guidelines of 
the Medical Ethical Committee of the 
Radboud University Nijmegen Medical 
Center. Specimens were sampled distant-
ly from the tumor or in an unaffected 
lobe. Upon histological analysis, speci-
mens did not show any sign of the un-
derlying disease. Lung function tests 
were performed before surgery. Lung 
function data for all patients studied 
were within normal range, according to 
ERS standards 35. 
Small tissue specimens were taken from 
resected lung lobes. Each specimen was 
cut into pieces of equal size. One part 
was immersed in phosphate-buffered 
saline (PBS) and inflated under vacuum 
(13 kPa) for 20 min using a routine water 
stream-driven device (water aspirator) to 
restore alveolar dimensions 36. This part 
was used for immunohistochemistry (see 
below). The other -adjacent- part was 
similarly inflated in PBS containing 4% 
formalin, embedded in paraffin, and used 
for morphological analysis (see below).
Three morphological parameters have 
been used to characterize human lung 
parenchyma and establish the severity 
of emphysema: the Destructive Index 
(DI, a measure for early parenchymal 
destruction) 37, the Mean Linear Intercept 
Experimental Methods
Lung tissue 
Morphological analysis
Tissue processing 
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clearly abnormal morphology, or (d) clas-
sic emphysematous changes 37. The per-
centage of all the points falling into these 
categories was computed to yield the DI. 
Generally, 750 points were analyzed per 
specimen with maxima up to 5000 points. 
A DI value of 0–30% was considered 
normal 37. 
The MLI is a measure for airspace 
enlargement. To determine the MLI, the
same images as described above were 
used. A transparent sheet with 10 hori-
zontal and 11 vertical lines was laid 
over the images, and intercepts of 
alveolar walls with these lines were 
counted. Values were corrected for tissue 
shrinkage by measuring the dimensions 
before and after histological processing. 
The correction factor was 0.82, which 
is in accordance with earlier studies 40. 
A total of 2,500 intercepts were counted 
(MLI, a measure for airspace enlarge-
ment) 38, and Panel Grading (PG, mor-
phological grading of emphysematous 
lesions) 39. Hematoxylin and eosin (Sig-
ma-Aldrich, St Louis, MO, USA)-stained 
sections (5 μm) were used.
Using a microscopic point count tech-
nique, the DI was evaluated. Microscopic 
fields devoid of large bronchioli, large
blood vessels, collapsed tissue, or exten-
sive fibrosis were selected. For each lung 
specimen, an average of five different 
sections was used, and representative 
non-overlapping fields were selected. 
Alveoli lying underneath the counting 
points were evaluated for the presence of 
destruction. Destruction was defined on 
the basis of one or more of the following 
criteria: (a) at least two alveolar wall 
defects, (b) at least two intraluminal 
parenchymal rags in alveolar ducts, (c)
Table 1: Characteristics of the study group and morphological data of the specimens studied
DI, Destructive Index; MLI, Mean Linear Intercept; PG, Panel Grading; FEV1, forced expiratory volume in 1 
s; % pred., perentage of predicted value; VC, vital capacity; Kco, diffusion capacity for CO; TLC, total lung 
capacity; RV, residual volume. 
All values are means ± SD. 
Destructive Index
Mean Linear Intercept
 
 
Normal  
(n = 12) 
Moderate degree of microscopical  
emphysema (n = 27) 
High degree of microscopical 
emphysema (n = 30) 
Study group 
 Age (year) 
 
60 ± 9 
 
61 ± 8 
 
65 ± 6 
 Pack years 29 ± 9 38 ± 20 39 ± 21 
 FEV1 (% pred.) 74 ± 15 82 ± 19 77 ± 17 
 FEV1/VC (% pred.) 82 ± 1 91 ± 1 78 ± 2 
 KCO (% pred.) 81 ± 26 82 ± 22 75 ± 19 
 TLC (% pred.) 93 ± 23 95 ± 17 102 ± 13 
 RV/TLC (% pred.) 105 ± 21 106 ± 21 108 ± 18 
Morphological data specimens 
 DI (%) 
 
25 ± 10 
 
58 ± 8 
 
83 ± 7 
 MLI (μm) 290 ± 41 319 ± 43 394 ± 55 
 PG (%) 31 ± 11 57 ± 9 78 ± 8 
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 mouse anti-fibrillin-1 (mAb 1919, raised
against bovine zonular fibrils; Chemicon 
International, Temecula, CA, USA) di-
luted 1:1000 in block buffer. After three 
washes in PBS, the primary antibody 
was detected with a biotinylated horse 
anti-mouse IgG antibody (Jackson Im-
muno Laboratories, West Grove, PA, 
USA) for 1 h, followed by enhancement 
with the avidin–biotin–peroxidase com-
plex (Vectastain ABC Elite kit; Vector 
Laboratories Inc., Burlingame, CA, USA)
for 1.5 h. After three washes in PBS, the 
sections were incubated with diamino-
benzidine substrate (DAB) (Sigma-Al-
drich), enhanced with nickel. After a 
final wash in PBS, the sections were 
counterstained with hematoxylin (Sig-
ma-Aldrich) and mounted in entellan 
(Merck, Darmstadt, Germany).
 Using the method described above, 
three other antibodies were used, namely, 
rabbit  anti-laminin (L9393, 1:100 di-
lution; Sigma Immuno Chemicals, St 
Louis, MO, USA), a rabbit antibody 
against bovine type I collagen (1:100 
dilution; Chemicon International), and 
a goat antibody against human type 
IV collagen (1340-01, 1:100 dilution; 
Southern Biotechnology Associates, Bir-
mingham, AL, USA). Biotinylated don-
key anti-rabbit IgG and donkey anti-goat 
IgG (Jackson Immuno Laboratories) were 
used to detect the primary antibodies. 
 All sections were randomly coded, 
and immunoreactivity was scored in-
dependently by two observers using a 
semiquantitative scale ranging from 0 
(linear staining, no fragmentation) to 6
(punctuate staining, extensive fragmen-
tation).
per specimen with maxima up to 18,000 
intercepts.
 
The degree of emphysema in the images
described above was analyzed by compa-
ring the images with a panel of reference 
images. The grading ranged from 0 (nor-
mal tissue) to 100% (complete des-
truction). The PG value was expressed as 
an average percentage of severity of the 
lesions. The average number of measured 
slides per specimen was six.
Study Group 
Sixty-nine lung parenchymal specimens, 
derived from patients without clinical 
emphysema, were selected on the basis 
of the three morphological parameters 
(DI, MLI, and PG). All of the specimens 
studied were derived from patients with 
a history of smoking, ranging from 10 
to 100 pack years. The characteristics 
of this study group are depicted in Table 
1. Specimens originating from patients 
who had never smoked and had values 
within the normal range were used as a 
control (n = 7). Specimens originating 
from patients with other pulmonary 
diseases (large cell carcinoma (n = 2) 
and sarcoidosis (n = 2)) were studied to 
evaluate the specificity of the data. 
Immunohistochemistry 
All incubations were performed at room 
temperature, unless stated otherwise. 
Cryosections of 2 μm were cut and 
endogenous peroxidase was blocked 
with 0.3% (v/v) H2O2 in PBS for 1 h. 
Subsequently, sections were washed in 
PBS and incubated for 30 min with 1% 
(w/v) bovine serum albumin (fraction V; 
Sigma-Aldrich) in PBS (block buffer). 
Sections were incubated overnight with
Panel Grading
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Statistics
Results were calculated with SPSS 11.0 
(SPSS Inc., Chicago, IL, USA) using 
Spearman’s two-sided ranked correlation 
and plotted in a scatter diagram.
Results
Study Group
As depicted in Table 1, lung function 
of the patients studied did not meet the 
GOLD (Global Initiative for Chronic 
Obstructive Lung Disease) criteria 41 for 
the diagnosis of emphysema. Sixty-nine 
lung specimens were morphologically 
characterized for their degree of micros-
copical emphysema using the DI as a
marker for early parenchymal destruc-
tion, the MLI as a marker for airspace 
enlargement, and the PG index as a 
value for emphysematous lesions. Three
groups were formed: normal specimens, 
specimens with a moderate degree of
microscopical emphysema, and speci-
mens with a high degree of microscopical 
emphysema (Table 1).
General 
To study fibrillin-1 expression, paren-
chymal lung specimens were stained 
with an antibody against fibrillin-1. In
control specimens, fibrillin-1 was abun-
dantly expressed in a characteristic fi-
brillar pattern (Figure 1a and b). Fibril-
lin-1 was identified in alveoli as elon-
gated fibers meandering throughout the
septa. No significant disruption of the
linear fibrillin-1 staining was observed. 
In contrast, in specimens with a high
degree of microscopical emphysema, 
the linear fibers were (almost com-
pletely) fragmented and had a punc-
tuate appearance (Figure 2f).
 Next to fibrillin-1, we studied other 
ECM components, namely, type IV 
collagen and laminin (both confined 
to basement membranes) and type I 
collagen. Type IV collagen and laminin 
showed a typical linear basement mem-
brane staining (Figure 3d–f and g–i, res-
pectively), whereas type I collagen was 
Figure 1. Fibrillin-1 immunostaining in normal 
human lung parenchyma. Two cryosections, 
derived from a 21-year-old patient who had never 
smoked and had no aberrant morphological 
parameters, were incubated with an antibody 
against fibrillin-1 (a, b). Bound antibody was 
visualized with biotinylated anti-mouse IgG 
followed by DAB incubation. Note the abundant 
fibrillar fibrillin-1 staining, which meandered 
throughout the alveolar septa. Scale bar, 50 μm.
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present as a typical fibrillar staining 
(Figure 3a–c). Staining for these ECM
components did not reveal any dif-
ferences in abundance or distribution for 
all specimens examined (Figure 3).
Aberrant fibrillin-1 staining is associated with 
early parenchymal destruction 
The DI reflects the degree of parenchy-
mal destruction and is considered the 
most sensitive marker for early em-
physematous lesions. Lung specimens 
characterized by a low DI (normal lung 
specimens), indicating no parenchymal 
destruction, expressed fibrillin-1 abun-
dantly (Figure 2d). This expression was 
comparable to the fibrillin-1 expression
seen in control tissue (Figure 1). In
lung specimens with moderate manifes-
tations of parenchymal destruction (mo-
derate degree of microscopical emphy-
sema), fibrillin-1 expression was mo-
derately disrupted and slightly re-
duced (Figure 2e). Lung specimens, 
characterized by severe manifestations 
of parenchymal destruction (high degree
of microscopical emphysema), dis-
played a markedly reduced and frag-
Figure 2. Fibrillin-1 immunostaining. Cryosections derived from a normal lung specimen (63 years, DI = 
18%, MLI = 231 μm, PG = 12%) (a, d), a specimen with a moderate degree of microscopical emphysema 
(58 years, DI = 60%, MLI = 273 μm, PG = 52%) (b, e), and a specimen with a high degree of microscopical 
emphysema (68 years, DI = 87%, MLI = 317 μm, PG = 85%) (c, f) were incubated with an antibody against 
fibrillin-1. Bound antibody was visualized with biotinylated anti-mouse IgG followed by DAB incubation. 
Note the parenchymal destruction and airspace enlargement in specimens with a moderate/high degree 
of microscopical emphysema (b, c). Compared to the lung specimens with no manifestations of alveolar 
destruction (d), where an abundant and branched fibrillin-1 staining was seen, a reduced fibrillin-1 staining 
was apparent in lung specimens with moderate manifestation of alveolar destruction (e). The staining 
showed fragmented fibers (arrows) instead of elongated fibers. In specimens with severe manifestations of 
alveolar destruction, fibrillin-1 staining was markedly reduced and had a dot-like or punctuate appearance 
(f, arrows). Scale bar, 50 μm.
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mented fibrillin-1 staining, characterized 
by a punctuate appearance (Figure 
2f). To semiquantify the degree of 
fragmentation, we used an arbitrary 
scale from 0 (no fragmentation) to 6 
(complete fragmentation). When the 
degree of fibrillin-1 fragmentation was 
plotted against the degree of parenchy-
mal destruction, that is, the DI, a sig-
nificant correlation (P < 0.001) was 
observed (Figure 4).
Aberrant fibrillin-1 staining is associated with 
airspace enlargement and emphysematous 
Figure 3. Type I collagen, type IV collagen, and laminin immunostaining. Cryosections derived from 
a normal lung specimen (63 years, DI = 18%, MLI = 231 μm, PG = 12%) (a, d, g), a specimen with a 
moderate degree of microscopical emphysema (58 years, DI = 60%, MLI = 273 μm, PG = 52%) (b, e, h), 
and a specimen with a high degree of microscopical emphysema (68 years, DI = 87%, MLI = 317 μm, PG 
= 85%) (c, f, i) were incubated with an antibody against type I collagen (a–c), type IV collagen (d–f), and 
laminin (g–i). Bound antibody was visualized with biotinylated IgG followed by DAB incubation. Note the 
fibrillar staining pattern for type I collagen and the liner basement membrane staining for type IV collagen 
and laminin. Type I collagen, type IV collagen, and laminin staining in specimens with a moderate or high 
degree of microscopical emphysema was similar to the staining in observed normal lung specimens. Scale 
bar, 50 μm.
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abnormalities 
The MLI is a parameter for airspace 
enlargement. The presence of fragmented 
fibrillin-1 staining was plotted against 
the MLI (Figure 5), and a significant 
correlation (P < 0.001) was observed. 
The PG value reflects the overall degree 
of emphysematous abnormalities. A sig-
nificant correlation (P < 0.001) was ob-
served between the amount of fibrillin-1 
fragmentation and PG (Figure 6).
Aberrant fibrillin-1 staining is not associated 
with age 
The process of emphysema is age-de-
pendent. Therefore, it may be assumed 
that the fibrillin-1 fragmentation is de-
pendent on age. However, this appears 
not to be the case. When fibrillin-1 
fragmentation was plotted against age 
(Figure 7a), no significant correlation 
was observed. Fibrillin-1 fragmentation 
was present at the same level in all age 
categories. For instance, staining derived 
in a specimen from a young individual 
(42 years) with a high DI (70%) was 
highly fragmented, as was staining in a 
specimen from an older individual (68 
years) with a high DI (87%) (Figure 7c 
and e). Likewise, a young individual (41 
years) with a low DI (11%) displayed 
a normal fibrillin-1 staining, as did an 
older individual (78 years) with a low DI 
(23%) (Figure 7b and d).
Figure 4. Fibrillin-1 fragmentation as a function 
of the Destructive Index (DI). By means of an 
arbitrary scale ranging from no fragmentation (0) to 
maximal fragmentation (6), fibrillin-1 fragmentation 
was plotted against the DI. A significant correlation 
was found between fibrillin-1 fragmentation and 
DI (P < 0.001). The regression coefficient equals 
0.71. Each point represents an individual patient.
 
Figure 5. Fibrillin-1 fragmentation as a function 
of mean linear intercept (MLI). By means of an 
arbitrary scale ranging from no fragmentation 
(0) to maximal fragmentation (6), fibrillin-1 
fragmentation was plotted against the MLI. A 
significant correlation was found between fibrillin-1 
fragmentation and MLI (P < 0.001). The regression 
coefficient equals 0.47. Each point represents an 
individual patient.
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Aberrant fibrillin-1 staining is not associated 
with smoking behavior 
The degree of clinical emphysema is
strongly correlated with smoking beha-
vior. However, when fibrillin-1 frag-
mentation was plotted against smoking 
behavior, as expressed in pack years (one 
pack year is equal to smoking one pack 
of cigarettes per day during one year), no 
correlation was detected (Figure 8).
Aberrant fibrillin-1 staining is not associated 
with other lung diseases 
To evaluate the specificity of the aberrant 
fibrillin-1 staining for the process of 
emphysema, specimens derived from pa-
tients with other lung diseases (large 
cell carcinoma and sarcoidosis) were 
immunostained for fibrillin-1 (Figure 
9, for large cell carcinoma). Fibrillin-
1 expression in these specimens was 
abundant with a striking absence of 
fibrillin-1 fragmentation, indicating the 
specificity of our observations.
Discussion
In this study, we showed that an aberrant 
fibrillin-1 staining in lung specimens was 
significantly associated with the three 
most important morphometric para-
meters for emphysema: the DI (alveolar 
destruction), the MLI (airspace enlarge-
ment), and the PG (emphysema-
related morphological abnormalities). 
Since emphysema is defined by an 
abnormal permanent enlargement of air-
spaces and by destruction of their 
walls, characterization of the disease 
with morphological parameters such 
as DI and MLI is a prerequisite to 
study the pathogenesis of emphysema. 
We collected lung specimens that had 
microscopical emphysema, as judged 
by morphometric analysis 34. Despite 
these morphological abnormalities, lung 
function tests were still within normal 
range, indicating that the process of lung 
destruction is still at an early stage. Lung 
function tests are a useful tool to diagnose 
COPD, a collective term including chro-
nic bronchitis and emphysema. How-
ever, because lung function tests reflect 
airway obstruction and not loss of 
pulmonary parenchyma, the use of these 
tests to merely establish emphysema 
is controversial 42-44. Besides that, the 
relationship between lung function da-
ta and the morphological assessment 
of emphysema has been described as 
poor 45-48. Owing to this insensitivity, 
lung function tests are of limited value 
to identify the onset of emphysema. 
Figure 6. Fibrillin-1 fragmentation as a function 
of panel grading (PG) value. By means of an 
arbitrary scale ranging from no fragmentation (0) 
to maximal fragmentation (6), fibrillin-1 fragmenta-
tion was plotted against the PG. A significant 
correlation was found between fibrillin-1 frag-
mentation and PG (P < 0.001). The regression 
coefficient equals 0.69. Each point represents an 
individual patient.
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Figure 7. Lack of correlation between
fibrillin-1 fragmentation and age. (a)
Fibrillin-1 as a function of age. By means
of an arbitrary scale ranging from no
fragmentation (0) to maximal frag-
mentation (6), fibrillin-1 fragmentation 
was plotted against age. No significant 
correlation was found between fibrillin-1 
fragmentation and age. The regression 
coefficient equals 0.15. Each point 
represents an individual patient. (b–e) 
Fibrillin-1 immunostaining in specimens 
from patients with similar age, but 
different DIs. Cryosections derived from 
a young patient (41 years) with a low DI 
(11%) (b) and a young patient (42 years) 
with a high DI (70%) (c) were incubated 
with an antibody against fibrillin-1. 
Likewise, cryosections from an older 
patient (78 years) with a low DI (23%) 
(d) and an older patient (68 years) with 
a high DI (87%) (e) were immunostained 
for fibrillin-1. Bound antibody was 
visualized with biotinylated anti-mouse 
IgG followed by DAB incubation. Note 
the abundant, helical, fibrillin-1 staining 
in the young patient and older patient 
with a low DI (a, d) and the small, dot-
like fibrillin-1 structures (arrows) in the 
young patient and older patient with a 
high DI (b, e). Scale bar, 50 μm.
Therefore, clinical manifestations of 
emphysema are only evident in patients 
with a wide spread and advanced emphy-
sema 46, 49-55. Indeed, autopsy studies have
indicated that one-third of the lung 
can be affected by emphysema before 
respiratory function is impaired 56. The 
onset of emphysema is a process that 
can only be measured accurately by 
microscopic measurements. Therefore, 
this study used lung specimens from 
patients without clinical manifestations, 
but with morphological abnormalities 
indicative of early-onset emphysema. 
This unique data set allowed us to ana-
lyze initiating molecular events in the 
pathogenesis of emphysema.
 Our data suggest that fibrillin-1 is 
an important player in the onset of adult 
emphysema. This notion is underlined 
by the observation that staining for 
other ECM molecules (laminin, type I 
collagen, and type IV collagen) was not 
aberrant. The hypothesis that fibrillin-1 is 
a major player in the onset of emphysema 
is corroborated by other lines of research 
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that have correlated fibrillin-1 with 
developmental emphysema. Mutated 
forms of fibrillin-1 are causative for 
developmental emphysema in mouse
models 30, 32. Tight skin mice, charac-
terized by a tandem duplication of 30–40 
kb in the gene encoding fibrillin-1 31, 
have an abnormal immunostaining for 
fibrillin-1 29. Fibroblasts from these mice 
synthesize and secrete normal as well 
as oversized fibrillin-1 protein 28, 29. The 
resulting abnormal fibrillin-1 assembly 
results in emphysema that is in many 
ways similar to that observed in humans. 
Emphysematous lesions are also observed 
in another mouse model harboring a 
targeted deletion of 6 kb in the fibrillin-1 
gene 33. As a result, elastic fibers have less 
tensile strength, resulting in mechanical 
collapse, overstretching, and fracturing. 
At such sites, the influx of inflammatory 
cells is noted. In man, mutations in the 
fibrillin-1 gene are causative for Marfan 
syndrome, an autosomal disorder affec-
ting the cardiovascular, skeletal, and ocu-
lar system 20, 22, 24. To date, over 500 fibril-
lin-1 mutations have been identified 57.
Mutations are found throughout the gene
and result in a reduced fibrillin-1 syn-
thesis, a delayed secretion, and thus 
an impaired fibrillin-1 deposition into 
the matrix. The fragmented fibrillin-1 
staining observed in our lung specimens 
is similar to the fibrillin-1 staining 
observed in skin specimens from Marfan 
patients 58, 59. Strikingly, developmental 
emphysema has been noticed in a number 
of Marfan syndrome patients, although 
studies are scarce. In one study, three out 
of four autopsied cases (44, 23, and 25 
years of age) displayed emphysema on 
microscopical examination, as indicated 
by dilatation of alveolar spaces and 
rupture of alveolar walls. Fragmented 
elastic fibers, with a granular appearance, 
and microfibrils were noticed 26. In an-
other study, four out of four infants 
with Marfan syndrome had microscopic 
emphysema similar to that observed 
in older patients with emphysema but 
without Marfan syndrome 19. In yet 
another study, four out of four infants 
with Marfan syndrome had microscopical 
features of emphysema, with interrupted, 
fragmented, and clumped fibers that were 
not observed in 13 control infants 25. 
About 5% of the Marfan patients develop 
bullous emphysema, as detected by 
chest radiography 27. In neonatal Marfan 
syndrome, a severe form of the disease, 
emphysema, is common 21, 23. It should 
 
Figure 8. Fibrillin-1 fragmentation as a function 
of smoking. By means of an arbitrary scale 
ranging from no fragmentation (0) to maximal 
fragmentation (6), fibrillin-1 fragmentation was 
plotted against smoking (expressed in pack 
years). No significant correlation was found 
between fibrillin-1 fragmentation and smoking. 
The regression coefficient equals 0.07. Each point 
represents an individual patient.
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be noted that the presence of emphysema 
in patients with Marfan syndrome may 
very well be underestimated. Patients are 
generally not examined for emphysema/
COPD. Before the use of β-blockers and 
cardiovascular surgery, patients gene-
rally died in their late 30s, an age at 
which clinical emphysema is generally 
not manifest.
 The observation that fibrillin-1 frag-
mentation is not correlated with smoking 
behavior or age is intriguing. Smoking 
is considered the most important risk 
factor for emphysema, but, for unknown 
reasons, only 15% of smokers actually 
develop clinical emphysema 60. This 
paradox suggests that, besides smoking, 
another factor must be involved in the 
susceptibility to emphysema. Is there 
another risk factor for emphysema 
besides smoking? Familial aggregation, 
implying a genetic predisposition, has 
been observed for emphysema 61-64. This 
suggests that next to environmental cau-
ses, genetic influences are of importance 
for the susceptibility to emphysema. 
Clinical emphysema would thus result 
from combined external risk factors and 
intrinsic host factors. Emphysema has 
been associated with polymorphisms in 
genes encoding epoxide hydrolase 65, 
vitamin D-binding protein 66, and heme 
oxygnase 67. However, strong associations 
between these polymorphisms and the 
elastic recoil properties of the lung are 
lacking and correlations with protein 
levels in human lung have not been 
reported 68, 69.
 Our study presents data that cor-
relate fibrillin-1 to the onset of adult 
emphysema. This, together with the no-
tion that mutations in the fibrillin-1 gene 
may result in emphysematous lesions 
in man (Marfan syndrome) as well as 
mice, makes the fibrillin-1 gene a strong 
candidate for the predisposition of 
smokers to emphysema. The following 
hypothesis may now be put forward: a 
mutation in the gene encoding fibrillin-1 
results in a (moderately) affected fibrillin-
1 protein in the lung. Once the lung is 
challenged, for example, by smoking, 
the affected fibrillin-1 will lead to defec-
tive elastic fibers and to the loss of 
elasticity, which is the major hallmark of 
emphysema. Owing to the loss of elastic 
fibers, breathing will be compromised 
and clinical emphysema will develop.
Figure 9. Fibrillin-1 immunostaining in a lung 
specimen derived from large cell carcinoma.  A 
cryosection from non-emphysematous tissue (DI = 
20%, MLI = 264 μm, PG = 22%; age of patient: 57 
years, and 40 pack years), affected by large cell 
carcinoma, was incubated with an antibody against 
fibrillin-1. The section contains alveolar fibrosis, 
due to a desmoplastic reaction, and infiltrated cells. 
Bound antibody was visualized with biotinylated 
anti-mouse IgG followed by DAB incubation. Note 
the abundant fibrillin-1 staining, which was present 
throughout the alveolar septa. Scale bar, 50 μm.
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eparan sulfate proteoglycans (HSPGs) are cell surface and extracellular matrix (ECM) 
components that control numerous cell processes. These glycoprotein molecules are 
comprised of a protein core to which linear polysaccharide chains of heparan sulfate (HS) are 
attached. Structural diversity is imparted by the HS component, which shows large structural 
complexity. Such complexity results in a number of sequence motifs that selectively bind 
and activate distinct effector proteins, including growth factors, proteases and lipoproteins. 
HS is a linear co-polymer of alternating glucosamine and uronic acid residues. Distinct HS 
domains are, in large part, defined by the number and position of sulfate groups that decorate 
the HS chain. Due to the presence of carboxylic and sulfate groups, HS molecules are highly 
negatively charged, and this property endows HSPGs with unique characteristics that are 
important in the integrity and functioning of the ECM. Today, evidence is accumulating for the 
involvement of HSPGs in the pathogenesis of pulmonary emphysema, a smoking-related 
lung disease, characterized by an imbalance of proteases/protease-inhibitors, oxidants/anti-
oxidants and ECM components.
H
The relevance of proteoglycans for the 
development of emphysema is demon-
strated in several studies. First, proteo-
glycans bind and modulate growth factors
and cytokines and act, mainly through 
HS, as strong protease inhibitors. Further-
more, proteoglycans play an important 
role in the neutralization of oxidants 
and free radicals. This, together with 
their strong association with collagen- 
and elastin fibers and their strategic 
location in the alveolar wall indicates 
the importance of proteoglycans in the 
alveolar matrix. Changes in the synthesis 
and/or composition of proteoglycans/
glycosaminoglycans (GAGs) could result 
in a disturbance of the alveolar matrix, 
which may eventually lead to emphysema. 
In the research towards the pathogenesis 
of emphysema, proteoglycans, especially 
agrin and perlecan, have been studied. 
However, these studies primarily focused 
on the protein core, ignoring the GAG 
moiety because of the lack of appropriate 
tools such as antibodies. 
 The aim underlying the study des-
cribed in this thesis was to select antibo-
dies against HS isolated from human lung, 
to investigate the distribution of HS in 
normal versus diseased (emphysematous) 
lung tissue, and to get a better view of 
the ECM molecules associated with the 
onset of emphysema.
 In Chapter 1 an overview is given 
on the present knowledge concerning 
proteoglycans in the lung. Special atten-
tion is given to the structure, biosyn-
thesis and function of HS, including 
its role in development and patho-
(physiology). In Chapter 2 is described
how phage display-derived antibodies 
directed against human GAG epitopes
can be generated and selected. We have 
used this phage display technology to 
select seven unique antibodies against 
human lung HS, as described in Chapter 
3. Using these novel antibodies, the ex-
pression of distinct HS epitopes in human 
lung tissue was evaluated. HS epitopes 
were found to be differentially distributed 
in human lung tissue. Whereas some 
HS epitopes were generally present in 
basement membranes, others had a more 
restricted distribution, especially with 
regard to macrophages and bronchiolar 
epithelial cells. We demonstrated that 
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some antibodies blocked a FGF-2-
binding site in HS, and that one antibody 
blocked a VEGF-binding site in heparin. 
Antibodies defining specific HS epitopes 
can be used as tools to study the structural 
dynamics of HS on a (sub)cellular level. 
In Chapter 4, the epitope recognized by 
phage display-derived antibody NS4F5
was studied in more detail. Using a
combination of biosynthetic HS oligo-
saccharide libraries, tissues from mice 
defective in HS biosynthetic enzymes, 
and a panel of chemically modified 
heparins we were able to establish the 
monosaccharide sequence of its epitope. 
The HS sequence was (GlcNS6S-IdoA-
2S)3 and this sequence was, next to 
heparin-containing mast cells, only pre-
sent in a very small subset of HS. A 
highly sulfated HS sequence suggests 
a specific role in cell behavior, and 
therefore we studied the cell biological 
relevance of this HS epitope. We have 
used the antibody as a blocking agent 
in cultures of human epithelial cells and 
showed that its HS epitope is involved in 
cell proliferation and apoptosis, but not 
in cell adhesion. The NS4F5 antibody is 
the first phage display-derived antibody 
against HS described in the literature 
of which the monosaccharide sequence 
could be revealed. In Chapter 5 we 
evaluated lung tissue from subjects with 
early signs of emphysema as revealed 
by the Destructive Index (DI), the most 
sensitive parameter for emphysema. We 
focused on early changes in the ECM, 
and found that in emphysematous lung 
tissue the expression of HSPGs (both 
side chain and core protein) was reduced, 
in contrast to other matrix components 
such as collagens and laminin. In addi-
tion, an upregulation of the HS-degrading 
enzyme heparanase was observed. To in-
vestigate whether heparanase expression 
could induce emphysematous lesions, 
lungs of transgenic mice overexpressing 
this enzyme were investigated. We de-
monstrated that lungs of heparanase-
overexpressing mice indeed developed 
emphysematous lesions, which became 
more severe at increasing age, resembling 
the human situation. From the results 
described in this chapter, we conclude 
that increase in heparanase expression 
and loss of HS in the lung are early events 
in the development of emphysema. These 
new findings argue that inhibitors of 
heparanase activity might be evaluated as 
potential drugs to slow down the process 
of emphysema. In Chapter 6 we turned 
to another ECM molecule, fibrillin-1. 
Fibrillin-1 is a major component of the 
microfibrillar part of elastic fibers, and 
binds to HS. We used lung specimens 
from patients with microscopical em-
physema, as defined by destruction of 
alveolar walls and enlargement of the 
airspaces. The hypothesis that fibrillin-
1 is a player in the onset of emphysema 
is corroborated by several lines of re-
search. Mutated forms of fibrillin-1 are 
causative for developmental emphysema 
in mouse models, including the tight 
skin mice, characterized by a tandem 
duplication of 30–40 kb in the gene en-
coding fibrillin-1, and mice harboring a 
targeted deletion of 6 kb in the fibrillin-
1 gene. We demonstrated that in controls, 
fibrillin-1 was abundantly expressed in
a characteristic fibrillar pattern. In con-
trast, in specimens with a high degree
of microscopical emphysema, the linear
fibers were almost completely fragmen-
ted and had a punctuate appearance. 
Staining for other ECM components as
collagen type I and IV and laminin 
did not reveal any differences in abun-
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determined by mass spectrometry and 
HS disaccharide analysis. As an alter-
native for the structural analysis of the 
total HS, partially digested HS derived 
from human lung may be affinity purified 
by anti-HS antibodies and then followed 
by HS structural analysis. Ultimately, this 
could lead to the rational development 
of defined HS-based therapeutics. The
potential role of such HS-based glyco-
mimetics in treating emphysema should 
be evaluated in in vivo experimental 
models of emphysema. 
 The present set of data offers new 
insights in the diversity and function of 
a number of novel HS epitopes. It has 
become clear that anti-HS antibodies 
have a strong preference for specific mo-
dification patterns on the HS chain. 
However, it still remains to be elucidated 
whether these HS epitopes are unique 
for specific core proteins. Besides this, 
it would also be challenging to elucidate 
the exact monosaccharide sequences 
of the HS epitopes recognized by the 
antibodies.
 GAGs, as HS, could play an im-
portant role in the neutralization of 
oxidants and free radicals. Given that 
cigarette smoke greatly increases the risk 
for the development of emphysema, it 
would be interesting to investigate the 
effect of cigarette smoke on alveolar 
proteoglycans. It would be interesting 
to apply fully characterized phage dis-
play-derived antibodies to lungs of rats
exposed to cigarette smoke to inves-
tigate the effect of smoking on HS 
(degradation).
dance or distribution. Aberrant fibrillin-
1 staining was associated with early pa-
renchymal destruction. We also showed 
that aberrant fibrillin-1 staining was 
associated with airspace enlargement 
and emphysematous abnormalities. In 
conclusion, we showed that an aberrant 
fibrillin-1 staining in lung specimens 
was significantly associated with the 
three most important morphometric 
parameters for emphysema: the DI 
(alveolar destruction), the MLI (airspace 
enlargement), and the PG (emphysema-
related morphological abnormalities). 
This, together with the notion that 
mutations in the fibrillin-1 gene may 
result in emphysematous lesions in men 
(Marfan syndrome) as well as mice, 
makes the fibrillin-1 gene an important 
player in the onset of pulmonary em-
physema.
In this thesis the role of HS in human 
lungs, including emphysematous lungs 
was addressed. Antibodies against HS 
were selected, and used to study the 
distribution of specific HS epitopes in 
normal lung. The panel of antibodies can 
now be used to study the involvement 
of specific HS epitopes in lung pa-
thology. There are clear indications 
that HS is associated with early events, 
ultimately resulting in emphysema. It 
will be challenging to identify the exact 
structures within HS that are important 
for the development of emphysema. To 
this end, HS from both emphysematous 
lungs and controls should be isolated 
and the chemical make-up should be 
Future perspectives
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eparansulfaat proteoglycanen (HSPGs) zijn celoppervlak- en extracellulaire matrix (ECM) 
gerelateerde componenten die verschillende cellulaire processen controleren. Deze 
glycoproteinen bestaan uit een eiwitketen waaraan lineaire polysaccharideketens van 
heparansulfaat (HS) zijn gekoppeld. Structurele diversiteit wordt voornamelijk teweeg 
gebracht door de HS component, welke een enorme structurele complexiteit vertoont. Een 
dergelijke complexiteit resulteert in een aantal sequenties welke selectief verschillende ef-
fectormoleculen kunnen binden en activeren, zoals groeifactoren, proteasen en lipoproteïnen. 
HS is een co-polymeer dat bestaat uit repeterende eenheden van glucosamine en uronzuur. 
Verscheidenheid in HS domeinen wordt grotendeels bepaald door de hoeveelheid en positie 
van sulfaatgroepen in de HS keten. Door de aanwezigheid van carboxyl- en sulfaatgroepen 
zijn HS moleculen sterk negatief geladen. Deze eigenschap zorgt ervoor dat HSPGs unieke 
eigenschappen bezitten die belangrijk zijn voor de integriteit en het functioneren van de 
ECM. Er zijn steeds meer aanwijzingen die duiden op de betrokkenheid van HSPGs bij 
de pathogenese van longemfyseem, een aan roken gerelateerde longaandoening, die 
gekenmerkt wordt door een onbalans van proteasen/proteaseremmers, oxidanten/anti-
oxidanten en ECM componenten.           
H
De relevantie van proteoglycanen bij 
de ontwikkeling van longemfyseem is 
aangetoond in verschillende studies. 
Ten eerste binden en moduleren pro-
teoglycanen talrijke groeifactoren en 
cytokinen en fungeren zij, voornamelijk 
via HS, als krachtige proteaseremmers. 
Bovendien spelen proteoglycanen een 
belangrijke rol bij de neutralisatie van 
oxidanten en vrije radicalen. Dit, alsmede 
de nauwe associatie met collageen- en 
elastinevezels en de strategische locatie 
in de alveolaire wand, geeft het belang 
van proteoglycanen in de alveolaire 
matrix aan. Veranderingen in de synthese 
en/of samenstelling van proteoglycanen/
glycosaminoglycanen (GAGs) kunnen 
resulteren in verstoring van de alveolaire 
matrix hetgeen uiteindelijk kan leiden 
tot longemfyseem. Onderzoek naar de 
pathogenese van longemfyseem heeft 
zich in de afgelopen jaren voornamelijk 
gericht op proteoglycanen, in het bij-
zonder agrine en perlecan. Deze studies 
waren echter hoofdzakelijk gericht op 
de eiwitketens, aangezien er nauwelijks 
hulpmiddelen, zoals antilichamen, be-
stonden om individuele GAG-ketens te 
onderzoeken. 
 Het doel van de in dit proefschrift 
beschreven studie was om antilichamen 
te genereren tegen HS geïsoleerd uit 
humaan longweefsel, de distributie van 
HS te bestuderen in normaal versus 
afwijkend (emfysemateus) longweefsel 
en een algemeen beter inzicht te krijgen 
in de ECM moleculen die geassocieerd 
zijn bij het ontstaan van emfyseem.  
 In Hoofdstuk 1 wordt een overzicht 
gegeven van de huidige kennis van 
proteoglycanen in de long. Hierbij is 
voornamelijk aandacht geschonken aan 
de structuur, biosynthese en functie van 
HS, alsmede aan de rol bij ontwikkeling 
en patho(fysiologie). In Hoofdstuk 2 
wordt beschreven hoe antilichamen 
gericht tegen specifieke GAG epitopen 
gegenereerd en geselecteerd kunnen 
worden met behulp van de phage dis-
play techniek. We hebben deze phage 
display techniek gebruikt om 7 unieke 
antilichamen te selecteren die gericht zijn 
tegen HS geïsoleerd uit humane long, 
zoals beschreven in Hoofdstuk 3. Deze 
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nieuwe antilichamen werden gebruikt 
om de expressie van verschillende HS 
epitopen in humane long te bestuderen. 
HS epitopen bleken op verschillende 
plaatsen in humaan longweefsel voor te 
komen. Sommige HS epitopen waren 
aanwezig in de basale membraan, terwijl 
anderen slechts op zeer specifieke 
plaatsen voorkwamen, in het bijzonder 
met betrekking tot macrofagen en 
bronchiolaire epitheelcellen. We hebben
aangetoond dat een aantal antilichamen 
in staat bleek om een FGF-2-bin-
dingsplaats op HS te blokkeren, terwijl 
slechts een enkel antilichaam een 
VEGF-bindingsplaats op heparine kon 
blokkeren. Antilichamen die specifieke 
HS epitopen herkennen, kunnen ge-
bruikt worden als hulpmiddelen om de 
structurele dynamica van HS op een 
(sub)cellulair niveau te bestuderen. In 
Hoofdstuk 4 wordt dieper ingegaan op 
de karakterisatie van het epitoop dat 
wordt herkend door antilichaam NS4F5. 
Door een combinatie van biosynthetische 
HS oligosacchariden, weefsels van mui-
zen die deficiënt zijn in HS-biosyn-
thetische enzymen en een panel van che-
misch gemodificeerde heparines, hebben
we de monosaccharidesequentie van het
epitoop achterhaald. De HS sequentie is 
(GlcNS6S-IdoA2S)3 en deze sequentie
was, naast heparine-bevattende mestcel-
len, uitsluitend aanwezig in een sub-
populatie van HS. Een hooggesulfateer-
de HS sequentie suggereert een specifieke 
rol in celgedrag en dit heeft ons doen 
besluiten om de celbiologische relevantie 
van dit HS-epitoop te bestuderen. Het 
antilichaam werd gebruikt als blok-
keermiddel in gecultiveerde humane epi-
theelcellen en we hebben laten zien 
dat het HS-epitoop betrokken is bij 
celproliferatie en apoptose, maar niet bij 
celadhesie. Het NS4F5 antilichaam is 
het eerste, met phage display techniek-
opgewekte, antilichaam, waarvan de mo-
nosaccharidesequentie bepaald kon wor-
den. In Hoofdstuk 5 hebben we long-
weefsel bestudeerd dat afkomstig is van 
patiënten die de eerste verschijnselen 
van emfyseem vertonen als bepaald op 
basis van de Destructive Index (DI), 
de meest gevoelige parameter voor het 
vaststellen van emfyseem. We hebben 
ons gefocuseerd op vroege veranderingen 
binnen de ECM en laten zien dat in 
emfysemateus longweefsel de expressie 
van HSPGs (zowel zijketen als eiwitke-
ten) is verminderd in tegenstelling tot
andere matrix componenten zoals colla-
genen en laminine. Bovendien laten 
we zien dat de expressie van het HS-
afbrekende enzym heparanase is toe-
genomen. We hebben muizen met een 
transgene overexpressie van humaan 
heparanase gebruikt om te bepalen of 
heparanase-expressie causaal kan zijn 
voor de inductie van emfysemateuse le-
sies. In vergelijking met controles werden 
in longen van muizen die heparanase tot 
overexpressie brengen, emfysemateuze 
lesies aangetroffen, welke toenamen met 
de tijd, zoals ook in de humane situatie het 
geval is. Deze resultaten suggereren dat 
een toegenomen heparanase-expressie en 
het verlies aan HS in de long belangrijke 
gebeurtenissen zijn bij de ontwikkeling 
van emfyseem. Deze nieuwe bevindingen 
suggereren dat remmers van heparanase 
activiteit als potentiële middelen kun-
nen worden gebruikt om het proces 
van emfyseemvorming te vertragen. In
Hoofdstuk 6 hebben we ons gericht op 
een ander ECM molecuul, fibrilline-1. 
Fibrilline-1 is een belangrijk component 
van het microfibrillaire gedeelte van 
elastische vezels en bindt aan HS. Ook 
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hier hebben we longweefsel gebruikt 
afkomstig van patiënten waarbij op mi-
croscopisch niveau de eerste verschijn-
selen van emfyseem zijn waar te nemen. 
De hypothese dat fibrilline-1 een rol 
kan spelen bij het begin van emfyseem 
is in verschillende studies aangetoond. 
Gemuteerde vormen van fibrilline-1 zijn
causaal voor de ontwikkeling van em-
fyseem in muizenmodellen, waaronder 
de ‘tight skin muizen’, die worden 
gekenmerkt door een tandem duplicatie 
van 30-40 kb in het gen dat codeert voor 
fibrilline-1, alsmede een muizenmodel 
dat een 6 kb deletie heeft in het fibrilline-
1 gen. Wij hebben aangetoond dat in 
controles, fibrilline-1 in overvloed aan-
wezig is, in een vezelachtig patroon, 
terwijl bij patiënten met een hoog gehalte 
aan microscopisch emfyseem de lineaire 
vezels bijna geheel gefragmenteerd 
zijn. Andere ECM componenten zoals 
type I en IV collageen en laminine 
vertoonden dit verschil niet. We hebben 
aangetoond dat een afwijkende fibrilline-
1-kleuring geassocieerd is met vroege 
parenchymale destructie en met het groter 
zijn van de alveoli. Concluderend kun-
nen we zeggen dat een afwijkende fi-
brilline-1-kleuring in longweefsel signi-
ficant geassocieerd is met de drie meest
belangrijke morfometrische parameters 
voor emfyseem: de DI (alveolaire des-
tructie), de MLI (grotere diameter van de 
alveoli), en de PG (emfyseem-gerelateer-
de morfologische abnormaliteiten). Dit, 
tesamen met het gegeven dat mutaties in 
het fibrilline-1-gen kunnen resulteren in 
emfysemateuze lesies bij de mens (Mar-
fan syndroom) en bij de muis, maakt het 
fibrilline-1-gen een belangrijke kandidaat 
bij het ontstaan van longemfyseem.
In dit proefschrift wordt de rol van HS in 
humane long, inclusief emfysemateuze 
long beschreven. Antilichamen gericht 
tegen HS zijn geselecteerd en gebruikt om 
de distributie van specifieke HS epitopen 
in de normale long te bestuderen. Dit 
panel aan antilichamen kan nu gebruikt 
worden om de betrokkenheid van spe-
cifieke HS-epitopen in longpathologie 
te onderzoeken. Er bestaan duidelijke 
aanwijzingen dat HS geassocieerd is met 
processen die uiteindelijk resulteren in 
emfyseem. Daarom is het een uitdaging 
om de exacte structuren binnen HS te 
identificeren welke van belang zijn bij de 
ontwikkeling van emfyseem. Hiertoe zou 
HS geïsoleerd moeten worden uit zowel 
emfysemateuze als controle longen en
zou de chemische samenstelling be-
paald moeten worden met behulp van 
massaspectrometrie en HS-disacchariden 
analyse. Dit zou uiteindelijk kunnen 
leiden tot de rationele ontwikkeling 
van gedefinieërde, op HS-gebaseerde 
therapeutica. De potentiële rol van zul-
ke op HS-gebaseerde glycomimetica 
bij de behandeling van emfyseem zou 
in vivo bestudeerd moeten worden in 
experimentele modellen voor emfyseem.
 De huidige gegevens geven inzicht in 
de diversiteit en de functie van een aantal 
HS-epitopen. Het is bekend dat anti-HS-
antilichamen een duidelijke voorkeur
hebben voor een specifiek modificatie 
patroon op de HS-keten. Echter, er zou
nader onderzocht moeten worden of de-
ze HS-epitopen ook uniek zijn voor 
specifieke eiwitketens. Daarnaast is het
een uitdaging om de exacte monosac-
charidesequenties te ontrafelen van de 
HS epitopen die door de antilichamen 
herkend worden.
 GAGs, waaronder HS, zouden een
Toekomstvisie
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belangrijke rol kunnen spelen bij de
neutralisatie van oxidanten en vrije radi-
calen. Sigarettenrook is een belangrijke 
risicofactor voor het ontstaan van em-
fyseem en het zou interessant zijn om het 
effect van sigarettenrook op alveolaire 
proteoglycanen te bestuderen. Het ligt nu 
voor de hand om goed gekarakteriseerde 
phage display antilichamen te gebruiken 
om het effect van roken op longen te 
bestuderen en zo te achterhalen welke 
HS-structuren worden afgebroken.
&
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et is AF! 
Maar is het nu ook ‘klaar’? In dit boekje misschien wel, maar een promotieonderzoek is 
eigenlijk nooit écht klaar. Na ruim vier jaar van phage-displayen, ‘peri’s maken’, coupes 
bekijken, antilichamen karakteriseren, pipetteren, op-en-neer pendelen naar Nijmegen en 
schrijven, zit ik hier op een ochtend in Lebanon achter mijn laptop en ben ik nog steeds niet 
uitgeschreven. Feit is dat bij de meeste proefschriften het dankwoord het meest gelezen 
en misschien ook wel het meest bediscussieerde deel (al dan niet openbaar!) is van het 
proefschrift. Een proefschrift schrijven doe je niet alleen en daarom wil ik iedereen bedanken 
die direct of indirect heeft bijgedragen aan ‘mijn boekje’. Het gebeurt immers niet vaak dat 
je in de gelegenheid bent om de mensen te bedanken die een rol hebben gespeeld bij het 
bereiken van een mijlpaal, als je een proefschrift tenminste als zodanig kunt beschouwen. 
Hierbij gaat mijn dank dan ook uit naar iedereen die ook maar enige bijdrage heeft geleverd 
of interesse heeft getoond in wat ik al die jaren tijdens mijn promotieonderzoek bij Biochemie 
heb gedaan, gepresenteerd en beschreven. 
H
Voor de totstandkoming van mijn proef-
schrift wil ik allereerst mijn copromotor 
Dr. Toin van Kuppevelt bedanken.Toin,
ik ben je vooral dankbaar dat je mij met 
mijn ‘HLO achtergrond’ de mogelijkheid 
hebt gegeven om een promotieonderzoek 
uit te voeren. Een carrière in de weten-
schap was iets dat ik na mijn opleiding 
ambieerde en jij hebt me deze gelegen-
heid gegeven. Dat ik bovenop mijn vier-
jarig contract nog een half jaar ver-
lenging heb gekregen, is zeker de moeite 
waard geweest voor ons ‘Blue Journal 
manuscript’! Daar wil ik jou en natuurlijk 
ook promotor Professor Jan Joep De Pont 
hartelijk voor bedanken.
 Promotor Professor Richard Dek-
huijzen wil ik bedanken voor de snelle 
correctie van mijn manuscripten, voor 
de nodige adviezen wat betreft long-
functie data van patiënten in onze ‘long-
bank’ en natuurlijk voor de financiële 
ondersteuning voor het bezoek aan het 
proteoglycanen congres in Stockholm 
waar ik destijds mijn huidige supervisor 
heb ontmoet.
 De afdeling Biochemie wil ik be-
danken voor de fijne samenwerking en 
de gezellige dagjes uit. Wat blijft zijn 
goede herinneringen aan mijn tijd in de 
Researchtoren en, niet te vergeten, lab 
2.66 in het Trigon, waar het voor mij 
als stagiaire allemaal begon. Een aantal 
mensen wil ik in het bijzonder danken:
 Allereerst Elly, jou wil ik bedanken 
voor alle hulp die je me tijdens mijn 
promotieonderzoek hebt gegeven. Jouw
bijdrage aan mijn proefschrift is van 
onschatbare waarde. Van het verzamelen 
van longweefsel bij Dekkerswald en het 
Canisius-Wilhelmina ziekenhuis, het op-
sturen van CD’s met extra foto’s naar de 
United States (omdat de reviewers om 
extra data vroegen en de files te groot 
waren om te emailen), het doorsturen 
van tabellen met longfunctie gegevens, 
tot aan het doorspitten van de ‘longbank’ 
(omdat ik daar zelf geen toegang meer 
tot had) en dan heb ik het niet eens over 
de experimenten die je allemaal hebt 
uitgevoerd/herhaald. Bedankt voor al je 
hulp! 
 Guido! Als mijn voormalig stage-
begeleider ben jij eigenlijk degene die 
mij heeft geïntroduceerd in het ‘GAG-
wereldje’ en heb je mij de fijne kneepjes 
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van het pipetteren, peri’s maken en cellen 
kweken bijgebracht. Daar kwamen nogal 
eens onverwachte resultaten uit, ken 
je deze misschien nog: RB4EA12 + 
C2C12 = ‘ALAAFS’! Het is overbodig 
te melden dat onze ‘ALAAFS’ rond de 
carnaval werden ontdekt... Jouw enorme 
motivatie en interesse in de research 
werkten erg aanstekelijk! Leuk dat we 
na jouw MIT periode nog een tijdje als 
collega’s hebben samengewerkt. De 
parachutesprong die we samen gemaakt 
hebben, even als de trip naar jouw stek-
kie in Boston zijn Eddie en ik nog niet 
vergeten! Als een professionele gids heb 
je ons destijds New York City en Boston 
laten verkennen en daar maken we nu 
zelf dankbaar gebruik van, bedankt daar-
voor! 
 Dan Arie, mijn ex-U-genoot! De 
eerste jaren van mijn AIO periode heb 
ik samen met jou als ‘King of Culture’ 
een U-tje gedeeld. ‘Chunky-time’, ‘C7’ 
en ‘oublie’ zullen een ander weinig 
zeggen, maar wij hebben er toch altijd 
een hoop schik om gehad! Dat we met 
‘Peking Express the Game’ niet één, 
maar zelfs twee keer in staat waren een 
reis voor twee personen naar Beijing te 
winnen, was natuurlijk ondenkbaar. Toch 
is het gelukt en onze reis naar China zit 
er inmiddels alweer een tijdje op. Blijft 
jammer dat we niet met zijn vieren 
tegelijk over ‘The Great Wall’ hebben 
kunnen lopen, maar de voorpret alleen 
was al meer dan geweldig! Ik ben blij 
dat ik jou aan mijn zijde heb staan, straks 
tegenover de corona!
 Theo en Paul, het elektronen 
microcopie-dreamteam! Jullie hebben 
heel wat bijgedragen aan het NS4F5 
hoofdstuk. Ik wil jullie dan ook enorm 
bedanken voor àl die uren die jullie 
hebben gestoken in het immuno EM 
werk dat jullie hebben uitgevoerd en dat 
jullie regelmatig tot in de late uurtjes 
van de straat wist te houden! Theo, jou 
wil ik natuurlijk ook bedanken voor je 
‘hulp op afstand’ bij het maken van mijn 
boekje. Bedankt voor je heldere tips 
waardoor het werken met InDesign een 
stuk eenvoudiger werd!
 Nu dan de vakbroeders, mijn mede 
AIO’s/OIO’s/junior onderzoekers; Paul, 
(Wicky), Joost, Tessa, Suzan, Mieke, 
Peter en niet te vergeten de ‘tissue-
twins’: Gerwen en Martin. Het bleek 
dat we naast het promoveren nog een 
andere gezamenlijke tijdsbesteding had-
den. We hebben namelijk allemaal bin-
nen zeer korte tijd een nieuwe woning 
gekocht dan wel gehuurd en daar ging 
zo ongeveer al onze vrije tijd (en die heb 
je nauwelijks als junior onderzoeker…) 
in zitten. Zo werd er regelmatig onder 
het genot van een ‘bakkie en een stuk 
biochemietaart’ gekletst over de Gamma, 
plamuren, schuren en schilderen, Knauf 
(niet te veel water bij doen…), nieuwe 
badkamers en keukens en natuurlijk de 
zeer gewaardeerde en onmisbare hel-
pende hand van pa en ma. Ik wens jullie 
allemaal heel veel succes bij het afronden 
van jullie promotie!
 Uiteraard wil ik ook alle andere (ex)-
collega’s van Matrixbiochemie bedan-
ken voor de plezierige samenwerking en 
gezelligheid zowel binnen als buiten het 
lab. Velen van jullie hebben je steentje 
bijgedragen aan mijn proefschrift. Jullie 
waren altijd bereid mij ergens mee te 
helpen: Cindy, Els, Gerdy, Herman, 
Kaeius, Marianne, Ronnie, Toon, Wille-
ke. Bedankt daarvoor!
  Bij het doen van experimenten, die 
aan de basis kunnen komen te liggen 
van een manuscript kun je natuurlijk alle 
ondersteuning gebruiken. Daarom wil ik 
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jullie: Bram, Maartje, Wan-Ying en ook 
Ellen heel erg bedanken voor jullie inzet 
en interesse in het onderzoek en voor het 
werk dat jullie hebben verzet. Dat niet 
elk experiment direct tot het gewenste 
resultaat leidt, hebben jullie zelf allemaal 
wel een keer ondervonden. Toch heeft 
jullie werk aan de basis gestaan voor 
een aantal mooie publicaties waarvan 
de resultaten in dit proefschrift staan 
beschreven. Ik wens jullie heel veel suc-
ces in jullie verdere loopbaan.
 Dr. Johan van der Vlag en Professor 
Jo Berden van de afdeling Nierziekten 
wil ik bedanken voor het beschikbaar 
stellen van hun antilichamen JM72 en 
JM403 waarvoor een belangrijke rol is 
weggelegd in hoofdstuk 5.
 Next, I would like to thank our 
collaborating colleagues. Professor Dr. 
Israel Vlodavsky, Dr. Eyal Zcharia and 
Dr. Jin-ping Li, I would like to thank 
you for providing the lungs from the 
transgenic heparanase overexpressing 
mice which we used in Chapter 5. Further 
I would like to thank our colleagues from 
Sweden, Dr. Dorothe Spillmann and Dr. 
Sindhulakshmi Kurup for all their input 
in our (never-ending) NS4F5 story. Dear 
Dorothe and Sindhu, with your expertise 
and help we were finally able to unravel 
the exact monosaccharide sequence 
of the NS4F5 epitope which greatly 
strengthened our manuscript. I greatly 
appreciate your help and input in this 
chapter. I would like to thank Professor 
Jeremy Turnbull for critical review of 
this manuscript. Last but not least, I 
would like to thank my current Princi-
pal Investigator, Dr. Nicholas Shworak. 
Dear Nick, I would like to thank you not 
only for your input in Chapter 1 but also 
for providing the funding that allows me 
to continue my research in the intriguing 
field of heparan sulfate proteoglycans.
 Sleutels… Ik weet ook niet wat dat is 
met die dingen, maar in mijn geval schijnt 
het een soort ‘must’ te zijn om ze vooral 
zo snel mogelijk te ‘verliezen’. Herman, 
bedankt dat je altijd weer paraat stond 
met de reservesleutel van mijn locker 36 
(ja, die met het oranje stickertje…). 
 Als je werkt in Nijmegen, maar woont 
in het pitoreske dorpje Zeddam dan ben 
je behoorlijk wat tijd kwijt met je woon-
werkverkeer. Mijn berekening is de vol-
gende: ongeveer een uurtje per dag enkele 
reis betekent dat je zo’n twee uur per dag 
onderweg bent. Twee uur × vijf dagen 
per week maakt tien. Tien uur × vier we-
ken is veertig uur per maand (en dat is 
weer ongeveer gelijk aan een volledige 
werkweek). Gelukkig bestaat er zoiets 
als carpoolen en daarvoor wil ik jou, Jan, 
bedanken. Samen met Luc, Emma en 
later ook Roos, hebben we regelmatig het 
retourtje Zeddam – Nijmegen afgelegd. 
Deze ritten werden dan nuttig besteed 
met gesprekken op het gebied van onze 
gezamenlijke wetenschappelijke interes-
se en afgewisseld met gezellige gesprek-
ken over koetjes en kalfjes, het eten van 
Duitse broodjes en het luisteren naar ‘de 
leeuw’ en ‘pieniemienie’. 
 Beste familie, vrienden en vriendinnen 
(ja, ook jullie van de VVRG!). Ook 
jullie kan ik natuurlijk niet vergeten te 
betrekken in mijn dankwoord. Ik neem 
aan dat jullie nog steeds niet helemaal 
begrijpen waar ik de afgelopen jaren in 
Nijmegen nou precies mee bezig ben 
geweest... Toch wil ik jullie allemaal 
enorm bedanken voor de interesse en 
natuurlijk voor de broodnodige afleiding 
die jullie me in het weekend vaak, onder 
het genot van een drankje (lees: wijn 
/ Martini), gaven. Ik ben blij dat jullie 
altijd wel weer een reden hadden om iets 
Author Information
136
C
h
ap
te
r 
8
hoef te bedanken in mijn proefschrift, 
maar ik weet zelf heel goed dat juist jij 
degene bent die veel meer verdient dan 
alleen een geschreven ‘dankjewel’. Jij 
hebt mij altijd vrij gelaten om mijn eigen 
keuzes te volgen ook al bracht die weg 
ons naar de andere kant van de oceaan. 
Mijn promotieperiode heb je van dichtbij 
en van begin tot eind meegemaakt en je 
weet dus als geen ander dat een promotie 
behalve ups ook de nodige downs met 
zich mee kan brengen. Bedankt voor 
al je vrolijkheid en afleiding waardoor 
het werk op het lab makkelijker te re-
lativeren was. Ik ben superblij en zeker 
ook trots dat we de stap hebben genomen 
om het eens ‘te gaan proberen’ in the 
States. We wonen straks alweer drie 
jaar in Lebanon, New Hampshire en de 
verhuizing hiernaartoe bleek de beste 
beslissing ooit! Fijn dat we hier allebei 
onze draai hebben kunnen vinden en dat 
we er nog elke dag vol overgave van 
genieten. Bedankt voor dat je bij me 
bent! 
te vieren, want geen reden is immers ook 
een hele goede reden…. Ik hoop dat ik 
jullie als deze harde kern van supporters 
nog lang in mijn omgeving aanwezig 
mag hebben, ook al zitten we nu wat ver-
der weg. Marieke, ik vind het super dat 
jij mijn paranimf wilt zijn! 
 Jurge en Mariska, jullie runnen met 
z’n beiden ‘ons’ vijf-sterren verblijf in 
Zeddam. Bedankt dat we tijdens onze 
bezoekjes aan Nederland telkens weer bij 
jullie terecht kunnen. Het is altijd weer 
fijn om thuis te komen in de Majella-
straat!
 Pap en mam, jullie hebben mij altijd 
gestimuleerd om eruit te halen wat erin 
zit en staan daarmee zonder twijfel aan de 
basis van mijn proefschrift. Ik waardeer 
het zeer dat jullie een onvoorwaardelijk 
vertrouwen in mij hebben, mij op allerlei 
manieren steunen en dat jullie tot op de 
dag van vandaag voor me klaar staan. 
Fijn dat jullie ons wekelijks op de hoogte 
houden van het reilen-en-zeilen in de 
Achterhoek!
   Mieneke, Wendy & Kevin, Wido, Ine 
& Dianthe! Ook al was hetgeen waar ik 
dagelijks mee bezig was niet altijd even 
makkelijk in begrijpelijke taal te vatten, 
jullie waren altijd razend enthousiast en 
geïnteresseerd, bedankt daarvoor!
 Het allerlaatste woord blijft voor jou, 
Eddie. Jij hebt vaak gezegd dat ik je niet 
augustus 2009
Lebanon, NH, USA
Color Figures
137
C
h
ap
te
r 
8
Chapter 4; Figure 8. Immuno blocking using antibody NS4F5 induces morphologic changes 
consistent with apoptosis. Human lung epithelial cells were treated with purified NS4F5 (A, D), irrelevant 
antibody MPB49 (B, E) or anti-HS antibody HS4C3 (C, F). Cells were fixed and concomitantly stained with 
M30 antibody (A-C) which recognizes caspase-cleaved cytokeratin 18 (CK-18) in the cytoplasm of epithelial 
cells, or with TUNEL (D-F) which labels DNA strand breaks (‘nicks’) generated by apoptosis. DAPI was 
used to identify nuclei. The arrows in A identify caspase-cleaved CK-18 in the cytoplasm of epithelial cells, 
whereas arrows in D identify TUNEL positive cells. Cells treated with the control antibody show normal 
nuclei (G), whereas cells treated with antibody NS4F5 cells show nuclear condensation (H, arrow). Scale 
bar, 50 μm.
Chapter 4; Figure 3. Restricted 
location of the antibody NS4F5-
defined heparan sulfate domain 
in rat kidney. A, B Cortical area. 
C. Cortical-medullary area. D-F. 
Medullary area. D-F Identification of 
antibody NS4F5-reactive structures by 
colocalization. Medullary areas were 
incubated with antibody NS4F5 (D, 
green) and with an antibody against 
aquaporin-1 (E, AQP), a marker for descending thin limbs of the Loops of Henle and proximal tubules (red). 
F: overlay. Note that the specific HS domain is only present in descending thin limbs and some small blood 
vessels. Scale bars, 50 μm. 
G, Glomerulus Asterisks in D, ascending thin limbs of the loops of Henle; arrows in D, ascending thick limbs 
of the loops of Henle; arrow heads in D, descending thin limbs of the loops of Henle
Arrows in E, proximal tubules; arrow heads in E, descending thin limbs of the loops of Henle
Arrow in F, small blood vessel
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Chapter 5; Figure 4. Overexpression of heparanase is associated with loss of heparan sulfate 
(HS). A-F: morphologically analyzed sections of subjects without clinically evident emphysema 
and with normal (DI < 30%, MLI normal A, D), slightly affected (DI 30 - 80%, MLI normal B, E), or 
moderately affected (DI > 80%, increased MLI C, F) lung parenchyma were incubated with antibodies 
against human heparanase (A-C) or HS (D-F). Heparanase expression increased with DI in
alveolar basement membranes (arrows), peri-vascular areas (arrowheads), and peribronchiolar areas (not 
shown) whereas HS decreased. Scale bars, 50 μm.
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